Functionalized long chain hydrocarbon monocarboxylic and dicarboxylic acids useful in the prevention or treatment of disease

Abstract

The present invention provides compounds of formula (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB), their pharmaceutically acceptable salts and solvates, and compositions thereof. The present invention further provides methods for treating diseases including, but not limited to, liver disease or abnormal liver conditions, cancer (e.g., hepatocellular carcinoma or cholangiocarcinoma), malignant or benign tumors of the lung, liver, gallbladder, bile duct, or gastrointestinal tract, intrahepatic or extrahepatic bile duct diseases, lipoprotein disorders, lipid and metabolic disorders, cirrhosis, fibrosis, disorders of glucose metabolism, cardiovascular or related vascular disorders, steatosis, diseases resulting from fibrosis or cirrhosis, diseases associated with advanced inflammation (e.g., liver inflammation or lung inflammation), hepatocellular ballooning, peroxisome proliferator-activated receptor-related disorders, ATP citrate lyase disorders, acetyl-coenzyme A carboxylase disorders, obesity, pancreatitis, or renal disease.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 878,852, filed July 26, 2019, and U.S. Provisional Application No. 62 / 901,739, filed September 17, 2019, the disclosures of each of which are incorporated herein by reference in their entireties.

[0002] The present invention provides compounds of formula (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB), and pharmaceutically acceptable salts and solvates thereof, and compositions thereof. The present invention further provides methods for preventing or treating diseases including, but not limited to, liver disease or abnormal liver conditions, cancer (e.g., hepatocellular carcinoma or cholangiocarcinoma), malignant or benign tumors of the lung, liver, gallbladder, bile duct or gastrointestinal tract, intrahepatic or extrahepatic bile duct diseases, lipoprotein disorders, lipid and metabolic disorders, cirrhosis, fibrosis, glucose metabolism disorders, cardiovascular or related vascular disorders, steatosis, diseases resulting from fibrosis or cirrhosis, diseases associated with advanced inflammation (e.g., liver inflammation or lung inflammation), hepatocellular ballooning, peroxisome proliferator-activated receptor-related disorders, ATP citrate lyase disorders, acetyl-coenzyme A carboxylase disorders, obesity, pancreatitis, or renal disease. [Background technology]

[0003] Hepatocellular carcinoma (HCC) is one of the most common primary liver malignancies. Patients with chronic liver diseases, such as cirrhosis and fibrosis, are at increased risk for HCC. Therefore, patients with chronic liver disease should be closely monitored for the development of HCC. Risk factors for HCC include cirrhosis, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), chronic alcohol use, hepatitis B and C, type IIb hyperlipidemia, mixed dyslipidemia, obesity, and type 2 diabetes.

[0004] Patients with type IIb hyperlipidemia are at high risk for developing NAFLD and nonalcoholic steatohepatitis (NASH), which may be caused by excessive hepatic triglyceride production and accumulation. Elevated low-density lipoprotein cholesterol (LDL-C) and triglyceride levels are associated with mixed dyslipidemia, including type IIb hyperlipidemia, which is characterized by elevated apolipoprotein B, very-low-density lipoprotein cholesterol (VLDL-C), intermediate-density lipoprotein cholesterol (IDL), and small-density low-density lipoprotein (LDL) levels in addition to elevated LDL-C and triglyceride levels.

[0005] Current therapeutic options for the treatment of type IIb hyperlipidemia are limited. While statins can be effective in lowering LDL-C and reducing inflammation, they are generally not very effective at lowering triglyceride levels. Furthermore, high-dose statin therapy is often poorly tolerated, potentially causing muscle pain (myalgia) and increasing the risk of serious muscle toxicities, such as rhabdomyolysis, in patients. Commonly used triglyceride-lowering agents administered in combination with statins are also often poorly tolerated. When administered with statins, fibrates are known to have drug-drug interactions, resulting in elevated statin blood levels, muscle pain, increased risk of muscle toxicity, and increased safety risks. In fact, an interaction between the statin Baychol (cerivastatin) and the fibrate gemfibrozil resulted in severe muscle toxicity and death, raising safety concerns and leading to Baychol's removal from the U.S. market. Fish oil, used to lower triglyceride levels, must be taken multiple times daily and may cause an oily aftertaste, burping, or reflux. Niacin, especially when given in combination with statins, can cause flushing.

[0006] Hepatocellular adenomas are benign liver tumors whose genetic and pathophysiological mechanisms are not fully understood. These lesions pose diagnostic and therapeutic challenges, and treatment after resection remains difficult. Bile duct adenomas pose similar therapeutic challenges. Adenomas of the digestive system are sporadic tumors arising from the glandular epithelium of the stomach, small intestine, biliary tract, colon, and rectum.

[0007] Gastrointestinal (GI) cancers are cancers that affect the gastrointestinal tract and other organs contained within it. Gastrointestinal stromal tumors (GISTs) are a rare type of sarcoma that form along the gastrointestinal tract, but most begin in the stomach or small intestine. The origin of gastrointestinal cancers has been strongly associated with chronic inflammation of the organ, developing through a series of histopathological stages depending on the affected organ. In the case of gastrointestinal or GIST cancers, surgery is likely recommended to remove the tumor and / or help maintain normal function. Other treatment options include radiation therapy, chemotherapy, hormone therapy, or targeted therapy.

[0008] Thus, there is a need for safe and effective therapies for the treatment or prevention of cancer (e.g., gastrointestinal cancer, hepatocellular carcinoma, or cholangiocarcinoma), malignant or benign tumors of the lung, liver, gallbladder, bile duct, or digestive tract, liver disease or abnormal liver conditions, intrahepatic or extrahepatic bile duct disease, lipoprotein disorders, lipid and metabolic disorders, cirrhosis, fibrosis, disorders of glucose metabolism, cardiovascular or related vascular disorders, steatosis, diseases resulting from fibrosis or cirrhosis, diseases associated with advanced inflammation (e.g., liver inflammation or lung inflammation), hepatocellular ballooning, peroxisome proliferator-activated receptor-related disorders, ATP citrate lyase disorders, acetyl-coenzyme A carboxylase disorders, obesity, pancreatitis, or kidney disease. Summary of the Invention

[0009] The present invention provides compounds of formula (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB), and pharmaceutically acceptable salts and solvates thereof (each compound, pharmaceutically acceptable salt, and solvate is referred to as a "compound of the invention").

[0010] The present invention also provides compositions comprising i) an effective amount of a compound of the present invention, and ii) a pharmaceutically acceptable carrier or vehicle (each composition being a "Composition of the Invention").

[0011] The present invention further provides a method for treating or preventing a disease, comprising administering an effective amount of a compound of the present invention to a subject in need thereof, wherein the disease is a liver disease or abnormal liver condition, cancer (e.g., hepatocellular carcinoma or cholangiocarcinoma), malignant or benign tumor of the lung, liver, gallbladder, bile duct or gastrointestinal tract, intrahepatic or extrahepatic bile duct disease, lipoprotein disorders, lipid and metabolic disorders, cirrhosis, fibrosis, glucose metabolism disorders, cardiovascular or related vascular disorders, steatosis, diseases resulting from fibrosis or cirrhosis, diseases associated with advanced inflammation (e.g., liver inflammation or lung inflammation), hepatocellular ballooning, peroxisome proliferator-activated receptor-related disorders, ATP citrate lyase disorders, acetyl-coenzyme A carboxylase disorders, obesity, pancreatitis, or renal disease.

[0012] The present invention further provides a method for treating or preventing a disease, wherein the disease is cancer, lipid and metabolic disorders, liver disorders, cirrhosis, fibrosis, glucose metabolism disorders, peroxisome proliferator-activated receptor-associated disorders, malignant or benign tumors of the lung, liver, biliary tract and gastrointestinal tract, ATP citrate lyase disorders, acetyl-coenzyme A carboxylase disorders, obesity, pancreatitis, kidney disease, hepatocellular ballooning, liver inflammation, or lung inflammation.

[0013] The present invention further relates to a method for determining the plasma or serum concentrations of a subject, i.e., C-reactive protein (CRP) concentration, serum amyloid A (SAA) concentration, alanine aminotransferase (ALT) concentration, aspartate aminotransferase (AST) concentration, alkaline phosphatase (ALP) concentration, gamma glutamyltransferase (GGT) concentration, serum creatinine concentration, 7α-hydroxy-4-cholesten-3-one (C4) concentration, protein:creatinine ratio, creatine kinase concentration, angiopoietin-like protein 3 concentration, and the like, of a subject. , angiopoietin-like protein 4 level, angiopoietin-like protein 8 level, fibrinogen level, total cholesterol level, low density lipoprotein cholesterol level, low density lipoprotein level, very low density lipoprotein cholesterol level, very low density lipoprotein level, non-HDL cholesterol level, non-HDL level, apolipoprotein B level, lipoprotein(a) level, or serum triglyceride level, the method comprising administering to a subject in need thereof an effective amount of a compound of the invention.

[0014] The present invention further provides a method for reducing triglyceride levels in the liver of a subject, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0015] The present invention further provides a method for increasing the concentration of high density lipoprotein cholesterol or high density lipoprotein in the plasma or serum of a subject, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0016] The present invention further provides a method for treating a disease, comprising administering to a subject in need thereof an effective amount of a compound of the present invention, wherein the disease is a gastrointestinal disease, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or an autoimmune disease.

[0017] The present invention further provides a method for regressing, slowing the rate of progression, or inhibiting the progression of fibrosis, hepatocellular ballooning, or liver inflammation, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0018] The present invention further provides a method for inhibiting, reducing, or delaying the development of lipid synthesis, hepatic steatosis, hepatocyte ballooning or inflammation, liver fibrosis, pulmonary fibrosis, or cirrhosis in a subject, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0019] The present invention further provides a method for reducing a subject's risk of developing or having atherosclerosis, coronary heart disease, peripheral vascular disease, stroke, or restenosis, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0020] The present invention further provides a method for increasing HDL levels in the serum or plasma of a subject, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0021] The present invention further provides a method for inhibiting NF-kB or astrocyte activation, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0022] The present invention further provides a method for activating PPAR (peroxisome proliferator-activated receptor), comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0023] The present invention further provides a method for reducing the fat or cholesterol content of livestock meat or poultry eggs, comprising administering to the livestock or poultry an effective amount of a compound of the present invention.

[0024] The present invention further provides a method for modulating, directly inhibiting, or allosterically inhibiting ATP citrate lyase in a subject, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0025] The present invention further provides a method for modulating, directly inhibiting, or allosterically inhibiting acetyl-CoA carboxylase 1 or acetyl-CoA carboxylase 2 in a subject, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0026] The present invention further provides a method for treating or preventing a disease, comprising administering to a subject in need thereof an effective amount of a composition of the present invention, wherein the disease is cancer, lipid and metabolic disorders, liver disorders, cirrhosis, fibrosis, glucose metabolism disorders, peroxisome proliferator-activated receptor-associated disorders, malignant or benign tumors of the lung, liver, biliary tract and gastrointestinal tract, ATP citrate lyase disorders, acetyl-coenzyme A carboxylase disorders, obesity, pancreatitis, kidney disease, hepatocellular ballooning, liver inflammation, or lung inflammation. [Brief explanation of the drawings]

[0027] [Figure 1A] The inhibitory effect of compounds I-32, I-61, I-1, and III-1, respectively, on lipogenesis in mouse primary hepatocytes as a percentage of the control is shown. [Figure 1B] The inhibitory effect of compounds I-32, I-61, I-1, and III-1, respectively, on lipogenesis in mouse primary hepatocytes as a percentage of the control is shown. [Figure 1C] The inhibitory effect of compounds I-32, I-61, I-1, and III-1, respectively, on lipogenesis in mouse primary hepatocytes as a percentage of the control is shown. [Figure 1D] The inhibitory effect of compounds I-32, I-61, I-1, and III-1, respectively, on lipogenesis in mouse primary hepatocytes as a percentage of the control is shown. [Figure 2A] The antiproliferative effects of compounds I-32, I-61, I-1, and III-1, respectively, on Hepa1-6 cells as a percentage of the vehicle control are shown. [Figure 2B] The antiproliferative effects of compounds I-32, I-61, I-1, and III-1, respectively, on Hepa1-6 cells as a percentage of the vehicle control are shown. [Figure 2C] The antiproliferative effects of compounds I-32, I-61, I-1, and III-1, respectively, on Hepa1-6 cells as a percentage of the vehicle control are shown. [Figure 2D] The antiproliferative effects of compounds I-32, I-61, I-1, and III-1, respectively, on Hepa1-6 cells as a percentage of the vehicle control are shown. [Figure 3A] The antiproliferative effect of compounds I-32, I-61, I-1, and III-1, respectively, on Hep3B cell proliferation as a percentage of vehicle control is shown. [Figure 3B] The antiproliferative effect of compounds I-32, I-61, I-1, and III-1, respectively, on Hep3B cell proliferation as a percentage of vehicle control is shown. [Figure 3C] The antiproliferative effect of compounds I-32, I-61, I-1, and III-1, respectively, on Hep3B cell proliferation as a percentage of vehicle control is shown. [Figure 3D] The antiproliferative effect of compounds I-32, I-61, I-1, and III-1, respectively, on Hep3B cell proliferation as a percentage of vehicle control is shown. [Figure 4A] The anti-clonogenic effects of compounds I-32, I-61, I-1, and III-1, respectively, in Hepa1-6 cells as a percentage of the vehicle control are shown. [Figure 4B] The anti-clonogenic effects of compounds I-32, I-61, I-1, and III-1, respectively, in Hepa1-6 cells as a percentage of the vehicle control are shown. [Figure 4C] The anti-clonogenic effects of compounds I-32, I-61, I-1, and III-1, respectively, in Hepa1-6 cells as a percentage of the vehicle control are shown. [Figure 4D] The anti-clonogenic effects of compounds I-32, I-61, I-1, and III-1, respectively, in Hepa1-6 cells as a percentage of the vehicle control are shown. [Figure 5A] The anti-clonogenic effects of compounds I-32, I-61, I-1, and III-1, respectively, in Hep3B cells as a percentage of the vehicle control are shown. [Figure 5B] The anti-clonogenic effects of compounds I-32, I-61, I-1, and III-1, respectively, in Hep3B cells as a percentage of the vehicle control are shown. [Figure 5C] The anti-clonogenic effects of compounds I-32, I-61, I-1, and III-1, respectively, in Hep3B cells as a percentage of the vehicle control are shown. [Figure 5D] The anti-clonogenic effects of compounds I-32, I-61, I-1, and III-1, respectively, in Hep3B cells as a percentage of the vehicle control are shown. [Figure 6A] 1 shows the antiproliferative effect of compound I-32 and sorafenib in the presence or absence of each other in Hep3B cells. [Figure 6B] 1 shows the antiproliferative effects of compound I-32 and lenvatinib in the presence or absence of each other in Hep3B cells. [Figure 6C] 1 shows the antiproliferative effect of compound I-61 and sorafenib in the presence or absence of each other in Hep3B cells. [Figure 6D] 1 shows the antiproliferative effects of compound I-61 and lenvatinib in the presence or absence of each other in Hep3B cells. [Figure 7A] Figure 1 shows the antiproliferative effect of compound I-32 and sorafenib in the presence or absence of each other in Hepa1-6 cells. [Figure 7B] 1 shows the antiproliferative effect of compound I-32 and lenvatinib in the presence or absence of each other in Hepa1-6 cells. [Figure 7C] Figure 1 shows the antiproliferative effect of compound I-61 and sorafenib in the presence or absence of each other in Hepa1-6 cells. [Figure 7D] 1 shows the antiproliferative effect of compound I-61 and lenvatinib in the presence or absence of each other in Hepa1-6 cells. [Figure 8A] 1 shows the synergistic antiproliferative effect of compound I-32 and sorafenib in Hep3B cells. [Figure 8B] 1 shows the synergistic antiproliferative effect of compound I-32 and lenvatinib in Hep3B cells. [Figure 8C] 1 shows the synergistic antiproliferative effect of compound I-61 and sorafenib in Hep3B cells. [Figure 8D] 1 shows the synergistic antiproliferative effect of compound I-61 and lenvatinib in Hep3B cells. DETAILED DESCRIPTION OF THE INVENTION

[0028] definition The term "about" immediately preceding a numerical value means up to ±20% of the numerical value. For example, "about" a numerical value means up to ±20% of the numerical value, and in some embodiments, up to ±19%, up to ±18%, up to ±17%, up to ±16%, up to ±15%, up to ±14%, up to ±13%, up to ±12%, up to ±11%, up to ±10%, up to ±9%, up to ±8%, up to ±7%, up to ±6%, up to ±5%, up to ±4%, up to ±3%, up to ±2%, up to ±1%, up to less than ±1%, or any other numerical value or range of values ​​therein.

[0029] Throughout this specification, numerical ranges are provided for specific quantities. These ranges include all subranges therein. Thus, a range of "50 to 80" includes all possible ranges therein (e.g., 51 to 79, 52 to 78, 53 to 77, 54 to 76, 55 to 75, 60 to 70, etc.). Furthermore, every value within a given range may be the upper or lower limit of the range it is included in (e.g., the range 50 to 80 includes ranges with upper and lower limits such as 55 to 80, 50 to 75, etc.).

[0030] The term "pharmaceutically acceptable salt" includes both acid and base addition salts. Pharmaceutically acceptable salts can be obtained by reacting a compound of the present invention, which functions as a base, with an inorganic or organic acid to form a salt, such as hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, and the like. Pharmaceutically acceptable salts can also be obtained by reacting a compound of the present invention, which functions as an acid, with an inorganic or organic base to form a salt, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, ammonia, isopropylamine, trimethylamine, and the like. Those skilled in the art will further recognize that pharmaceutically acceptable salts can be prepared by reacting a compound of the present invention with the appropriate inorganic or organic acid or base using any of several known methods.

[0031] The term "solvate" refers to a solvated complex. A solvate can be formed by solvation (the combination of a solvent molecule with a molecule or ion of a compound of the present invention), or it can be an aggregate containing a solute ion or molecule or a solvent molecule. The solvent can be water, in which case the solvate is a hydrate. Examples of hydrates include, but are not limited to, hemihydrate, monohydrate, dihydrate, trihydrate, hexahydrate, etc. A solvate can be formed through hydration, including the absorption of water. A pharmaceutically acceptable salt can also be a solvate. When the solvate is obtained by crystallization from a solvent, the solvent can be an alcohol, such as methanol or ethanol, an aldehyde, a ketone, such as acetone, or an ester, such as ethyl acetate.

[0032] The compounds of the present invention may have one or more asymmetric centers and may therefore be enantiomers, racemates, diastereomers, other stereoisomers, and mixtures thereof. The compounds of the present invention include all such possible isomers (including geometric isomers), as well as their racemic and optically pure forms, whether or not specifically depicted herein. Optically active (+)- and (-), (R)- and (S)-, or (D)- and (L)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for the preparation or isolation of individual enantiomers include chiral synthesis from suitable optically pure precursors, or resolution of racemates using, for example, chiral high-pressure liquid chromatography (HPLC). When a compound of the present invention contains an olefinic double bond or another center of geometric asymmetry, unless otherwise specified, the compound includes both E- and Z-geometric isomers. Similarly, the compounds of the present invention include all tautomeric forms.

[0033] When used in connection with a compound of the present invention, "effective amount" means an amount of a compound of the present invention that, when administered to a subject, alone or together with another pharmaceutically active agent, is effective to treat or prevent a disease.

[0034] When used in reference to another pharmaceutically active agent, "effective amount" means the amount of that other pharmaceutically active agent that is effective alone, or in combination with a compound of the invention, to treat or prevent a disease.

[0035] A "subject" is a human or non-human mammal, such as a cow, horse, cat, dog, rodent, or non-human primate. A human can be male or female, a child, adolescent, or adult. A female can be premenstrual or postmenstrual.

[0036] "Mammals" includes humans, domestic animals such as laboratory animals (e.g., mice, rats, rabbits, monkeys, dogs, etc.) and household pets (e.g., cats, dogs, pigs, cows, sheep, goats, horses, rabbits), and non-domestic wild animals.

[0037] All weight percentages (i.e., "wt %" and "wt %" and "wt / wt") referred to herein are relative to the total weight of the mixture or composition, as the case may be, unless otherwise indicated.

[0038] As used herein, the following terms have the following meanings unless otherwise indicated:

[0039] "Halo", "Hal", or "halogen" refers to Br, Cl, F, or I.

[0040] "Alkyl" refers to a straight or branched hydrocarbon chain having from 1 to 12 carbon atoms, connected to an atom by a single bond, and fully saturated. Alkyl groups having 1 to 12 carbon atoms are included. Alkyl groups having 1 to 12 carbon atoms include C1-C 12Alkyl and alkyl groups having 1 to 10 carbon atoms are C1-C 10 An alkyl group having 1 to 6 carbon atoms is a C1-C6 alkyl, and an alkyl group having 1 to 5 carbon atoms is a C1-C5 alkyl. C1-C5 alkyl includes C5 alkyl, C4 alkyl, C3 alkyl, C2 alkyl, and C1 alkyl (i.e., methyl). C1-C6 alkyl includes all of the moieties described above for C1-C5 alkyl, but also includes C6 alkyl. C1-C 10 Alkyl includes all of the moieties described above for C1-C5 alkyl and C1-C6 alkyl, but also includes C7, C8, C9 and C 10 Also includes alkyl. Similarly, C1-C 12 Alkyl includes all of the above moieties, but C 11 and C 12 Includes alkyl. C1-C 12 Non-limiting examples of alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl. Unless otherwise specified, alkyl groups can be unsubstituted or substituted with the substituents disclosed herein.

[0041] "Alkylene" refers to a fully saturated, straight or branched chain divalent hydrocarbon having 1 to 12 carbon atoms. C1-C 12 Non-limiting examples of alkylene include methylene, ethylene, propylene, n-butylene, etc. Each alkylene end is connected to an atom by a single bond. The attachment points of the alkylene chain can be one or two atoms. Unless otherwise stated, the alkylene chain can be unsubstituted or substituted with the substituents disclosed herein.

[0042] "Alkenyl" refers to a straight or branched hydrocarbon chain having 2 to 12 carbon atoms and one or more carbon-carbon double bonds. Each alkenyl group is connected to an atom by a single bond. Alkenyl groups having 2 to 12 carbon atoms are included. Alkenyl groups having 2 to 12 carbon atoms are C2-C 12 Alkenyl, an alkenyl group having 2 to 10 carbon atoms, is C2-C 10 An alkenyl group having 2 to 6 carbon atoms is C2-C6 alkenyl, and an alkenyl group having 2 to 5 carbon atoms is C2-C5 alkenyl. C2-C5 alkenyl includes C5 alkenyl, C4 alkenyl, C3 alkenyl, and C2 alkenyl. C2-C6 alkenyl includes all of the moieties described above for C2-C5 alkenyl, but also includes C6 alkenyl. C2-C 10 Alkenyl includes all of the moieties described above for C2-C5 alkenyl and C2-C6 alkenyl, but also includes C7, C8, C9 and C 10 Also includes alkenyl. Similarly, C2-C 12 Alkenyl includes all of the above moieties, but C 11 and C 12 Includes alkenyl. C2-C 12Non-limiting examples of alkenyl include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), isopropenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, and 3-nonenyl. , 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, and 11-dodecenyl. Unless otherwise specified, alkyl groups can be unsubstituted or substituted with the substituents disclosed herein.

[0043] "Alkenylene" refers to a straight or branched divalent hydrocarbon chain radical having 2 to 12 carbon atoms and one or more carbon-carbon double bonds. 12 Non-limiting examples of alkenylene include ethenylene, propenylene, butenylene, etc. Each end of the alkenylene chain is connected to an atom by a single bond. The attachment points of the alkenylene chain can be through one or two atoms. Unless otherwise specified, the alkenylene chain can be unsubstituted or substituted with the substituents disclosed herein.

[0044] "Alkynyl" refers to a straight or branched hydrocarbon chain radical having 2 to 12 carbon atoms and one or more carbon-carbon triple bonds. Each alkynyl group is connected to an atom by a single bond. Alkynyl groups having numbers of 2 to 12 carbon atoms are included. Alkynyl groups having 2 to 12 carbon atoms are C2-C 12 Alkynyl, an alkynyl group having 2 to 10 carbon atoms, is C2-C 10 An alkynyl group having 2 to 6 carbon atoms is C2-C6 alkynyl, and an alkynyl group having 2 to 5 carbon atoms is C2-C5 alkynyl. C2-C5 alkynyl includes C5 alkynyl, C4 alkynyl, C3 alkynyl, and C2 alkynyl. C2-C6 alkynyl includes all of the moieties described above for C2-C5 alkynyl, but also includes C6 alkynyl. C2-C 10 Alkynyl includes all of the moieties described above for C2-C5 alkynyl and C2-C6 alkynyl, but also includes C7, C8, C9 and C 10 Also includes alkynyl. Similarly, C2-C 12 Alkynyl includes all of the above moieties, but C 11 and C 12 Alkynyl is also included. C2-C 12 Non-limiting examples of alkenyls include ethynyl, propynyl, butynyl, pentynyl, etc. Unless otherwise specified, alkyl groups can be unsubstituted or substituted with the substituents disclosed herein.

[0045] "Alkynylene" refers to a straight or branched divalent hydrocarbon chain radical having 2 to 12 carbon atoms and one or more carbon-carbon triple bonds. 12 Non-limiting examples of alkynylene include ethynylene, propynylene, butynylene, etc. Each end of the alkynylene chain is bonded to an atom via a single bond. The attachment points of the alkynylene chain can be through one or two atoms. Unless otherwise specified, the alkynylene chain can be unsubstituted or substituted with the substituents disclosed herein.

[0046] "Alkoxy" means a group of the formula -OR a where R a is an alkyl, alkenyl, or alkynyl radical, as defined herein. Unless otherwise specified, an alkoxy group can be unsubstituted or substituted with the substituents disclosed herein.

[0047] "Aryl" refers to a hydrocarbon ring system radical containing hydrogen, 6 to 18 carbon atoms, and at least one aromatic ring. Aryl radicals can be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which can include fused or bridged ring systems. Aryl radicals include, but are not limited to, aceanthrlenyl, acenaphthylenyl, acephenanthrilenyl, anthracenyl, azulenyl, chrysenyl, fluoranthenyl, fluorenyl, as-indacenyl, s-indacenyl, indanyl, indenyl, naphthalenyl, phenalenyl, phenanthrenyl, phenyl, pleiadenyl, pyrenyl, and triphenylenyl. Unless otherwise specified, aryl can be unsubstituted or substituted with the substituents disclosed herein.

[0048] "Arylene" refers to a divalent aryl group, where aryl is as defined herein. Unless otherwise specified, an arylene group can be unsubstituted or substituted with the substituents disclosed herein.

[0049] "Arylalkyl" refers to a group of the formula -R b -R c where R b is an alkylene group as defined herein, and R c is an aryl radical as defined herein, for example, benzyl, diphenylmethyl, and the like. Unless otherwise stated, arylalkyl groups can be unsubstituted or substituted with the substituents disclosed herein. "Arylalkenyl" refers to a group of the formula -R b -R c where Rb is an alkenylene group as defined herein, and R c is an aryl radical, as defined herein. Unless otherwise specified, an arylalkenyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0050] "Arylalkynyl" refers to a group of the formula -R b -R c where R b is an alkynylene group as defined herein, and R c is an aryl radical, as defined herein. Unless otherwise specified, an arylalkynyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0051] "Cycloalkyl" refers to a non-aromatic, monocyclic or polycyclic, fully saturated hydrocarbon radical consisting of carbon and hydrogen atoms, having 3 to 20 carbon atoms, preferably 3 to 10 carbon atoms, which may include fused or bridged ring systems, and is connected to the atoms by a single bond. Monocyclic cycloalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise specified, cycloalkyl groups can be unsubstituted or substituted with the substituents disclosed herein.

[0052] "Aryloxy" refers to a radical of the formula -O(aryl), where aryl radical is as defined herein. Aryloxy includes, but is not limited to, phenoxy (-O(phenyl)). Unless otherwise specified, aryloxy groups can be unsubstituted or substituted with the substituents disclosed herein.

[0053] "Cycloalkenyl" refers to a non-aromatic, monocyclic or polycyclic hydrocarbon radical consisting of carbon and hydrogen atoms and having one or more carbon-carbon double bonds. Cycloalkenyls can include fused or bridged ring systems having 3 to 20 carbon atoms, and in some embodiments, 3 to 10 carbon atoms. Cycloalkenyl groups are linked to atoms by single bonds. Monocyclic cycloalkenyl radicals include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like. Polycyclic cycloalkenyl radicals include, for example, bicyclo[2.2.1]hept-2-enyl, and the like. Unless otherwise specified, cycloalkenyl groups can be unsubstituted or substituted with the substituents disclosed herein.

[0054] "Cycloalkynyl" refers to a non-aromatic, monocyclic or polycyclic hydrocarbon radical, consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon triple bonds, and which may include fused or bridged ring systems, having from 5 to 20 carbon atoms, in some embodiments from 5 to 10 carbon atoms, and which is attached to the remainder of the molecule by a single bond. Monocyclic cycloalkynyl radicals include, for example, cycloheptynyl, cyclooctynyl, and the like. Unless otherwise specified, cycloalkynyl groups can be unsubstituted or substituted with the substituents disclosed herein.

[0055] "Cycloalkylalkyl" refers to a group of the formula -R b -R d where R b is an alkylene group as defined herein, and R d is a cycloalkyl radical, as defined herein. Unless otherwise specified, a cycloalkylalkyl group can be unsubstituted or substituted with the substituents disclosed herein. "Cycloalkylalkenyl" refers to a group of the formula -R b -R d where R b is an alkenylene group as defined herein, and R dis a cycloalkyl radical, as defined herein. Unless otherwise specified, a cycloalkylalkenyl group can be unsubstituted or substituted with the substituents disclosed herein. "Cycloalkylalkynyl" refers to a group of the formula -R b -R d where R b is an alkynylene group as defined herein, and R d is a cycloalkyl radical, as defined herein. Unless otherwise specified, a cycloalkylalkynyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0056] A "cycloalkenylalkyl" is a group of the formula -R b -R d where R b is an alkylene group as defined herein, and R d is a cycloalkenyl radical, as defined herein. Unless otherwise specified, a cycloalkenylalkyl group can be unsubstituted or substituted with the substituents disclosed herein. "Cycloalkenylalkenyl" refers to a group of the formula -R b -R d where R b is an alkenylene group as defined herein, and R d is a cycloalkyl radical, as defined herein. Unless otherwise specified, a cycloalkenylalkynyl group can be unsubstituted or substituted with the substituents disclosed herein. "Cycloalkenylalkynyl" refers to a group of the formula -R b -R d where R b is an alkynylene group as defined herein, and R d is a cycloalkyl radical, as defined herein. Unless otherwise specified, a cycloalkenylalkynyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0057] A "cycloalkynylalkyl" is a group of the formula -R b-R d where R b is an alkylene group as defined herein, and R d is a cycloalkynyl radical, as defined herein. Unless otherwise specified, a cycloalkynylalkyl group can be unsubstituted or substituted with the substituents disclosed herein. "Cycloalkynylalkenyl" refers to a group of the formula -R b -R d where R b is an alkenylene group as defined herein, and R d is a cycloalkyl radical, as defined herein. Unless otherwise specified, a cycloalkynylalkenyl group can be unsubstituted or substituted with the substituents disclosed herein. "Cycloalkynylalkynyl" refers to a group of the formula -R b -R d where R b is an alkynylene group as defined herein, and R d is a cycloalkyl radical, as defined herein. Unless otherwise specified, a cycloalkynylalkynyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0058] "Carbocyclyl," "carbocyclyl ring," or "carbocycle" refers to a cyclic structure in which each atom forming the ring is carbon. A carbocyclyl, carbocyclyl ring, or carbocycle can contain 3 to 20 carbon atoms in the ring. A carbocyclyl, carbocyclyl ring, or carbocycle includes aryl, cycloalkyl, cycloalkenyl, and cycloalkynyl as defined herein. A carbocyclyl, carbocyclyl ring, or carbocycle can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system and can include fused, bridged, and helical ring systems. Unless otherwise specified, a carbocyclyl group, carbocyclyl ring, or carbocycle can be unsubstituted or substituted with the substituents disclosed herein.

[0059] "Haloalkyl" refers to an alkyl radical, as defined herein, that is substituted by one or more halo radicals, as defined herein, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, etc. Unless otherwise specified, a haloalkyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0060] "Haloalkenyl" refers to an alkenyl radical, as defined herein, that is substituted by one or more halo radicals, as defined herein, e.g., 1-fluoropropenyl, 1,1-difluorobutenyl, etc. Unless otherwise stated, a haloalkenyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0061] "Haloalkynyl" refers to an alkynyl radical, as defined herein, that is substituted by one or more halo radicals, as defined herein, e.g., 1-fluoropropynyl, 1-fluorobutynyl, etc. Unless otherwise stated, a haloalkenyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0062] "Heterocyclyl" refers to a 3- to 20-membered non-aromatic, partially unsaturated, or aromatic ring radical containing 2 to 12 carbon atoms and 1 to 6 nitrogen, oxygen, or sulfur heteroatoms. Heterocyclyl includes heteroaryl as defined herein. Unless otherwise specified, the heterocyclyl radical can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, and can include fused, bridged, and helical ring systems; the nitrogen, carbon, or sulfur atoms in the heterocyclyl radical can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl radical can be partially or fully saturated. Examples of heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxothiomorpholinyl, and 1,1-dioxothiomorpholinyl. Unless otherwise stated, heterocyclyl groups can be unsubstituted or substituted with the substituents disclosed herein.

[0063] "Heterocyclylalkyl" refers to a group of the formula -R b -R e where R b is an alkylene group as defined herein, and R e is a heterocyclyl radical, as defined herein. Unless otherwise specified, a heterocyclylalkyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0064] "Heterocyclylalkenyl" refers to a group of the formula -R b -R e where Rb is an alkenylene group as defined herein, and R e is a heterocyclyl radical, as defined herein. Unless otherwise specified, a heterocyclylalkenyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0065] "Heterocyclylalkynyl" refers to a group of the formula -R b -R e where R b is an alkynylene group as defined herein, and R e is a heterocyclyl radical, as defined herein. Unless otherwise specified, a heterocyclylalkynyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0066] "N-heterocyclyl" refers to a heterocyclyl radical, as defined herein, containing at least one nitrogen, and the point of attachment of the heterocyclyl radical to an atom of a compound of the invention is through a nitrogen atom in the heterocyclyl radical. Unless otherwise specified, N-heterocyclyl groups can be unsubstituted or substituted with substituents disclosed herein.

[0067] "Heteroaryl" refers to a 5- to 20-membered ring system radical containing a hydrogen atom, 1 to 13 carbon atoms, 1 to 6 nitrogen, oxygen, or sulfur heteroatoms, and at least one aromatic ring. The heteroaryl radical can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which can include fused or bridged ring systems, and the nitrogen, carbon, or sulfur atoms in the heteroaryl radical can be optionally oxidized, and the nitrogen atom can be optionally quaternized. Examples of heteroaryl include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophene), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophene, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indo Examples of aryl include aryl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thienyl. Unless otherwise specified, a heteroaryl group can be unsubstituted or substituted.

[0068] "N-heteroaryl" refers to a heteroaryl radical, as defined herein, having at least one nitrogen atom, and the point of attachment of the heteroaryl radical to an atom of a compound of the invention is through a nitrogen atom in the heteroaryl radical. Unless otherwise specified, an N-heteroaryl group can be unsubstituted or substituted with the substituents disclosed herein.

[0069] "Heteroarylalkyl" refers to a group of the formula -R b -R f where R b is an alkylene chain as defined herein, and R f is a heteroaryl radical, as defined herein. Unless otherwise specified, a heteroarylalkyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0070] "Heteroarylalkenyl" refers to a group of the formula -R b -R f where R b is an alkenylene chain as defined herein, and R f is a heteroaryl radical, as defined herein. Unless otherwise specified, a heteroarylalkenyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0071] "Heteroarylalkynyl" refers to a group of the formula -R b -R f where R b is an alkynylene chain as defined herein, and R f is a heteroaryl radical, as defined herein. Unless otherwise specified, a heteroarylalkynyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0072] "Ring" refers to a cyclic group that can be saturated or can contain one or more double or triple bonds. The ring can be monocyclic, bicyclic, tricyclic, or tetracyclic. Unless otherwise specified, the ring can be unsubstituted or substituted with the substituents disclosed herein.

[0073] A "thioalkyl" is a group of the formula -SR a where R a is an alkyl, alkenyl, or alkynyl radical, as defined herein. Unless otherwise specified, a thioalkyl group can be unsubstituted or substituted with the substituents disclosed herein.

[0074] The groups or radicals disclosed herein can be substituted with one or more of the following substituents: halogen atoms such as F, Cl, Br, and I, hydroxyl, alkoxy or ester, thiol, thioalkyl, sulfone, sulfonyl or sulfoxide, amine, amide, alkylamine, dialkylamine, arylamine, alkylarylamine, diarylamine, N-oxide, imide and enamine, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, and triarylsilyl, and other groups, optionally containing one or more heteroatoms.

[0075] The groups or radicals disclosed herein may alternatively or additionally be substituted with one or more of the following substituents: oxo, carbonyl, carboxyl, or ester groups, or imines, oximes, hydrazones, and nitriles.

[0076] Examples of other substituents include, but are not limited to: Amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and heteroarylalkyl groups, -NR g R h , -NR g C(=O)R h , -NR g C(=O)NR g R h , -NR g C(=O)OR h , -NR g SO2R h , -OC(=O)NR g R h , -OR g , -SR g , -SOR g , -SO2R g , -OSO2R g , -SO2OR g , =NSO2R g , -SO2NR g R h , -C(=O)R g , -C(=O)OR g , -C(=O)NR g R h , -CH2SO2R g , and -CH2SO2NR g R h and R g and R hare the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl, or heteroarylalkyl, each of the foregoing substituents being unsubstituted or substituted with one or more substituents disclosed herein.

[0077] As used herein, the symbols [ka] ("bond point") denotes a bond that is a point of attachment between two chemical entities, one of which is depicted as being attached to the bond point and the other of which is not depicted as being attached to the bond point. For example, [ka] indicates that a chemical entity "XY" is attached to another chemical entity through a point of attachment.

[0078] Compounds of the Invention Compounds of formula (IA) In some embodiments, the compound of the present invention is a compound of formula (IA): [ka] or a pharmaceutically acceptable salt or solvate thereof; each p is independently 1, 2, 3, 4, 5, 6, or 7; Z 1 and Z 2 are independently -C(R 1A )(R 2A )-(CH2) d -X A or -W-(CH2) d -C(R 3 )(R 4 )-Y, each d is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; Each R 1A and R 2A is independently H, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or each carbon atom is independently a R bonded to a carbon atom; 1A and R 2A together form a -C3-C7 cycloalkyl group, Each R 3 and R 4 is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —O(C1-C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2, or CF3, or each carbon atom is independently an R bonded to a carbon atom; 3 and R 4 together form a -C3-C7 cycloalkyl group, each X A are independently H, -OH, -SO3H, [ka] and Each R 6 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl; each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; Each Y is independently -OH, -COOH, -COOR 5 , -SO3H, [ka] and Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups.

[0079] In some embodiments of the compound of Formula (IA), Z 1 and Z 2 are independently -C(R 1A )(R 2A )-(CH2) d -X A is.

[0080] In some embodiments of the compound of Formula (IA), each R 1A and R 2A is independently —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl. In some embodiments, each R 1A and R 2A is independently -C1-C3 alkyl, -C2-C3 alkenyl, or -C2-C3 alkynyl. In some embodiments, each R 1A and R 2A is independently H or -C1-C6 alkyl. In some embodiments, R 1A and R 2A is methyl.

[0081] In some embodiments of the compound of Formula (IA), each p is 2, 3, 4, or 5.

[0082] In some embodiments of the compound of Formula (IA), each d is 0, 1, 2, or 3. In some embodiments, d is 0 or 1.

[0083] In some embodiments, the compound of the present invention is a compound of formula (IA): [ka] or a pharmaceutically acceptable salt or solvate thereof; each p is independently 4, 5, 6, or 7; Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y, each c is independently 0, 1, 2, or 3; Each R 1 and R 2 is independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or each carbon atom is independently a R bonded to a carbon atom; 1 and R 2 together form a -C3-C7 cycloalkyl group, Each R 3 and R 4 is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —O(C1-C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2, or CF3, or each carbon atom is independently an R bonded to a carbon atom; 3 and R 4 together form a -C3-C7 cycloalkyl group, Each X and Y is independently -OH, -COOH, -COOR 5 , -SO3H, [ka] and Each R 6 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl; each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups.

[0084] In some embodiments, the compound of formula (IA) has any one of the structures shown in Table A-1, or a pharmaceutically acceptable salt or solvate thereof. [Table 1-1] [Table 1-2]

[0085] Compound of formula (IB) In some embodiments, the compound of the present invention is a compound of formula (IB): [ka] or a pharmaceutically acceptable salt or solvate thereof; each p is independently 1, 2, 3, 4, 5, 6, or 7; each Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y, each c is independently 0, 1, 2, or 3; Each R1 and R 2 is independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or each carbon atom is independently a R bonded to a carbon atom; 1 and R 2 together form a -C3-C7 cycloalkyl group, Each R 3 and R 4 is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —O(C1-C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2, or CF3, or each carbon atom is independently an R bonded to a carbon atom; 3 and R 4 together form a -C3-C7 cycloalkyl group, Each X and Y is independently -OH, -COOH, -COOR 5 , -SO3H, [ka] and Each R 6 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl; each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups.

[0086] In some embodiments, the compound of formula (IB) has any one of the structures shown in Table A-2, or a pharmaceutically acceptable salt or solvate thereof. [Table 2-1] [Table 2-2]

[0087] Compounds of formula (IC) In some embodiments, the compound of the present invention is a compound of formula (IC): [ka] or a pharmaceutically acceptable salt or solvate thereof; each p is independently 1, 2, 3, 4, 5, 6, or 7; each Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y, each c is independently 0, 1, 2, or 3; Each R 1 and R 2 is independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or each carbon atom is independently a R bonded to a carbon atom; 1 and R 2 together form a -C3-C7 cycloalkyl group, Each R 3 and R 4is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —O(C1-C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2, or CF3, or each carbon atom is independently an R bonded to a carbon atom; 3 and R 4 together form a -C3-C7 cycloalkyl group, Each X and Y is independently -OH, -COOH, -COOR 5 , -SO3H, [ka] and Each R 6 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl; each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups.

[0088] In some embodiments of compounds of formula (IA), (IB), or (IC), Z 1 and Z 2 are each independently -C(R 1 )(R 2 )-(CH2) c In some embodiments, Z 1 and Z 2One or both of the following may be -W-(CH2) c -C(R 3 )(R 4 )-Y.

[0089] In some embodiments of the compound of Formula (IA), (IB), or (IC), X is —COOH or —COOR 5 is.

[0090] In some embodiments of compounds of Formula (IA), (IB), or (IC), each R 1 and R 2 is independently —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl. In some embodiments, each R 1 and R 2 is independently -C1-C3 alkyl, -C2-C3 alkenyl, or -C2-C3 alkynyl. In some embodiments, R 1 and R 2 is methyl.

[0091] In some embodiments of compounds of formula (IA), (IB), or (IC), Z 1 and Z 2 are each independently -C(R 1 )(R 2 )-(CH2) c -X, where X is -COOH or -COOR 5 and R 1 and R 2 is methyl.

[0092] In some embodiments of the compound of Formula (IA), (IB), or (IC), c is 0 or 1.

[0093] In some embodiments of compounds of formula (IA), (IB), or (IC), Z 1 and Z 2 are respectively -C(R 1 )(R 2 )-(CH2) c In some embodiments, Z 1and Z 2 are respectively -C(R 1 )(R 2 )-(CH2) c -X, where each X is -COOH.

[0094] In some embodiments of compounds of Formula (IA), (IB), or (IC), each carbon atom independently has an R bonded to the carbon atom. 1 and R 2 and together form a -C3-C7 cycloalkyl group. In some embodiments, each carbon atom is independently selected from the R bonded to the carbon atom. 1 and R 2 Together with

[0095] In some embodiments of compounds of formula (IA), (IB), or (IC), Z 1 and Z 2 are respectively -C(R 1 )(R 2 )-(CH2) c -X and at least one R 1 and one R 2 together with the carbon atom to which they are attached form a -C3-C7 cycloalkyl group. 1 and Z 2 are respectively -C(R 1 )(R 2 )-(CH2) c -X and at least one R 1 and one R 2 together with the carbon atoms to which they are attached form a cyclopropyl ring.

[0096] In some embodiments of compounds of formula (IA), (IB), or (IC), R 3 and R 4 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl.

[0097] In some embodiments of the compound of formula (IA), (IB), or (IC), Y is —COOH or —COOR 5 is.

[0098] In some embodiments of compounds of formula (IA), (IB), or (IC), R 5 is -C1-C6 alkyl, -C2-C6 alkenyl, or -C2-C6 alkynyl. In some embodiments, R 5 is -C1-C3 alkyl, -C2-C3 alkenyl, or -C2-C3 alkynyl.

[0099] In some embodiments of the compound of Formula (IA), (IB), or (IC), p is 3, 4, 5, 6, or 7. In some embodiments, p is 4, 5, 6, or 7. In some embodiments of compounds of formula (IA), (IB), or (IC), Z 1 and Z 2 One or both of the following may be -W-(CH2) c -C(R 3 )(R 4 )-Y and R 3 and R 4 is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl. 1 and Z 2 One or both of the following may be -W-(CH2) c -C(R 3 )(R 4 )-Y, where Y is -COOH or -COOR 5 In some embodiments, Z 1 and Z 2 One or both of the following may be -W-(CH2) c -C(R 3 )(R 4 )-Y, where Y is -COOH or -COOR 5 and R 5 is -C1-C6 alkyl, -C2-C6 alkenyl, or -C2-C6 alkynyl. In some embodiments, Z 1 and Z2 One or both of the following may be -W-(CH2) c -C(R 3 )(R 4 )-Y, where Y is -COOH or -COOR 5 and R 5 is -C1-C3 alkyl, -C2-C3 alkenyl, or -C2-C3 alkynyl.

[0100] In some embodiments, the compound of formula (IC) has any one of the structures shown in Table A-3, or a pharmaceutically acceptable salt or solvate thereof. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5]

[0101] Compounds of formula (ID) In some embodiments, the compound of the present invention is a compound of formula (ID): [ka] or a pharmaceutically acceptable salt or solvate thereof; each p is independently 1, 2, 3, 4, 5, 6, or 7; Z 1 and Z 2 are independently -C(R 1A )(R 2A )-(CH2) d -X A or -W-(CH2) d -C(R 3 )(R 4 )-Y, each d is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; Each R 1A and R 2A is independently H, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or each carbon atom is independently a R bonded to a carbon atom; 1A and R 2A together form a -C3-C7 cycloalkyl group, Each R 3 and R 4 is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —O(C1-C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2, or CF3, or each carbon atom is independently an R bonded to a carbon atom; 3 and R 4 together form a -C3-C7 cycloalkyl group, Q 1 and Q 2 are independently H, OH, -C1-C6 alkyl, -O(C1-C6 alkyl), phenoxy, aryloxy, benzyl, -S-aryl, -SR 1A , -NR 1A R 2A , F, Cl, Br, I, -CF3, -COR 1A , heteroaryl, heterocyclyl, or -V-OH, or each carbon atom independently has Q bonded to it. 1 and Q 2 together with V is (CH2) t or arylene, t is 0, 1, 2, 3, or 4; each X A are independently H, -OH, -SO3H, [ka] and Each R 6are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl; each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; Each Y is independently -OH, -COOH, -COOR 5 , -SO3H, [ka] and Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups.

[0102] In some embodiments of the compound of Formula (ID), Z 1 and Z 2 are independently -C(R 1A )(R 2A )-(CH2) d -X A is.

[0103] In some embodiments of the compound of Formula (ID), each R 1A and R 2A is independently —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl. In some embodiments, each R 1A and R 2A is independently -C1-C3 alkyl, -C2-C3 alkenyl, or -C2-C3 alkynyl. In some embodiments, each R1A and R 2A is independently H or -C1-C6 alkyl. In some embodiments, R 1A and R 2A is methyl.

[0104] In some embodiments of the compound of Formula (ID), each p is 2, 3, 4, or 5.

[0105] In some embodiments of the compound of Formula (ID), each d is 0, 1, 2, or 3. In some embodiments, d is 0 or 1.

[0106] In some embodiments, the compound of the present invention is a compound of formula (ID): [ka] or a pharmaceutically acceptable salt or solvate thereof; each p is independently 4, 5, 6, or 7; Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y, each c is independently 0, 1, 2, or 3; Each R 1 and R 2 is independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or each carbon atom is independently a R bonded to a carbon atom; 1 and R 2 together form a -C3-C7 cycloalkyl group, Each R 3 and R 4is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —O(C1-C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2, or CF3, or each carbon atom is independently an R bonded to a carbon atom; 3 and R 4 together form a -C3-C7 cycloalkyl group, Q 1 and Q 2 are independently H, OH, -C1-C6 alkyl, -O(C1-C6 alkyl), phenoxy, aryloxy, benzyl, -S-aryl, -SR 1A , -NR 1A R 2A , F, Cl, Br, I, -CF3, -COR 1A , heteroaryl, heterocyclyl, or -V-OH, or each carbon atom independently has Q bonded to it. 1 and Q 2 together with Each R 1A and R 2A are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, phenyl, or benzyl; V is (CH2) t or arylene, t is 0, 1, 2, 3, or 4; Each X and Y is independently -OH, -COOH, -COOR 5 , -SO3H, [ka] and Each R 6 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl; each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups.

[0107] In some embodiments, the compound of formula (ID) has the structure shown in Table A-1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (ID) has the structure shown in Table A-5, or a pharmaceutically acceptable salt or solvate thereof, mono- or disubstituted on the phenyl with -OH or methyl groups.

[0108] Compound of formula (IG) In some embodiments, the compound of the present invention is a compound of formula (IG): [ka] or a pharmaceutically acceptable salt or solvate thereof; each p is independently 1, 2, 3, 4, 5, 6, or 7; Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y, each c is independently 0, 1, 2, or 3; Each R 1 and R 2is independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or each carbon atom is independently a R bonded to a carbon atom; 1 and R 2 together form a -C3-C7 cycloalkyl group, Each R 3 and R 4 is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —O(C1-C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2, or CF3, or each carbon atom is independently an R bonded to a carbon atom; 3 and R 4 together form a -C3-C7 cycloalkyl group, Q 1 and Q 2 are independently H, OH, -C1-C6 alkyl, -O(C1-C6 alkyl), phenoxy, aryloxy, benzyl, -S-aryl, -SR 1A , -NR 1A R 2A , F, Cl, Br, I, -CF3, -COR 1A , heteroaryl, heterocyclyl, or -V-OH, or each carbon atom independently has Q bonded to it. 1 and Q 2 together with Each R 1A and R 2A are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, phenyl, or benzyl; V is (CH2) t or arylene, t is 0, 1, 2, 3, or 4; Each X and Y is independently -OH, -COOH, -COOR 5 , -SO3H, [ka] and Each R 6are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl; each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups.

[0109] In some embodiments, in the compound of formula (IG), Q 1 and Q 2 are H respectively.

[0110] In some embodiments, in the compound of formula (IG), p is 2, 3, 4, 5, 6, or 7. In some embodiments, in the compound of formula (IG), p is 2.

[0111] In some embodiments, the compound of formula (IG) has the structure shown in Table A-4, or a pharmaceutically acceptable salt or solvate thereof. [Table 4]

[0112] Compounds of formula (IE) In some embodiments, the compound of the present invention is a compound of formula (IE): [ka] or a pharmaceutically acceptable salt or solvate thereof; each p is independently 1, 2, 3, 4, 5, 6, or 7; each Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y, each c is independently 0, 1, 2, or 3; Each R 1 and R 2 is independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or each carbon atom is independently a R bonded to a carbon atom; 1 and R 2 together form a -C3-C7 cycloalkyl group, Each R 3 and R 4 is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —O(C1-C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2, or CF3, or each carbon atom is independently an R bonded to a carbon atom; 3 and R 4 together form a -C3-C7 cycloalkyl group, Q 1 and Q 2 are independently H, OH, -C1-C6 alkyl, -O(C1-C6 alkyl), phenoxy, aryloxy, benzyl, -S-aryl, -SR 1A , -NR 1A R 2A , F, Cl, Br, I, -CF3, -COR 1A , heteroaryl, heterocyclyl, or -V-OH, or each carbon atom independently has Q bonded to it. 1 and Q 2 together with Each R1A and R 2A are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, phenyl, or benzyl; V is (CH2) t or arylene, t is 0, 1, 2, 3, or 4; Each X and Y is independently -OH, -COOH, -COOR 5 , -SO3H, [ka] and Each R 6 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl; each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups.

[0113] In some embodiments, the compound of formula (IE) has the structure shown in Table A-2, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IE) has the structure shown in Table A-6, or a pharmaceutically acceptable salt or solvate thereof, mono- or di-substituted on the phenyl with -OH or methyl groups.

[0114] Compounds of formula (IF) In some embodiments, the compound of the present invention is a compound of formula (IF): [ka] or a pharmaceutically acceptable salt or solvate thereof; each p is independently 1, 2, 3, 4, 5, 6, or 7; each Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y, each c is independently 0, 1, 2, or 3; Each R 1 and R 2 is independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or each carbon atom is independently a R bonded to a carbon atom; 1 and R 2 together form a -C3-C7 cycloalkyl group, Each R 3 and R 4 is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —O(C1-C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2, or CF3, or each carbon atom is independently an R bonded to a carbon atom; 3 and R 4 together form a -C3-C7 cycloalkyl group, Q 1 and Q 2 are independently H, OH, -C1-C6 alkyl, -O(C1-C6 alkyl), phenoxy, aryloxy, benzyl, -S-aryl, -SR 1A , -NR 1A R 2A , F, Cl, Br, I, -CF3, -COR 1A, heteroaryl, heterocyclyl, or -V-OH, or each carbon atom independently has Q bonded to it. 1 and Q 2 together with Each R 1A and R 2A are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, phenyl, or benzyl; V is (CH2) t or arylene, t is 0, 1, 2, 3, or 4; Each X and Y is independently -OH, -COOH, -COOR 5 , -SO3H, [ka] and Each R 6 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl; each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups.

[0115] In some embodiments, the compound of formula (IF) has the structure shown in Table A-3, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IE) has the structure shown in Table A-7, or a pharmaceutically acceptable salt or solvate thereof, mono- or disubstituted on the phenyl with -OH or methyl groups.

[0116] Compounds of formula (IH) and (IJ) to (IL) In some embodiments, the compound of the present invention is a compound of formula (IH): [ka] or a pharmaceutically acceptable salt or solvate thereof; each p is independently 1, 2, 3, 4, 5, 6, or 7; each Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y, each c is independently 0, 1, 2, or 3; Each R 1 and R 2 is independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or each carbon atom is independently a R bonded to a carbon atom; 1 and R 2 together form a -C3-C7 cycloalkyl group, Each R 3 and R 4 is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —O(C1-C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2, or CF3, or each carbon atom is independently an R bonded to a carbon atom; 3 and R 4together form a -C3-C7 cycloalkyl group, Q is independently —OH, methyl, or methoxy; t is 1, 2, 3, or 4; Each X and Y is independently -OH, -COOH, -COOR 5 , -SO3H, [ka] and Each R 6 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl; each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups.

[0117] In some embodiments of Formula (IH), the compound has the structure of Formula (IJ), (IK), or (IL), or a pharmaceutically acceptable salt thereof. [ka]

[0118] In some embodiments of the compound of formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z2 are each independently -C(R 1 )(R 2 )-(CH2) c In some embodiments of the compound of formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 One or both of the following may be -W-(CH2) c -C(R 3 )(R 4 )-Y.

[0119] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), X is —COOH or —COOR 5 is.

[0120] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), each R 1 and R 2 is independently -C1-C6 alkyl, -C2-C6 alkenyl, or -C2-C6 alkynyl. In some embodiments of a compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), each R 1 and R 2 is independently -C1-C3 alkyl, -C2-C3 alkenyl, or -C2-C3 alkynyl. In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), R 1 and R 2 is methyl.

[0121] In some embodiments of the compound of formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 are each independently -C(R 1 )(R 2 )-(CH2) c-X, where X is -COOH or -COOR 5 and R 1 and R 2 is methyl.

[0122] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), c is 0 or 1.

[0123] In some embodiments of the compound of formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 are respectively -C(R 1 )(R 2 )-(CH2) c In some embodiments of the compound of formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 are respectively -C(R 1 )(R 2 )-(CH2) c -X, where each X is -COOH.

[0124] In some embodiments of a compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), each carbon atom independently has an R bonded to the carbon atom. 1 and R 2 and together form a -C3-C7 cycloalkyl group. In some embodiments of a compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), each carbon atom independently has an R bonded to the carbon atom. 1 and R 2 Together with

[0125] In some embodiments of the compound of formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 are respectively -C(R1 )(R 2 )-(CH2) c -X and at least one R 1 and one R 2 together with the carbon atom to which they are attached form a -C3-C7 cycloalkyl group. In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 are respectively -C(R 1 )(R 2 )-(CH2) c -X and at least one R 1 and one R 2 together with the carbon atoms to which they are attached form a cyclopropyl ring.

[0126] In some embodiments of the compound of formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), R 3 and R 4 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl.

[0127] In some embodiments of the compound of formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Y is —COOH or —COOR 5 is.

[0128] In some embodiments of the compound of formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), R 5 is -C1-C6 alkyl, -C2-C6 alkenyl, or -C2-C6 alkynyl. In some embodiments of a compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), R 5 is -C1-C3 alkyl, -C2-C3 alkenyl, or -C2-C3 alkynyl.

[0129] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), p is 3, 4, 5, 6, or 7. In some embodiments, p is 4, 5, 6, or 7.

[0130] In some embodiments of the compound of formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and one or both of Z2 is -W-(CH2) c -C(R 3 )(R 4 )-Y and R 3 and R 4 is independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl. In some embodiments of a compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 One or both of the following may be -W-(CH2) c -C(R 3 )(R 4 )-Y, where Y is -COOH or -COOR 5 In some embodiments of the compound of formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 One or both of the following may be -W-(CH2) c -C(R 3 )(R 4 )-Y, where Y is -COOH or -COOR 5 and R 5 is -C1-C6 alkyl, -C2-C6 alkenyl, or -C2-C6 alkynyl. In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 One or both of the following may be -W-(CH2) c -C(R 3 )(R 4 )-Y, where Y is -COOH or -COOR5 and R 5 is -C1-C3 alkyl, -C2-C3 alkenyl, or -C2-C3 alkynyl.

[0131] In some embodiments of compounds of Formula (IH), (IJ), (IK), or (IL), Q is independently methyl or —OH.

[0132] In some embodiments of a compound of Formula (IH), (IJ), (IK), or (IL), t is 1. In some embodiments, t is 2. In some embodiments, t is 3.

[0133] In some embodiments, the compound of Formula (IH), (IJ), (IK), or (IL) has any one of the structures shown in Table A-5, Table A-6, or Table A-7, or a pharmaceutically acceptable salt or solvate thereof. [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6] [Table 6-1] [Table 6-2] [Table 6-3] [Table 6-4] Table 6-5 Table 6-6 Table 6-7 Table 6-8 Table 6-9 Table 6-10 Table 6-11 Table 6-12 Table 6-13 Table 6-14 Table 7-1 Table 7-2 Table 7-3 Table 7-4 Table 7-5 Table 7-6 Table 7-7 Table 7-8 Table 7-9 Table 7-10 Table 7-11 Table 7-12 Table 7-13 Table 7-14 Table 7-15 Table 7-16 Table 7-17 Table 7-18 Table 7-19 Table 7-20 Table 7-21 Table 7-22 Table 7-23 Table 7-24 [Table 7-25] [Table 7-26] [Table 7-27] [Table 7-28] [Table 7-29] [Table 7-30] [Table 7-31] [Table 7-32] [Table 7-33] [Table 7-34] [Table 7-35] [Table 7-36] [Table 7-37] [Table 7-38] [Table 7-39]

[0134] Compound of formula (II) In some embodiments, the compound of the present invention is a compound of formula (II): [ka] or a pharmaceutically acceptable salt or solvate thereof; Each R 1 and R 2 is independently H, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or each carbon atom is independently a R bonded to a carbon atom; 1 and R 2 together form a -C3-C7 cycloalkyl group, each n is independently 0, 1, 2, or 3; each m is independently 1, 2, 3, 4, 5, 6, 7, 8, or 9; X is -C(=O)-, -CHR 3 -, -CH-CH2(OR 3 )-, -O-, -S-, -S(=O)-, -S(O)2-, -NR 3 -, -N(OH)-, -N(→O)-, or -Se-; R 3 is H, —OH, —O(C1-C6 alkyl), —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C7 cycloalkyl, C4-C7 cycloalkenyl, C5-C8 cycloalkynyl, phenyl, or benzyl, wherein each —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C7 cycloalkyl, C4-C7 cycloalkenyl, C5-C8 cycloalkynyl, phenyl, and benzyl is unsubstituted or substituted with one or more halogen, —CN, —NO2, or —CF3 groups; each Y is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; Each Z is independently -OH, -COOH, -COOR 5 , -SO3H, -SO3R 5 , [ka] and Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups; Each R 6 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl.

[0135] In some embodiments of the compound of Formula (II), X is —C(═O)—, —CHR 3 In some embodiments, X is -, -O-, -S-, -S(=O)-, or Se. In some embodiments, X is -C(=O)-, -CH(OH)-, -O-, -S-, -S(=O)-, or Se.

[0136] In some embodiments of the compound of Formula (II), R 3 is H, —OH, —O(C1-C3 alkyl), or —C1-C3 alkyl.

[0137] In some embodiments of the compound of Formula (II), each Y is independently —O— or —S—.

[0138] In some embodiments of the compound of Formula (II), each R 1 and R 2 is independently H, —C1-C3 alkyl, —C2-C3 alkenyl, or —C2-C3 alkynyl. In some embodiments, each R 1 and R 2 is independently H or methyl.

[0139] In some embodiments of the compound of Formula (II), each Z is independently —COOH or —COOR 5 In some embodiments, each Z is —COOH.

[0140] In some embodiments of the compound of Formula (II), each R 5 is independently —C1-C3 alkyl, —C2-C3 alkenyl, or —C2-C3 alkynyl.

[0141] In some embodiments of compounds of Formula (II), each n is independently 0, 1, or 2. In some embodiments, n is 1.

[0142] In some embodiments of the compound of Formula (II), each m is independently 3, 4, 5, or 6. In some embodiments, each m is independently 4 or 5.

[0143] In some embodiments, the compound of Formula (II) has any one of the structures shown in Table B1, or a pharmaceutically acceptable salt or solvate thereof. [Table 8-1] [Table 8-2] [Table 8-3] [Table 8-4]

[0144] Compounds of Formulae (III), (IIIA), and (IIIB) In some embodiments, the compound of the present invention is a compound of formula (III): [ka] or a pharmaceutically acceptable salt or solvate thereof; R 1 and R 2 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or R 1 and R 2 together with the carbon atom to which it is attached form a -C3-C7 cycloalkyl group, each m is independently 3, 4, 5, 6, or 7; each n is independently 0, 1, 2, 3, 4, or 5; each q is 0, 1, 2, 3, or 4; X is -O-, -S-, -S(=O)-, -S(O)2-, -NH-, -N(OH)-, -N(→O)-, N(alkyl)-, or -N(aryl)-; Z1 and Z2 are independently -C1-C6 alkyl, -OH, -COOH, -COOR 5 , -SO3H, -SO3R 5 , [ka] and Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups; Each R 6 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl.

[0145] In some embodiments, the compound of the present invention is a compound of formula (IIIA): [ka] or a pharmaceutically acceptable salt or solvate thereof; R 1 and R 2 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or R 1 and R 2 together with the carbon atom to which it is attached form a -C3-C7 cycloalkyl group, each m is independently 2, 3, 4, 5, 6, or 7; each n is independently 0, 1, 2, 3, 4, or 5; each q is 0, 1, 2, 3, or 4; X is -O-, -S-, -S(=O)-, -S(O)2-, -NH-, -N(OH)-, -N(→O)-, N(alkyl)-, or -N(aryl)-; Z1 and Z2 are -C1-C6 alkyl, -COOH, -COOR 5 , -SO3R 5 , [ka] and Z1 and Z2 are the same, Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups; Each R 6 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl.

[0146] In some embodiments, the compound of the present invention is a compound of formula (IIIB): [ka] or a pharmaceutically acceptable salt or solvate thereof; R 1 and R 2 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or R 1 and R 2 together with the carbon atom to which it is attached form a -C3-C7 cycloalkyl group, each m is independently 2, 3, 4, 5, 6, or 7; each n is independently 0, 1, 2, 3, 4, or 5; each q is 0, 1, 2, 3, or 4; X is -S-, -S(=O)-, -S(O)2-, -NH-, -N(OH)-, -N(→O)-, N(alkyl)-, or -N(aryl)-; Z1 and Z2 are independently -C1-C6 alkyl, -OH, -COOH, -COOR 5 , -SO3H, -SO3R 5 , [ka] and Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or substituted with one or more halogen, -OH, -O(C1-C6 alkyl), or phenyl groups; Each R 6are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl, wherein —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl is unsubstituted or substituted with one or two halogen, —OH, —O(C1-C6 alkyl), or phenyl groups; Each R 7 are independently H, —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl.

[0147] In some embodiments of compounds of Formula (III) and (IIIB), each Z 1 and Z 2 are independently -OH, -COOH, or -COOR 5 In some embodiments, each Z 1 and Z 2 is independently —C1-C6 alkyl.

[0148] In some embodiments of compounds of Formula (III), (IIIA), and (IIIB), Z 1 and Z 2 are the same groups, -OH, -COOH, or -COOR 5 In some embodiments, Z 1 and Z 2 are both -C1-C6 alkyl.

[0149] In some embodiments of the compound of Formula (III), X is -S-, -S(=O)-, -S(O)2-, -NH-, -N(OH)-, -N(→O)-, N(alkyl)-, or -N(aryl)-.

[0150] In some embodiments of compounds of Formula (III) and (IIIA), X is O. In some embodiments of compounds of Formula (III), when X is O, m is 2, 3, 5, 6, or 7.

[0151] In some embodiments of compounds of Formula (III), (IIIA), and (IIIB), each n is independently 0 or 1. In some embodiments, n is 0. In some embodiments, n is 1.

[0152] In some embodiments of compounds of Formula (III), (IIIA), and (IIIB), each m is independently 4, 5, or 6. In some embodiments, m is 5 or 6. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 2 or 3.

[0153] In some embodiments of compounds of Formula (III), (IIIA), and (IIIB), R 1 and R 2 together with the attached carbon atom form a -C3-C7 cycloalkyl group.

[0154] In some embodiments, the compound of Formula (III) or (IIIA) has any one of the structures shown in Table B2, or a pharmaceutically acceptable salt or solvate thereof. [Table 9]

[0155] Compositions of the Invention In some embodiments, the compositions of the present invention comprise (i) an effective amount of a compound of the present invention, and (ii) a pharmaceutically acceptable carrier or vehicle.

[0156] In some embodiments, the compositions of the present invention comprise: (i) an effective amount of a compound of formula (IA): [ka] or a pharmaceutically acceptable salt or solvate thereof, each p is independently 1, 2, 3, 4, 5, 6, or 7; Z 1 and Z2 are independently -C(R 1 )(R 2 )-(CH2) c -COOH or -C(R 1 )(R 2 )-(CH2) c -COOR 5 and each c is independently 0, 1, 2, or 3; Each R 1 and R 2 is independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, or each carbon atom is independently a R bonded to a carbon atom; 1 and R 2 together form a -C3-C7 cycloalkyl group, Each R 5 are independently -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, phenyl, or benzyl, each of which is unsubstituted or contains one or more of halogen, -OH, -O(C 1- a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is substituted with a C6 alkyl, or a phenyl group; (ii) a pharmaceutically acceptable carrier or vehicle.

[0157] In some embodiments of the composition comprising a compound of Formula (IA), each R 1 and R 2 is independently —C1-C6 alkyl, —C2-C6 alkenyl, or —C2-C6 alkynyl. In some embodiments, each R 1 and R 2 is independently -C1-C3 alkyl, -C2-C3 alkenyl, or -C2-C3 alkynyl. In some embodiments, R 1 and R 2 is methyl.

[0158] In some embodiments of the composition comprising a compound of Formula (IA), c is 0 or 1.

[0159] In some embodiments of the composition comprising a compound of Formula (IA), R 5 is -C1-C6 alkyl, -C2-C6 alkenyl, or -C2-C6 alkynyl. In some embodiments, R 5 is -C1-C3 alkyl, -C2-C3 alkenyl, or -C2-C3 alkynyl.

[0160] In some embodiments of the composition comprising a compound of Formula (IA), the compound is compound I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, or I-10, or a pharmaceutically acceptable salt or solvate thereof; [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0161] In some embodiments, the compositions of the invention comprise an effective amount of a compound having a structure as set forth in Table A-1, A-2, A-3, or A-4, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compositions of the invention comprise an effective amount of a compound having a structure as set forth in Table B1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compositions of the invention comprise an effective amount of a compound having a structure as set forth in Table B2, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compositions of the invention comprise an effective amount of a compound having a structure as set forth in Table C, or a pharmaceutically acceptable salt or solvate thereof. [Table 10]

[0162] In some embodiments, the compositions of the present invention further comprise another pharmaceutically active agent.

[0163] In some embodiments, the other pharmaceutically active agent is a statin, a thiazolidinedione or a fibrate, a bile acid-binding resin, niacin, an anti-obesity drug, a hormone, a tyrphostin, a sulfonylurea-based drug, a biguanide, an α-glucosidase inhibitor, an apolipoprotein AI agonist, an apolipoprotein E agonist, a phosphodiesterase type-5 inhibitor, a cardiovascular drug, an HDL-enhancing agent, an HDL enhancer, an agonist of the apolipoprotein AI gene or protein, an agonist of the apolipoprotein A-IV gene or protein, an agonist of an apolipoprotein gene, an ATP citrate lyase modulator, an ATP citrate lyase allosteric inhibitor, an acetyl-CoA carboxylase modulator, or an acetyl-CoA carboxylase allosteric inhibitor.

[0164] In some embodiments, the other pharmaceutically active agent is an antagonist or inhibitor of a pro-inflammatory gene or protein, or an agonist of an anti-inflammatory gene or protein. In some embodiments, the other pharmaceutically active agent inhibits or reduces the pro-inflammatory function or increases the anti-inflammatory function of IL-6, CRP, TNF-α, MCP-1, MIP-1β, CCR5, CCR2, NF-κB, or TGF-β1.

[0165] In some embodiments, the other pharmaceutically active agent affects the expression or function of a fibrotic gene or protein, or a mitotic gene or protein, hi some embodiments, the other pharmaceutically active agent modulates the expression or function of FGF-21, MMP-2, TIMP-1, ASK1, or type 3 collagen.

[0166] In some embodiments, the other pharmaceutically active agent is a regulator of a lipid metabolism-related or transport-related gene, a regulator of PPAR-α target genes such as, but not limited to, HD(ECHS1), PDK4 and Cyp7A1, a regulator of SGLT1, SGL2, ApoC-III, Sulf-2, ANGPTL3, ANGPTL4 and LPL genes.

[0167] In some embodiments, the other pharmaceutically active agent is a statin. In some embodiments, the statin is atorvastatin, simvastatin, pravastatin, rosuvastatin, fluvastatin, lovastatin, pitavastatin, mevastatin, dalvastatin, dihydrocompactin, or cerivastatin, or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is lovastatin.

[0168] In some embodiments, the other pharmaceutically active agent is a fibrate, hi some embodiments, the fibrate is fenofibrate, gemfibrozil, or fenofibric acid.

[0169] In some embodiments, the other pharmaceutically active agent is sorafenib. In yet some other embodiments, the other pharmaceutically active agent is taxol. In yet some other embodiments, the other pharmaceutically active agent is carotuximab. In yet some other embodiments, the other pharmaceutically active agent is pembrolizumab. In yet some other embodiments, the other pharmaceutically active agent is lenvatinib. In yet some other embodiments, the other pharmaceutically active agent is avelumab. In some embodiments, the other pharmaceutically active agent is durvalumab. In yet some other embodiments, the other pharmaceutically active agent is tremelimumab. In yet some other embodiments, the other pharmaceutically active agent is nivolumab. In yet some other embodiments, the other pharmaceutically active agent is a T cell receptor (TCR) immune cell therapy such as tazemetostat, cemiplimab, ABX196, LioCyx™, TBI-302, namodenoson, MM-310, tumor-injected oncolytic viruses or recombinant oncolytic viruses, including, but not limited to, telomelysin and Imligic, or an immunomodulatory gene therapy such as MDA-7 / IL-24, GLIPR1 / RTVP-1, and REIC / Dkk-3.

[0170] In yet some other embodiments, the other pharmaceutically active agent is selected from the group consisting of cenicriviroc, elafibranor, eicosapentaenoic acid, galunisertib, LY2109761, LDE225, nivolumub, filscostat, aparalenone, metformin, leucine-metformin-sildenafil combination, IMM-124E, RG-125, vitamin E, cysteamine, selonsertib, losartan, RO5093151, prazigastat, sitagliptin, vildagliptin, NGM282, pegbelfermin, PF-05231023, obeticholic acid, cilofexor, Tropifexor, EDP-305, INT-767, galactoarabino-rhamnogalacturonate, liraglutide, semaglutide, exenatide, ND-L02-s0201 / BMS-986263, vorixivato, amlexanox, PF-06835919, leptin, metreleptin, simtuzumab, tipelukast, oltipraz, MSDC-0602K, ASP9831, roflumilast, elafibranor, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanifibranor, aramchol, ipragliflozin, dapagliflozin, empagliflozin, BI1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, or nalmafene. In some embodiments, the other pharmaceutically active agent is pentamidine, berberine, L-carnitine, EYP001a, silymarin, myricolinant, ursodeoxycholic acid, metadoxine, ezetimibe, cystadan, L-alanine, saroglitazar magnesium, vorixivato, filocostat, cilofexor, elafibranor, nalmefene, solithromycin, 99mtechnetium-mebrofenin, tropifexon ol, S-adenosylmethionine, pentoxifylline, olesoxime, AKR-001, seladelpar, fisogatinib, doxorubicin, cabozantinib, deferoxamine, itacitinib, chiauranib, SF1126, anlotinib, P1101, varlitinib, SHR-1210, SHR6390, capmatinib, dabrafenib, trametinib, sapanisertib, meclizine, enzalutamide, H3B-6527, OBI-3 424, brivanib, tepotinib, temsirolimus, epacadostat, RO7119929, guadecitabine, linrodostat, copanlisib, MIV-818, borolanib, RO7070179, axitinib, sunitinib, zotiraclib citrate, sintilimab, camrelizumab, spartalizumab, toripalimab, bispecific antibody XmAb20717, mapatumumab, tremelimumab, carotuximab, tocilizumab, ipilimumab Limumab, atezolizumab, bevacizumab, ramucirumab, IBI305, asclinicalvaccumab, sitravatinib, cytokine-based biologic IRX-2, bempegaldesleukin, DKN-01, PTX-9908, AK104, PT-112, SRF388, ET1402L1-CART, glypican 3-specific chimeric antigen receptor-expressing T cells (CAR-T cells), CD147-targeting CAR-T cells, NKG2D-based CAR T cells, neoantigen-reactive T cells, Pexastimogene, Devacirepec, TalimogeneLaherparepvec, GNOS-PV02, INO-9012, ABBV-176, NCI-4650, DNAJB1-PRKACA fusion kinase peptide vaccine, or IMA970A, novantrone, prednisone, pixantrone, losoxantrone, cytidine-phosphate-guanosine (CpG) DNA, paclitaxel, oraxol, MTL-CEBPA, ribavirin, elbasvir, grazoprevir, lipotecan, ZSP1241, U3-1784, avadomide, INCAGN01949, or CMP-001.

[0171] In some embodiments, the other pharmaceutically active agent is an anti-cancer agent. In some embodiments, the anti-cancer agent is sorafenib, taxol, lenvatinib, tazemetostat, TBI-302, namodenoson, MM-310, cenicriviroc, elafibranor, eicosapentaenoic acid, galunisertib, LY2109761, LDE225, filsocostat, aparalenone, metformin, leucine-metformin-sildenafil combination, vitamin E, cysteamine, selonsertib, losartan, RO5093151, prazigastat, sitagliptin, vildagliptin, NGM282, pegbelfermin, PF-05231023, or ointment. Beticholic acid, cilofexor, tropifexor, EDP-305, INT-767, galactoarabino-rhamnogalacturonate, liraglutide, semaglutide, exenatide, vorixivato, amlexanox, PF-06835919, leptin, metreleptin, simtuzumab, tipelukast, oltipraz, MSDC-0602K, ASP9831, roflumilast, elafibranor, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanifibranor, aramchol, ipragliflozin, dapagliflozin, empagliflozin, BI1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, nalmafene, pentamidine, berberine, L-carnitine, EYP001a, silymarin, myricolinant, ursodeoxycholic acid, metadoxine, ezetimibe, cystadan, L-alanine, saroglitazar magnesium, vorixiva, elafibranor, nalmefene, solithromycin, 99mTechnetium-Mebrofenin, S-Adenosylmethionine, pentoxifylline, olesoxime, AKR-001, seladelpearl, fisogatinib, doxorubicin rubicin, cabozantinib, deferoxamine, itacitinib, tiauranib, SF1126, anlotinib, P1101, vallitinib, SHR-1210, SHR6390, capmatinib, dabrafenib, trametinib, sapanisertib, meclizine, enzalutamide, H3B-6527, OBI-3424, brivanib, tepotinib, temsirolimus, epacadostat, RO7119929, guadecitabine, linrodostat, copanlisib, MIV-818, borolanib, RO7070179, axitinib, sunitinib, or zotiraclib citrate.

[0172] In some embodiments, the compositions of the present invention further comprise an anti-cancer agent.

[0173] In some embodiments, the other pharmaceutically active agent is an immunotherapeutic agent. In some embodiments, the immunotherapeutic agent is selected from the group consisting of pembrolizumab, avelumab, durvalumab, nivolumab, cemiplimab, ABX196, sintilimab, camrelizumab, spartalizumab, toripalimab, bispecific antibody XmAb20717, mapatumumab, tremelimumab, carotuximab, tocilizumab, ipilimumab, atezolizumab, bevacizumab, ramucirumab, IBI305, ascribacumab, TCR These include T-cell therapy, sitravatinib, cytokine-based biologic IRX-2, bempegaldesleukin, DKN-01, PTX-9908, AK104, PT-112, SRF388, ET1402L1-CART, glypican 3-specific chimeric antigen receptor-expressing T cells (CAR-T cells), CD147-targeted CAR-T cells, NKG2D-based CAR T cells, or neoantigen-reactive T cells.

[0174] In some embodiments, the compositions of the invention further comprise an immunotherapeutic agent.

[0175] In some embodiments, the other pharmaceutically active agent is an oncogenic virus. In some embodiments, the oncogenic virus is Pexastimogene Devacirepvec or Talimogene Laherparepvec. In some embodiments, the composition of the present invention further comprises an oncogenic virus.

[0176] In some embodiments, the other pharmaceutically active agent is a vaccine. In some embodiments, the vaccine is GNOS-PV02, INO-9012, ABBV-176, NCI-4650, DNAJB1-PRKACA fusion kinase peptide vaccine, or IMA970A. In some embodiments, the composition of the present invention further comprises a vaccine.

[0177] In some embodiments, the other pharmaceutically active agent is novantrone, prednisone, pixantrone, losoxantrone, cytidine-phosphate-guanosine (CpG) DNA, paclitaxel, oraxol, MTL-CEBPA, ribavirin, elbasvir, grazoprevir, lipotecan, ZSP1241, U3-1784, avadomide, INCAGN01949, or CMP-001.

[0178] In some embodiments, the compositions of the present invention further comprise two or more other pharmaceutically active agents, which in some embodiments are oncolytic agents, such as, but not limited to, nanatinostat and valganciclovir.

[0179] In some embodiments, the compositions of the present invention further comprise as a pharmaceutically active agent sorafenib, taxol, lenvatinib, tazemetostat, TBI-302, namodenoson, MM-310, cenicriviroc, elafibranor, eicosapentaenoic acid, galunisertib, LY2109761, LDE225, filsocostat, aparalenone, metformin, leucine-metformin-sildenafil combination, vitamin E, cysteamine, selonsertib, losartan, RO5093151, prazigastat, sitagliptin, vildagliptin, NGM282, pegbelfermin, PF-05 231023, obeticholic acid, cilofexor, tropifexor, EDP-305, INT-767, galactoarabino-rhamnogalacturonate, liraglutide, semaglutide, exenatide, vorixivato, amlexanox, PF-06835919, leptin, metreleptin, simtuzumab, tipelukast, oltipraz, MSDC-0602K, ASP9831, roflumilast, elafibranor, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanifibranor, aramchol, ipragliflozin, dapagliflozin, empagliflozin, BI 1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, nalmafene, pentamidine, berberine, L-carnitine, EYP001a, silymarin, myricolinant, ursodeoxycholic acid, metadoxine, ezetimibe, cystadan, L-alanine, saroglitazar magnesium, vorixivato, elafibranor, nalmefene, solithromycin, 99mTechnetium-Mebrofenin, S-Adenosylmethionine, pentoxifylline , oresoxime, AKR-001, seladelpearl, fisogatinib, doxorubicin, cabozantinib, deferoxamine, itacitinib, tiauranib, SF1126, anlotinib, P1101, varlitinib, SHR-1210, SHR6390, capmatinib, dabrafenib, trametinib, sapanisertib, meclizine, enzalutamide, H3B-6527, OBI-3424, brivanib, tepotinib, temsirolimus, epacadostat, RO7119929, guadecitabine,including linrodostat, copanlisib, MIV-818, borolanib, RO7070179, axitinib, sunitinib, or zotiraclib citrate. In some embodiments of the compositions of the present invention, the composition comprises (a) Compound I-1, Compound I-32, Compound I-61, or Compound III-1, or a pharmaceutically acceptable salt or solvate thereof; and (b) as the pharmaceutically active agent, sorafenib, taxol, lenvatinib, tazemetostat, TBI-302, namodenoson, MM-310, cenicriviroc, elafibranor, eicosapentaenoic acid, galunisertib, LY2109761, LDE225, filosocostat, aparalenone, metformin, leucine-metformin-sildenafil combination, vitamin E, cysteamine, selonsertib, losartan, RO5093151, prazigastat, sitagliptin, or the like. tin, vildagliptin, NGM282, pegbelfermin, PF-05231023, obeticholic acid, cilofexor, tropifexor, EDP-305, INT-767, galactoarabino-rhamnogalacturonate, liraglutide, semaglutide, exenatide, vorixibate, amlexanox, PF-06835919, leptin, metreleptin, simtuzumab, tipelukast, oltipraz, MSDC-0602K, ASP9831, roflumilast, elafibranor, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanifibranor, aramchol, ipragliflozin, dapagliflozin, empagliflozin, BI 1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, nalmafene, pentamidine, berberine, L-carnitine, EYP001a, silymarin, myricolinant, ursodeoxycholic acid, metadoxine, ezetimibe, cystadan, L-alanine, saroglitazar magnesium, vorixiva, elafibranor, nalmefene, solithromycin, 99m technetium-mebrofenin, S-adenosylmethionine, pentoxifylline, oresoxime, AKR-001, seladelpearl, fisogatinib, doxorubicin, cabozantinib, deferoxamine, itacitinib, tiauranib, SF1126, anlotinib,P1101, vallitinib, SHR-1210, SHR6390, capmatinib, dabrafenib, trametinib, sapanisertib, meclizine, enzalutamide, H3B-6527, OBI-3424, brivanib, tepotinib, temsirolimus, epacadostat, RO7119929, guadecitabine, linrodostat, copanlisib, MIV-818, borolanib, RO7070179, axitinib, sunitinib, or zotiraclib citrate.

[0180] In some embodiments of the compositions of the invention, the composition comprises a compound of the invention and sorafenib, taxol, carotuximab, pembrolizumab, lenvatinib, avelumab, durvalumab, tremelimumab, nivolumab, tazemetostat, cemiplimab, ABX196, a T-cell receptor (TCR) immune cell therapy, TBI-302, namodenoson, MM-310, a tumor-injected oncolytic virus or a genetically engineered oncolytic virus, or an immunomodulatory gene therapy agent as the pharmaceutically active agent. In some embodiments, the composition comprises (a) compound I-1, compound I-32, compound I-61, or compound III-1, or a pharmaceutically acceptable salt or solvate thereof; and (b) a pharmaceutically active agent selected from sorafenib, taxol, carotuximab, pembrolizumab, lenvatinib, avelumab, durvalumab, tremelimumab, nivolumab, tazemetostat, cemiplimab, ABX196, a T-cell receptor (TCR) immune cell therapy, TBI-302, namodenoson, MM-310, a tumor-injected oncolytic virus or a genetically engineered oncolytic virus, or an immunomodulatory gene therapy agent.

[0181] In some embodiments of the compositions of the present invention, the composition comprises a compound of the present invention and sorafenib or lenvatinib. In some embodiments, the composition comprises (a) compound I-1, compound I-32, compound I-61, or compound III-1, or a pharmaceutically acceptable salt or solvate thereof, and (b) sorafenib or lenvatinib. In some embodiments, the composition comprises (a) compound I-1, or a pharmaceutically acceptable salt or solvate thereof, and (b) sorafenib or lenvatinib. In some embodiments, the composition comprises (a) compound I-32, or a pharmaceutically acceptable salt or solvate thereof, and (b) sorafenib or lenvatinib. In some embodiments, the composition comprises (a) compound I-32, or a pharmaceutically acceptable salt or solvate thereof, and (b) sorafenib or lenvatinib. In some embodiments, the composition comprises (a) compound I-32, or a pharmaceutically acceptable salt or solvate thereof, and (b) sorafenib. In some embodiments, the composition comprises (a) compound I-32, or a pharmaceutically acceptable salt or solvate thereof, and (b) lenvatinib. In some embodiments, the composition comprises (a) compound I-61, or a pharmaceutically acceptable salt or solvate thereof, and (b) sorafenib or lenvatinib. In some embodiments, the composition comprises (a) compound I-61, or a pharmaceutically acceptable salt or solvate thereof, and (b) sorafenib. In some embodiments, the composition comprises (a) compound I-61, or a pharmaceutically acceptable salt or solvate thereof, and (b) lenvatinib. In some embodiments, the composition comprises (a) compound III-1, or a pharmaceutically acceptable salt or solvate thereof, and (b) sorafenib or lenvatinib.

[0182] Table D shows embodiments A1-A4, B1-B4, C1-C4, D1-D4, E1-E4, F1-F4, G1-G4, H1-H4, I1-I4, J1-J4, K1-K4, L1-L4, M1-M4, N1-N4, O1-O4, P1-P4, Q1-Q4, R1-R4, and S1-S4. Each embodiment of Table D refers to a particular compound of the invention and another pharmaceutically active agent. For example, embodiment A1 refers to compound I-1 (or a pharmaceutically acceptable salt or solvate thereof) and sorafenib, embodiment A2 refers to compound I-32 (or a pharmaceutically acceptable salt or solvate thereof) and sorafenib, etc. In some embodiments, compositions of the invention comprise an effective amount of a compound of the invention described in an embodiment of Table D and another pharmaceutically active agent. [Table 11]

[0183] In some embodiments, pharmaceutically acceptable carriers or vehicles include, but are not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, colorants, dye transfer inhibitors, sweetening agents, or flavoring agents.

[0184] Binders or granulating agents provide cohesiveness to the tablet so that it remains intact after compression. Suitable binders or granulating agents include, but are not limited to, starches such as corn starch, potato starch, and pregelatinized starch (e.g., STARCH 1500), gelatin, sugars such as sucrose, glucose, dextrose, molasses, and lactose, acacia, alginic acid, alginates, extract of Irish moss, Panwar gum, ghatti gum, mucilage of isabgol husk, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP), veegum, larch arabogalactan, and the like. natural and synthetic gums such as arabogalactan, powdered tragacanth, and guar gum; celluloses such as ethyl cellulose, cellulose acetate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC); microcrystalline celluloses such as AVICEL-PH-101, AVICEL-PH-103, AVICEL RC-581, AVICEL-PH-105 (FMC Corp., Marcus Hook, PA), and mixtures thereof.

[0185] Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrate, kaolin, mannitol, silicic acid, sorbitol, starch, pregelatinized starch, and mixtures thereof. In some embodiments, the binder is hydroxypropyl cellulose.

[0186] The binder or filler can be present in the compositions of the present invention from about 2% to about 49% by weight, or any range within these values. In some embodiments, the binder or filler is present in the compositions of the present invention from about 5% to about 15% by weight. In some embodiments, the binder or filler is present in the compositions of the present invention at about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% by weight, or any range within any of these values.

[0187] Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar. Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol, when present in sufficient amounts, can impart properties to some compressed tablets that allow them to disintegrate in the mouth by chewing. Such compressed tablets can be used as chewable tablets. In some embodiments, the diluent is lactose monohydrate. In some embodiments, the diluent is lactose monohydrate Fast-Flo 316 NF.

[0188] The compositions of the present invention can include a diluent, for example, from about 5% to about 49% by weight of the composition, or any range between any of these values. In some embodiments, the diluent is present in the compositions of the present invention at about 15% to about 30% by weight. In some embodiments, the diluent is present in the compositions of the present invention at about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% by weight, or any range within any of these values.

[0189] Suitable disintegrants include, but are not limited to, agar, bentonite, celluloses such as methylcellulose and carboxymethylcellulose, wood products, natural sponge, cation exchange resins, alginic acid, gums such as guar gum and Veegum HV, citrus pulp, cross-linked celluloses such as croscarmellose, cross-linked polymers such as crospovidone, cross-linked starch, calcium carbonate, microcrystalline cellulose such as sodium starch glycolate, polacrilin potassium, starches such as corn starch, potato starch, tapioca starch, and pregelatinized starch, clays, algins, and mixtures thereof. The amount of disintegrant in the compositions of the present invention can vary. In some embodiments, the disintegrant is croscarmellose sodium. In some embodiments, the disintegrant is croscarmellose sodium NF (Ac-Di-Sol).

[0190] The compositions of the present invention can include a disintegrant, for example, from about 0.5% to about 15% or from about 1% to about 10% by weight of disintegrant, hi some embodiments, the compositions of the present invention include a disintegrant in an amount of about 5%, 6%, 7%, 8%, 9%, 8%, 10%, 11%, 12%, 13%, 14%, or 15% by weight of the composition, or any range within any of these values.

[0191] Suitable lubricants include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, glycols such as sorbitol, mannitol, glycerol behenate, and polyethylene glycol (PEG), stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oils such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil, zinc stearate, ethyl oleate, ethyl laurate, agar, starch, lycopodium, silica or silica gel, such as AEROSIL® 200 (WR Grace Co., Baltimore, MD) and CAB-O-SIL® (Cabot Co., Boston, MA), and mixtures thereof. In some embodiments, the lubricant is magnesium stearate.

[0192] The compositions of the present invention can include a lubricant, for example, about 0.1 to about 5% by weight of a lubricant. In some embodiments, the compositions of the present invention include a lubricant in an amount of about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, or 3.0% by weight of the composition, or any range within any of these values.

[0193] Suitable glidants include colloidal silicon dioxide, CAB-O-SIL® (Cabot Co. of Boston, Mass.), and talc (such as asbestos-free talc).

[0194] Coloring agents include any of the approved, certified, water-soluble FD&C dyes and water-insoluble FD&C dyes suspended on alumina hydrate, and lake colors, and mixtures thereof.

[0195] Flavoring agents include natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which provide a pleasant taste sensation, such as peppermint and methyl salicylate.

[0196] Sweetening agents include sucrose, lactose, mannitol, syrups, glycerin, sucralose, and artificial sweeteners, such as saccharin and aspartame.

[0197] Suitable emulsifying agents include gelatin, acacia, tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate (TWEEN® 20), polyoxyethylene sorbitan monooleate 80 (TWEEN® 80), and triethanolamine oleate. Suspending and dispersing agents include sodium carboxymethylcellulose, pectin, tragacanth, Veegum, acacia, sodium carbomethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Preservatives include glycerin, methyl and propylparaben, benzoic acid additive, sodium benzoate, and alcohol. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether.

[0198] Solvents include glycerin, sorbitol, ethyl alcohol, and syrup.

[0199] Examples of non-aqueous liquids utilized in emulsions include mineral oil and cottonseed oil. Organic acids include citric acid and tartaric acid. Sources of carbon dioxide include sodium bicarbonate and sodium carbonate.

[0200] The compounds and compositions of the present invention can be formulated into formulations containing pharmaceutically acceptable carriers, adjuvants, and vehicles for various means of administration, for example, orally, parenterally, by inhalation spray, topically, or rectally. As used herein, the term "parenteral" includes subcutaneous, intravenous, intramuscular, and intraarterial injections using various infusion techniques. As used herein, intraarterial and intravenous infusions include administration via a catheter.

[0201] The compounds and compositions of the present invention can be formulated according to conventional procedures compatible with the desired route of administration. Thus, the compositions of the present invention can take the form of suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing, and / or dispersing agents. The compounds and compositions of the present invention can be formulated as preparations suitable for implantation or injection. Thus, for example, the compositions of the present invention can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., as a sparingly soluble salt). The compounds and compositions of the present invention may also be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use. Suitable formulations for each of these administration methods can be found, for example, in Remington: The Science and Practice of Pharmacy, A. Gennaro, ed., 20th edition, Lippincott, Williams & Wilkins, Philadelphia, PA.

[0202] In some embodiments, the compositions of the present invention are suitable for oral administration. These compositions can include solid, semi-solid, gel matrix, or liquid dosage forms suitable for oral administration. As used herein, oral administration includes buccal, lingual, and sublingual administration. Suitable oral dosage forms include, but are not limited to, tablets, capsules, pills, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, granules, bulk powders, effervescent or non-effervescent powders or granules, solutions, emulsions, suspensions, solutions, wafers, sprinkles, elixirs, syrups, or any combination thereof. In some embodiments, the compositions of the present invention are suitable for oral administration in the form of a tablet or capsule. In some embodiments, the compositions of the present invention are in the form of a tablet. In some embodiments, the compositions of the present invention are in the form of a capsule. In some embodiments, the compound of the present invention is contained in a capsule.

[0203] In some embodiments, the capsule is an immediate release capsule. A non-limiting example of a capsule is a coni-snap® hard gelatin capsule.

[0204] The compositions of the present invention may be in the form of compressed tablets, powder tablets, chewable lozenges, quick-dissolve tablets, multiple compressed tablets, or enteric-coated, sugar-coated, or film-coated tablets. Enteric-coated tablets are compressed tablets coated with a substance that resists the action of stomach acid but dissolves or disintegrates in the intestine, thus protecting the active ingredient from the acidic environment of the stomach. Enteric coatings include, but are not limited to, fatty acids, fats, phenyl salicylates, waxes, shellac, ammonium shellac, and cellulose acetate phthalate. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which can be beneficial for masking unpleasant tastes or odors and protecting the tablets from oxidation. Film-coated tablets are compressed tablets covered with a thin layer or film of a water-soluble material. Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coatings can impart the same general properties as sugar coatings. Multiple compressed tablets are compressed tablets made by multiple compression cycles, including layered tablets and press-coated or dry-coated tablets.

[0205] In some embodiments, the coating is a film coating. In some embodiments, the film coating comprises Opadry White and simethicone emulsion 30% USP.

[0206] In some embodiments, the compounds of the present invention are contained in a tablet. In some embodiments, the compounds of the present invention are contained in a compressed tablet. In some embodiments, the compounds of the present invention are contained in a film-coated compressed tablet. In some embodiments, the compositions of the present invention are in the form of a film-coated compressed tablet.

[0207] In some embodiments, compositions of the present invention are prepared by fluid-bed granulation of a compound of the present invention with one or more pharmaceutically acceptable carriers, vehicles, or excipients. In some embodiments, compositions of the present invention prepared by a fluid-bed granulation process can provide tablet formulations with good flowability, good compressibility, rapid dissolution, good stability, and / or minimal to no cracking. In some embodiments, a fluid-bed granulation process allows for the preparation of formulations with high drug loadings of the compound of the present invention, such as greater than 70% or greater than 75%.

[0208] The compositions of the present invention can be in the form of soft or hard capsules, which can be made from gelatin, methylcellulose, starch, or calcium alginate. Hard gelatin capsules, also known as dry-filled capsules (DFCs), can contain two sections, one slipping over the other, completely enclosing the active ingredient. Soft elastic capsules (SECs) are soft, spherical shells, such as gelatin shells, plasticized by adding glycerin, sorbitol, or similar polyols. Soft gelatin shells can contain preservatives to prevent microbial growth. Suitable preservatives are as described herein, including methyl and propyl parabens and sorbic acid. The liquid, semisolid, and solid dosage forms provided herein can be encapsulated. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils, or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Patent Nos. 4,328,245, 4,409,239, and 4,410,545. The capsules can also be coated as known to those skilled in the art to control or maintain dissolution of the active ingredient.

[0209] The compositions of the present invention can be in liquid or semisolid dosage forms, such as emulsions, solutions, suspensions, elixirs, and syrups. Emulsions can be two-phase systems in which one liquid is dispersed in the form of small globules throughout another liquid, and can be oil-in-water or water-in-oil. Emulsions can contain a pharmaceutically acceptable non-aqueous liquid or solvent, an emulsifier, and a preservative. Suspensions can contain a pharmaceutically acceptable suspending agent and a preservative. Hydroalcoholic solutions can contain a pharmaceutically acceptable acetal, e.g., a di-(lower alkyl) acetal of a lower alkyl aldehyde (the term "lower" means an alkyl having 1 to 6 carbon atoms), such as acetaldehyde diethyl acetal, and a water-miscible solvent having one or more hydroxyl groups, such as propylene glycol and ethanol. Elixirs can be clear, sweetened, and hydroalcoholic solutions. Syrups can be concentrated aqueous solutions of a sugar, e.g., sucrose, and can contain a preservative. For a liquid dosage form, the solution, for example, in a polyethylene glycol, may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g., water, to be conveniently measured for administration.

[0210] The compositions of the present invention for oral administration can also be provided in the form of liposomes, micelles, microspheres, or nanosystems. Micelle dosage forms can be prepared as described in U.S. Patent No. 6,350,458.

[0211] The compositions of the present invention can be provided as non-effervescent or effervescent granules and powders to be reconstituted into a liquid dosage form. Pharmaceutically acceptable carriers and excipients used in non-effervescent granules or powders can include diluents, sweeteners, and wetting agents. Pharmaceutically acceptable carriers and excipients used in effervescent granules or powders can include organic acids and a carbon dioxide source.

[0212] Coloring and flavoring agents can be used in all of the above dosage forms, and flavoring and sweetening agents are especially useful in the formation of chewable tablets and lozenges.

[0213] The compositions of the invention may be formulated as immediate or modified release, including delayed-, sustained-, pulsed-, controlled-, targeted-, and programmed-release.

[0214] In some embodiments, the compositions of the present invention include a film coating.

[0215] The compositions of the present invention may contain other active ingredients that do not impair the therapeutic or prophylactic efficacy of the composition, or may contain substances that enhance or complement the effectiveness of the composition.

[0216] The tablet dosage form may contain a compound of the invention in powdered, crystalline, or granular form and may further include a carrier or vehicle as described herein, such as a binder, disintegrant, controlled-release polymer, lubricant, diluent, or colorant.

[0217] In some embodiments, the compositions of the present invention can further comprise excipients such as diluents, disintegrants, wetting agents, binders, glidants, lubricants, or any combination thereof. In some embodiments, the tablet comprises a binder. Also, in some embodiments, the binder comprises microcrystalline cellulose, dibasic calcium phosphate, sucrose, corn starch, polyvinylpyridone, hydroxypropyl cellulose, hydroxymethyl cellulose, or any combination thereof. In other embodiments, the tablet comprises a disintegrant. In other embodiments, the disintegrant comprises croscarmellose sodium, sodium starch glycolate, or any combination thereof. In other embodiments, the tablet comprises a lubricant. In some embodiments, the lubricant comprises magnesium stearate stearic acid, hydrogenated oil, sodium stearyl fumarate, or any combination thereof.

[0218] In some embodiments, a composition of the present invention is in the form of a tablet that includes a binder, eg, any of the binders described herein.

[0219] In some embodiments, the compositions of the present invention are in the form of a tablet that includes a disintegrant, eg, any of the disintegrants described herein.

[0220] In some embodiments, the compositions of the present invention are in the form of a tablet that includes a lubricant, for example, any of the lubricants described herein.

[0221] In some embodiments, the compositions of the present invention may be in a modified-release or controlled-release dosage form. In some embodiments, the compositions of the present invention may contain particles that exhibit a specific release profile. For example, the compositions of the present invention may contain an immediate-release form of a compound of the present invention and a modified-release form of a statin or a pharmaceutically acceptable salt thereof, both of which are compressed into a single tablet. Other combinations and modifications of the release profile may be implemented as understood by those skilled in the art. Examples of modified release dosage forms suitable for the pharmaceutical compositions of the present invention include, but are not limited to, those described in U.S. Pat. Nos. 3,845,770, 3,916,899, 3,536,809, 3,598,123, 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, 5,639,480, 5,733,566, 5,739,108, Nos. 5,891,474, 5,922,356, 5,972,891, 5,980,945, 5,993,855, 6,045,830, 6,087,324, 6,113,943, 6,197,350, 6,248,363, 6,264,970, 6,267,981, 6,376,461, 6,419,961, 6,589,548, 6,613,358, and 6,699,500.

[0222] In some embodiments, the compositions of the present invention are matrix controlled-release dosage forms. For example, the compositions of the present invention can contain about 300 mg to about 600 mg of the compound of the present invention provided as a matrix controlled-release form. In some embodiments, the matrix controlled-release form can further contain another pharmaceutically active agent. In some embodiments, the release profiles of the compound of the present invention and the other pharmaceutically active agent are the same or different. Suitable matrix controlled-release dosage forms are described, for example, in Takada et al., "Encyclopedia of Controlled Drug Delivery," Vol. 2, Mathiowitz ed., Wiley, 1999.

[0223] In some embodiments, the compositions of the present invention comprise about 10 mg to about 400 mg of another pharmaceutically active agent and about 300 mg to about 600 mg of a compound of the present invention. In some embodiments, the compositions of the present invention comprise about 10 mg to about 400 mg of an anticancer agent and about 300 mg to about 600 mg of a compound of the present invention. In some embodiments, the compositions are in a matrix-controlled modified-release dosage form.

[0224] In some embodiments, the compositions of the invention comprise about 10 mg to about 40 mg of a statin and about 300 mg to about 600 mg of a compound of the invention, wherein the composition is in a matrix-controlled modified-release dosage form.

[0225] In some embodiments, the matrix controlled-release form comprises an erodible matrix comprising water-swellable, erodible, or soluble polymers, including synthetic polymers and naturally occurring polymers and derivatives such as polysaccharides and proteins.

[0226] In some embodiments, the erodible matrix of the matrix controlled-release form is selected from the group consisting of chitin, chitosan, dextran or pullulan, gum agar, gum arabic, gum karaya, locust bean gum, tragacanth gum, carrageenan, gum ghatti, guar gum, xanthan gum or scleroglucan, starch (e.g., dextrin or maltodextrin), hydrocolloids (e.g., pectin), phosphatides (e.g., lecithin), alginate, propylene glycol alginate, gelatin, collagen, cellulosics (e.g., ethyl cellulose (EC), methyl ethyl cellulose (MEC), carboxymethyl cellulose (CMC), carboxymethyl ethyl cellulose (CMEC), hydroxyethyl cellulose (HEC), hydrogels, and the like. Examples of suitable cellulose copolymers include hydroxypropyl cellulose (HPC), cellulose acetate (CA), cellulose propionate (CP), cellulose butyrate (CB), cellulose acetate butyrate (CAB), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose (HPMC), HPMCP, HPMCAS, hydroxypropyl methylcellulose acetate trimellitate (HPMCAT) or ethyl hydroxyethyl cellulose (EHEC), polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, glycerin fatty acid esters, polyacrylamide, polyacrylic acid, copolymers of ethacrylic acid or methacrylic acid (EUDRAGIT® (Rohm The polymers include, for example, polymers of acrylic acid such as acrylic acid copolymers, ...

[0227] In other embodiments, the compositions of the present invention are matrix-controlled modified-release forms comprising a non-erodible matrix. In some embodiments, the statin compounds of the present invention are dissolved or dispersed in an inert matrix and, after administration, are released primarily by diffusion through the inert matrix. In some embodiments, the non-erodible matrix of the matrix-controlled modified-release form is an insoluble polymer, such as polyethylene, polypropylene, polyisoprene, polyisobutylene, polybutadiene, polymethyl methacrylate, polybutyl methacrylate, chlorinated polyethylene, polyvinyl chloride, methyl acrylate-methyl methacrylate copolymer, ethylene-vinyl acetate copolymer, ethylene / propylene copolymer, ethylene / ethyl acrylate copolymer, vinyl chloride-vinyl acetate copolymer, vinylidene chloride, ethylene or propylene, ionomer polyethylene terephthalate, butyl rubber, epichlorohydrin, etc. rubber, ethylene / vinyl alcohol copolymer, ethylene / vinyl acetate / vinyl alcohol terpolymer, ethylene / vinyloxyethanol copolymer, polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, silicone rubber, polydimethylsiloxane, silicone carbonate copolymer, or a hydrophilic polymer such as ethyl cellulose, cellulose acetate, crospovidone or cross-linked partially hydrolyzed polyvinyl acetate, an aliphatic compound (e.g., carnauba wax, microcrystalline wax or triglyceride), or any combination thereof.

[0228] The compositions of the present invention that are modified release dosage forms can be prepared by methods known to those skilled in the art, such as direct compression, dry or wet granulation followed by compression, melt granulation followed by compression, and the like.

[0229] In some embodiments, the compositions of the present invention include a tablet-in-capsule system, which can be a multi-function, multi-unit system containing multiple-use minitablets in a hard gelatin capsule. The minitablets can be immediate-release, sustained-release, pulsed-release, delayed-sustained-release minitablets, or any combination thereof. In some embodiments, combinations of minitablets or combinations of minitablets and minibeads containing multiple active agents can have specific lag times, such as multiple pulse-release drug delivery systems (DDSs), site-specific DDSs, delayed-fast DDSs, fast / delayed DDSs, and zero-order DDSs.

[0230] In some embodiments, the compositions of the present invention are in an osmotic controlled release dosage form.

[0231] In some embodiments, the osmotically controlled release device comprises a one-chamber system, a two-chamber system, an asymmetric membrane technology (AMT), an extruded core system (ECS), or any combination thereof. In some embodiments, such a device comprises at least two components: (a) a core containing an active agent(s), and (b) a semipermeable membrane having at least one delivery port that encapsulates the core. The semipermeable membrane controls the influx of water from an aqueous environment into the core during use to cause drug release by extrusion through the delivery port(s).

[0232] In some embodiments, the core of the osmotic device optionally comprises an osmotic agent, which creates a driving force for the transport of water from the environment of use of the device into the core. One class of osmotic agents useful in the compositions of the present invention comprises water-swellable hydrophilic polymers, also referred to as "osmopolymers" or "hydrogels," including, but not limited to, hydrophilic vinyl and acrylic polymers, polysaccharides (e.g., calcium alginate), polyethylene oxide (PEO), polyethylene glycol (PEG), polypropylene glycol (PPG), poly(2-hydroxyethyl methacrylate), poly(acrylic) acid, poly(methacrylic) acid, polyvinylpyrrolidone (PVP), crosslinked PVP, polyvinyl alcohol (PVA), PVA / PVP copolymers, PVA / PVP copolymers with hydrophobic monomers (e.g., methyl methacrylate and vinyl acetate), hydrophilic polyurethanes containing large PEO blocks, sodium croscarmellose, carrageenan, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose (CMC), and carboxyethyl cellulose (CEC), sodium alginate, polycarbophil, gelatin, xanthan gum, and sodium starch glycolate.

[0233] Another class of osmogens useful in the compositions of the present invention includes osmogens capable of imbibing water to affect an osmotic pressure gradient across the barrier of the surrounding coating. Suitable osmogens include, but are not limited to, inorganic salts (e.g., magnesium sulfate, magnesium chloride, calcium chloride, sodium chloride, lithium chloride, potassium sulfate, potassium phosphate, sodium carbonate, sodium sulfite, lithium sulfate, potassium and sodium chloride), sugars (e.g., dextrose, fructose, glucose, inositol, lactose, maltose, mannitol, raffinose, sorbitol, sucrose, trehalose and xylitol), organic acids (e.g., ascorbic acid, benzoic acid, fumaric acid, citric acid, maleic acid, sebacic acid, sorbic acid, adipic acid, edetic acid, glutamic acid, p-toluenesulfonic acid, succinic acid and tartaric acid), urea, and mixtures thereof.

[0234] Osmotic agents with different dissolution rates can be used to affect the rapid dissolution of the compounds of the invention after administration. For example, the inclusion of an amorphous sugar, such as Mannogeme EZ (SPI Pharma, Lewis, DE), can provide more rapid delivery during the first few hours (e.g., about 1 to about 5 hours) to rapidly produce prophylactic or therapeutic efficacy, followed by a gradual and continuous release of the remaining amount to maintain a desired level of therapeutic or prophylactic efficacy over an extended period of time. In some embodiments, the compounds of the invention are released from the compositions of the invention at a rate that replaces the amount of compound of the invention metabolized or excreted by the subject.

[0235] The core can also contain a wide variety of other excipients and carriers as described herein to enhance the performance of the dosage form or improve stability or processability.

[0236] Materials useful for forming semipermeable membranes include various grades of acrylics, vinyls, ethers, polyamides, polyesters, and cellulose derivatives, which are either water-permeable and water-insoluble at physiologically relevant pH or readily rendered water-insoluble by chemical alteration, such as crosslinking. Examples of suitable polymers useful for forming coatings include plasticized, unplasticized, and reinforced cellulose acetate (CA), cellulose diacetate, cellulose triacetate, CA propionate, nitrocellulose, cellulose acetate butyrate (CAB), CA ethyl carbamate, CAP, CA methyl carbamate, CA succinate, cellulose acetate trimellitate (CAT), CA dimethylaminoacetate, CA ethyl carbonate, CA chloroacetate, CA ethyl oxalate, CA methyl sulfonate, CA butyl sulfonate, CA p-toluenesulfonate, agar acetate, amylose triacetate, beta-glucan acetate, beta-glucan triacetate, acetaldehyde dimethyl acetate, locust bean gum triacetate, hydroxylated ethylene-vinyl acetate, EC, PEG, PPG, PEG / PPG copolymers, PVP, HEC, HPC, CMC, CMEC, HPMC, HPMCP, HPMCAS, HPMCAT, poly(acrylic) acids and esters and poly(methacrylic) acids and esters and copolymers thereof, starch, dextran, dextrin, chitosan, collagen, gelatin, polyalkenes, polyethers, polysulfones, polyethersulfones, polystyrene, polyvinyl halides, polyvinyl esters and ethers, natural waxes and synthetic waxes.

[0237] The semipermeable membrane can be a hydrophobic microporous membrane, the pores of which are substantially gas-filled and not wetted by aqueous media, but which is permeable to water vapor, as disclosed in U.S. Patent No. 5,798,119. Such hydrophobic but water vapor-permeable membranes are typically composed of hydrophobic polymers such as polyalkenes, polyethylene, polypropylene, polytetrafluoroethylene, polyacrylic acid derivatives, polyethers, polysulfones, polyethersulfones, polystyrene, polyvinyl halides, polyvinylidene fluoride, polyvinyl esters and ethers, natural waxes, and synthetic waxes.

[0238] The delivery port(s) on the semipermeable membrane can be formed by post-coating, either mechanically or by laser drilling. The delivery port(s) can also be formed in situ by erosion of a plug of water-soluble material or by a thinner portion of the membrane rupturing over a depression in the core. In addition, the delivery port(s) can be formed during the coating process, as in the case of asymmetric membrane coatings of the type disclosed in U.S. Patent Nos. 5,612,059 and 5,698,220.

[0239] The total amount and rate of release of the compounds of the present invention can be substantially controlled through the thickness and porosity of the semipermeable membrane, the composition of the core, and the number, size, and location of the delivery ports.

[0240] In some embodiments, the osmotic controlled-release dosage form of the pharmaceutical composition can further comprise additional conventional excipients described herein to facilitate performance or processing of the formulation.

[0241] Osmotic controlled release dosage forms may be prepared according to conventional methods and techniques known to those skilled in the art (see Remington: The Science and Practice of Pharmacy (supra); Santus and Baker, J. Controlled Release 1995, 35, 1-21; Verma et al., Drug Development and Industrial Pharmacy 2000, 26, 695-708; Verma et al., J. Controlled Release 2002, 79, 7-27).

[0242] In some embodiments, the pharmaceutical compositions provided herein are formulated as asymmetric membrane technology (AMT) controlled-release dosage forms, which comprise an asymmetric osmotic membrane coating a core containing the active ingredient(s) and other pharmaceutically acceptable excipients. See U.S. Patent No. 5,612,059 and WO 2002 / 17918. AMT controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art, such as direct compression, dry granulation, wet granulation, and dip-coating.

[0243] In some embodiments, the pharmaceutical compositions provided herein are formulated as ESC controlled-release dosage forms comprising an osmotic membrane coating a core comprising a compound of the invention, hydroxyethyl cellulose, and other pharmaceutically acceptable excipients.

[0244] In some embodiments, the compositions of the present invention are modified release dosage forms manufactured as multiparticulate controlled release dosage forms comprising a plurality of particles, granules, or pellets, microparticles, beads, microcapsules, and microtablets ranging in diameter from about 10 μm to about 3 mm, from about 50 μm to about 2.5 mm, or from about 100 μm to 1 mm.

[0245] Multiparticulate controlled release dosage forms can provide extended release dosage forms with improved bioavailability. Suitable carriers for maintaining the release rate of the compounds of the present invention include, but are not limited to, ethyl cellulose, HPMC, HPMC-phthalate, colloidal silicon dioxide and Eudragit-RSPM.

[0246] The pellet-form compositions of the present invention may contain 50-80% (w / w) of the drug and 20-50% (w / w) of microcrystalline cellulose or other polymers, including, but not limited to, microcrystalline wax, pregelatinized starch, and maltose dextrin.

[0247] Beads can be prepared in capsule and tablet dosage forms. Beads in tablet dosage forms can exhibit a slower dissolution profile than microparticles in capsule form. Suitable microparticle fillers for the compositions and therapeutic or preventive methods of the present invention include, but are not limited to, sorbitan monooleate (Span 80), HPMC, or any combination thereof. Suitable dispersions for controlled-release latex include, for example, ethyl acrylate and methyl acrylate.

[0248] In some embodiments, the compositions of the present invention are in the form of microcapsules and / or microtablets. In some embodiments, the microcapsules comprise sustained-release polymer microcapsules containing a statin and a compound of the present invention with various solubility characteristics. The sustained-release polymer microcapsules can be prepared by colloidal polymer dispersion in an aqueous environment. In other embodiments, microcapsules suitable for the compositions and methods provided herein can be prepared using conventional microencapsulation techniques (Bodmeier & Wang, 1993).

[0249] Such multiparticulates can be made by processes known to those skilled in the art, such as wet and dry granulation, extrusion / spheronization, roller compaction, melt congealing, and spray coating of seed cores. See, e.g., Multiparticulate Oral Drug Delivery; Marcel Dekker: 1994, and Pharmaceutical Pelletization Technology; Marcel Dekker: 1989. Excipients for such techniques are commercially available and are described in the United States Pharmacopeia.

[0250] Other excipients, as described herein, can be blended with the compositions of the present invention to aid in the processing and formation of multiparticulates. The resulting particles can themselves constitute the multiparticulate dosage form or can be coated with various film-forming materials, such as enteric polymers, water-swellable polymers, or water-soluble polymers. The multiparticulates can be further processed into capsules or tablets.

[0251] In another embodiment, the compositions of the present invention are in a dosage form having an immediate release component and at least one delayed release component, which can provide discontinuous release of the compound in at least two consecutive pulses separated by a time interval of about 0.1 hours to about 24 hours.

[0252] In some embodiments, the compositions of the present invention comprise about 1 mg to about 1000 mg of a compound of the present invention, or any amount within these ranges. In some embodiments, the compositions of the present invention comprise about 1 mg to about 500 mg of a compound of the present invention, or any amount within these ranges. In some embodiments, the compositions of the present invention comprise about 1 mg to about 400 mg of a compound of the present invention, or any amount within these ranges.

[0253] In another embodiment, the composition of the present invention comprises a compound of the present invention in an amount that is the molar equivalent of about 1 mg to about 1000 mg of a compound of the present invention, or any amount within these ranges. In another embodiment, the composition of the present invention comprises a compound of the present invention in an amount that is the molar equivalent of about 1 mg to about 500 mg of a compound of the present invention, or any amount within these ranges. In another embodiment, the composition of the present invention comprises a compound of the present invention in an amount that is the molar equivalent of about 1 mg to about 400 mg of a compound of the present invention, or any amount within these ranges.

[0254] In some embodiments, the composition of the present invention comprises a compound of the present invention in an amount of about 10% to about 99% by weight, based on the total weight of the composition of the present invention.

[0255] Methods of the Invention The present invention provides a method for treating or preventing a disease, comprising administering an effective amount of a compound of the present invention or a composition of the present invention to a subject in need thereof, wherein the disease is a liver disease or abnormal liver condition, cancer (e.g., hepatocellular carcinoma or cholangiocarcinoma), malignant or benign tumor of the lung, liver, gallbladder, bile duct or gastrointestinal tract, intrahepatic or extrahepatic bile duct disease, lipoprotein disorders, lipid and metabolic disorders, cirrhosis, fibrosis, glucose metabolism disorders, cardiovascular or related vascular disorders, steatosis, diseases resulting from fibrosis or cirrhosis, diseases resulting from steatosis, fibrosis, and cirrhosis, diseases associated with advanced inflammation (e.g., liver inflammation or lung inflammation), hepatocellular ballooning, peroxisome proliferator-activated receptor-related disorders, ATP citrate lyase disorders, acetyl-coenzyme A carboxylase disorders, obesity, pancreatitis, or renal disease.

[0256] The present invention provides a method for treating or preventing a disease, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention, wherein the disease is cancer, lipid and metabolic disorders, liver disorders, cirrhosis, fibrosis, glucose metabolism disorders, peroxisome proliferator-activated receptor-associated disorders, malignant or benign tumors of the lung, liver, biliary tract and gastrointestinal tract, ATP citrate lyase disorders, acetyl-coenzyme A carboxylase disorders, obesity, pancreatitis, kidney disease, hepatocellular ballooning, liver inflammation, or lung inflammation.

[0257] In some embodiments of the methods disclosed herein, the disease is cancer. In some embodiments, the cancer is hepatocellular carcinoma (HCC), HCC with cirrhosis, HCC without cirrhosis, cholangiocarcinoma, colorectal cancer, biliary tract cancer, or lung cancer. In some embodiments, the cancer is fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteosarcoma, chordoma, angiosarcoma, endothelial tumor, lymphangiosarcoma, lymphangioendothelial tumor, synovium, mesothelioma, myeloid sarcoma, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophageal cancer, gastric cancer, oral cancer, nasal cancer, laryngeal cancer, squamous cell carcinoma, basal cell carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatic carcinoma, cholangiocarcinoma, or choriocarcinoma. , seminoma, embryonal carcinoma, nephroblastoma, cervical cancer, uterine cancer, testicular cancer, small cell lung cancer, bladder cancer, lung cancer, epithelial carcinoma, glioma, glioblastoma, pleomorphic, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, skin cancer, melanoma, neuroblastoma, retinoblastoma, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute granulocytic leukemia (AML), acute promyelocytic leukemia (APL), acute monocytic leukemia, acute erythroleukemia (ALE), acute myeloid leukemia (AML), acute myeloid leukemia (AML), acute myeloid leukemia (APL), acute myeloid leukemia (ALE), acute erythroleukemia (ALE), acute myeloid ... erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocytic leukemia, acute undifferentiated leukemia, chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), hairy cell leukemia, multiple myeloma, lymphoblastic leukemia, myelogenous leukemia, lymphocytic leukemia, myelocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, gastrointestinal cancer, head and neck cancer, hematopoietic cancer, or polycythemia vera.

[0258] In some embodiments, the gastrointestinal (digestive) cancer is gastrointestinal stromal tumor (GIST), esophageal cancer, gallbladder cancer, gastrointestinal carcinoid tumor, bile duct cancer, duodenal cancer, gastroesophageal (GE) junction cancer, islet cell carcinoma, pancreatic cancer, stomach cancer, colon cancer, rectal cancer, colorectal cancer, anal cancer, liver cancer, biliary tract cancer, cholangiocarcinoma, cancer of the small intestine, seudomyxoma peritonei, small bowel cancer, or cancer of unknown primary origin.

[0259] In some embodiments, the hematopoietic cancer is non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), multiple myeloma (MM), B-chronic lymphocytic leukemia (B-CLL), B and T acute lymphocytic leukemia (ALL), T-cell lymphoma (TCL), acute myeloid leukemia (AML), hairy cell leukemia (HCL), Hodgkin's lymphoma (HL), or chronic myeloid leukemia (CML).

[0260] In some embodiments of the methods disclosed herein, the cancer is at any stage. In some embodiments, the cancer may be at stage 0, stage I, stage II, stage III, or stage IV. In some embodiments of the methods disclosed herein, the disease is a tumor, and the tumor may be at any stage. In some embodiments, the tumor is grade 1, grade 2, grade 3, or grade 4.

[0261] In some embodiments of the methods disclosed herein, the disease is a lipid and metabolic disorder. In some embodiments, the lipid and metabolic disorder is characterized by high C-reactive protein (CRP), high serum amyloid A (SAA), high alanine aminotransferase (ALT), high aspartate aminotransferase (AST), high alkaline phosphatase (ALP), high gamma glutamyltransferase (GGT), high low-density lipoprotein (LDL), high very-low-density lipoprotein (VLDL), high apolipoprotein B (ApoB) and ApoB / Lp(a) (lipoprotein(a)) ratio, high total cholesterol, low high-density lipoprotein (HDL), or high non-HDL cholesterol in the subject's plasma or serum, or by high glucose and insulin resistance in a subject with diabetes. In some embodiments, the lipid and metabolic disorder is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or alcoholic steatohepatitis (ASH).

[0262] In some embodiments of the methods disclosed herein, the disease is a glucose metabolism disorder. In some embodiments, the glucose metabolism disorder is type I diabetes or type II diabetes.

[0263] In some embodiments of the methods disclosed herein, the disease is a disease caused by steatosis, fibrosis, and cirrhosis. In some embodiments, the disease caused by steatosis is inflammation. In some embodiments, the disease caused by steatosis is NAFLD, NASH, or ASH. In some embodiments, the disease caused by fibrosis is cirrhosis or liver failure. In some embodiments, the disease caused by cirrhosis is hepatocellular carcinoma, liver damage, or hepatic encephalopathy.

[0264] The present invention relates to measuring plasma or serum concentrations of C-reactive protein (CRP), serum amyloid A (SAA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), serum creatinine, 7α-hydroxy-4-cholesten-3-one (C4), protein:creatinine ratio, creatine kinase, angiopoietin-like protein 3, angiopoietin-like protein 4, and angiopoietin-like protein 5 in a subject. and a method for reducing serum triglyceride levels, including erythropoietin-like protein 4 levels, angiopoietin-like protein 8 levels, fibrinogen levels, total cholesterol levels, low-density lipoprotein cholesterol levels, low-density lipoprotein levels, very-low-density lipoprotein cholesterol levels, very-low-density lipoprotein levels, non-HDL cholesterol levels, non-HDL levels, apolipoprotein B levels, lipoprotein(a) levels, or serum triglyceride levels, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0265] The present invention provides a method for reducing triglyceride levels in the liver of a subject, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0266] The present invention provides a method for increasing the concentration of high density lipoprotein cholesterol or high density lipoprotein in the plasma or serum of a subject, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0267] The present invention provides a method for increasing the functionalization of high density lipoprotein cholesterol without increasing the concentration of high density lipoprotein cholesterol in the subject's plasma or serum, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention, wherein the amount or rate of excretion of cholesterol and triglycerides is increased.

[0268] The present invention provides a method for treating a disease, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention, wherein the disease is a gastrointestinal disease, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or an autoimmune disease.

[0269] In some embodiments of the methods disclosed herein, the disease is inflammatory bowel disease, hi some embodiments, the inflammatory bowel disease is Crohn's disease or ulcerative colitis.

[0270] In some embodiments of the methods disclosed herein, the disease is an autoimmune disease, hi some embodiments, the autoimmune disease is systemic lupus erythematosus.

[0271] The present invention provides a method for regressing, slowing the rate of progression, or inhibiting the progression of fibrosis, hepatocellular ballooning, or liver inflammation, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0272] The present invention provides a method for inhibiting, reducing, or delaying the development of lipid synthesis, hepatic steatosis, hepatocyte ballooning or inflammation, liver fibrosis, pulmonary fibrosis, or cirrhosis in a subject, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0273] The present invention provides a method for reducing a subject's risk of developing or having atherosclerosis, coronary heart disease, peripheral vascular disease, stroke, or restenosis, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0274] The present invention provides a method for increasing HDL concentration in the serum or plasma of a subject, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0275] The present invention provides a method for inhibiting NF-κB or astrocyte activation, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0276] The present invention provides a method for activating PPAR (peroxisome proliferator-activated receptor) in a subject, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0277] The present invention provides a method for downregulating the CCR2 / CCR5 gene, comprising administering to a subject in need thereof an effective amount of a compound of the present invention.

[0278] The present invention provides a method for inhibiting one or more of NF-κB activation, CCR2 activation, CCR5 activation, and astrocyte activation, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0279] The present invention provides a method for inhibiting the activation or concentration of an interleukin, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention. In some embodiments, the interleukin (IL) is IL-2, IL-6, IL-17, or IL-18.

[0280] The present invention provides a method for inhibiting fibrin / fibrinogen, gastrin, lactate dehydrogenase, prostatic acid phosphatase (PAP), thyroglobulin, urinary catecholamines, urinary vanillylmandelic acid (VMA), or urinary homovanillic acid (HVA), comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0281] The present invention provides a method for inhibiting beta-human chorionic gonadotropin (beta-hCG), beta-2-microglobulin (B2M), a B-cell immunoglobulin, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0282] The present invention provides a method for inhibiting alpha-fetoprotein (AFP), comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0283] The present invention also provides a method for inhibiting fatty acid or sterol synthesis in the liver, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0284] The present invention also provides a method for treating or preventing a disease or disorder that can be treated or prevented by increasing HDL levels, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0285] The present invention also provides a method for treating or preventing a disease or disorder that can be treated or prevented by lowering LDL levels, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a composition of the present invention.

[0286] Without being bound by theory, it is believed that the compounds of the present invention favorably alter lipid metabolism, at least in part, by enhancing fatty acid oxidation via the ACC / malonyl-CoA / CPT-I regulatory axis.Therefore, the present invention also provides a method for treating or preventing metabolic syndrome disorders, comprising administering to a subject in need thereof an effective amount of the compounds of the present invention or the compositions of the present invention.

[0287] The present invention further provides a method for modulating, directly inhibiting, or allosterically inhibiting ATP citrate lyase in a subject, comprising administering to the subject an effective amount of a compound of the present invention or a composition of the present invention.

[0288] The present invention further provides a method for modulating, directly inhibiting, or allosterically inhibiting acetyl-CoA carboxylase 1 (ACC1) or acetyl-CoA carboxylase 2 (ACC2) in a subject, comprising administering to the subject an effective amount of a compound of the present invention or a composition of the present invention.

[0289] The present invention further provides a method for reducing the fat or cholesterol content of livestock meat or poultry eggs, comprising administering to the livestock or poultry an effective amount of a compound of the present invention or a composition of the present invention.

[0290] In some embodiments of the methods disclosed herein, the compounds of the present invention are administered to a subject in need thereof in an amount ranging from about 1 mg to about 1000 mg, or any amount within these ranges. In some embodiments, the compounds of the present invention are administered to a subject in need thereof in an amount ranging from about 1 mg to about 900 mg, about 1 mg to about 800 mg, about 1 mg to about 700 mg, about 1 mg to about 600 mg, about 1 mg to about 500 mg, about 1 mg to about 400 mg, or about 1 mg to about 300 mg.

[0291] In some embodiments of the methods disclosed herein, the compounds of the present invention are administered to a subject in need thereof at a daily dose ranging from about 1 mg to about 1000 mg, or any amount within these ranges. In some embodiments, the compounds of the present invention are administered to a subject in need thereof at a daily dose of about 1000 mg, about 950 mg, about 900 mg, about 850 mg, about 800 mg, about 750 mg, about 700 mg, about 650 mg, about 600 mg, about 550 mg, about 500 mg, about 450 mg, about 400 mg, about 350 mg, about 300 mg, about 250 mg, about 200 mg, about 150 mg, about 100 mg, about 80 mg, about 60 mg, about 40 mg, about 20 mg, about 10 mg, about 5 mg, or about 1 mg.

[0292] In some embodiments of the methods disclosed herein, the compounds of the invention are administered to a subject in need thereof once daily at a dose of about 1 mg to about 1000 mg, or any amount within these ranges.

[0293] In some embodiments of the methods disclosed herein, the compounds of the present invention are administered to a subject in need thereof twice daily, each dose comprising about 1 mg to about 500 mg of the compound of the present invention, or any amount within these ranges. In some embodiments, the compounds of the present invention are administered to a subject in need thereof twice daily, each dose comprising about 500 mg, about 450 mg, about 400 mg, about 350 mg, about 300 mg, about 250 mg, about 200 mg, about 150 mg, about 100 mg, about 80 mg, about 60 mg, about 40 mg, about 20 mg, about 10 mg, about 5 mg, or about 1 mg of the compound of the present invention.

[0294] In some embodiments of the methods disclosed herein, the compounds of the present invention are administered to a subject in need thereof three times daily, each dose comprising about 1 mg to about 400 mg of the compounds of the present invention, or any amount within these ranges. In some embodiments, the compounds of the present invention are administered to a subject in need thereof three times daily, each dose comprising about 400 mg, about 350 mg, about 300 mg, about 250 mg, about 200 mg, about 150 mg, about 100 mg, about 80 mg, about 60 mg, about 40 mg, about 20 mg, about 10 mg, about 5 mg, or about 1 mg of the compounds of the present invention.

[0295] In some embodiments of the methods disclosed herein, the method further comprises administering an effective amount of another pharmaceutically active agent. In some embodiments, the other pharmaceutically active agent is administered simultaneously with or sequentially (before or after) the administration of the compound of the present invention or the composition of the present invention. In some embodiments, the other pharmaceutically active agent is a statin, a thiazolidinedione or fibrate, a bile acid-binding resin, niacin, an anti-obesity drug, a hormone, a tyrphostin, a sulfonylurea-based drug, a biguanide, an α-glucosidase inhibitor, an apolipoprotein AI agonist, an apolipoprotein E agonist, a phosphodiesterase type-5 inhibitor, a cardiovascular drug, an HDL-enhancing agent, an HDL enhancer, a modulator of the apolipoprotein AI gene, a modulator of the apolipoprotein A-IV gene, a modulator of an apolipoprotein gene, an ATP citrate lyase modulator, an ATP citrate lyase allosteric inhibitor, an acetyl-CoA carboxylase modulator, or an acetyl-CoA carboxylase allosteric inhibitor. In some embodiments, the other pharmaceutically active agent is lovastatin. In some embodiments, the other pharmaceutically active agent is sorafenib, taxol, carotuximab, pembrolizumab, lenvatinib, avelumab, durvalumab, tremelimumab, nivolumab, tazemetostat, cemiplimab, ABX196, T-cell receptor (TCR) immune cell therapy, TBI-302, namodenoson, MM-310, tumor-injected oncolytic virus or genetically engineered oncolytic virus (such as, but not limited to, telomelysin and imligic), or immunomodulatory gene therapy (such as MDA-7 / IL-24, GLIPR1 / RTVP-1, and REIC / Dkk-3).

[0296] In some embodiments of the methods disclosed herein, the methods further comprise administering two or more other pharmaceutically active agents. In some embodiments, the methods of the present invention comprise administering two or more other pharmaceutically active agents, optionally in combination. In some embodiments, the two or more other pharmaceutically active agents are oncolytic agents, such as, but not limited to, nanatinostat and valganciclovir. In other embodiments, the methods of the present invention comprise orally administering a compound of the present invention and further comprise administering a tumor injection oncolytic treatment. In some embodiments, the combination is administered orally.

[0297] In some embodiments, the other pharmaceutically active agent is selected from the group consisting of cenicriviroc, elafibranor, eicosapentaenoic acid, galunisertib, LY2109761, LDE225, nivolumab, firsocostat, aparalenone, metformin, leucine-metformin-sildenafil combination (NS-0200), IMM-124E, RG-125, vitamin E, cysteamine, selonsertib, losartan, RO5093151, prazigastat, sitagliptin, vildagliptin, NGM282, pegbelfermin, PF-05231023, obeticholic acid, cilofexor, tropif Exol, EDP-305, INT-767, galactoarabino-rhamnogalacturonate, liraglutide, semaglutide, exenatide, ND-L02-s0201 / BMS-986263, vorixivato, amlexanox, PF-06835919, leptin, metreleptin, simtuzumab, tipelukast, oltipraz, MSDC-0602K, ASP9831, roflumilast, elafibranor, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanifibranor, aramchol, ipragliflozin, dapagliflozin, empagliflozin, BI 1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, nalmafen, pentamidine, berberine, L-carnitine, EYP001a, silymarin, myricolinant, ursodeoxycholic acid, metadoxine, ezetimibe, cystadant, L-alanine, saroglitazar magnesium, vorixiva, solithromycin, technetium-99m-mebrofenin, tropifexor, S-adenosylmethionine, pentoxifylline, olesoxime, AKR-001, or seladelpar.

[0298] In some embodiments of the methods disclosed herein, the method for treating or preventing a disease comprises administering Compound I-1, Compound I-32, Compound I-61, or Compound III-1, or a pharmaceutically acceptable salt or solvate thereof.

[0299] In some embodiments of the methods disclosed herein, the method for treating or preventing a disease comprises administering to a patient an effective amount of (a) a compound of the invention and (b) another pharmaceutically active agent, such as sorafenib, taxol, lenvatinib, tazemetostat, TBI-302, namodenoson, MM-310, cenicriviroc, elafibranor, eicosapentaenoic acid, galunisertib, LY2109761, LDE225, filsocostat, aparalenone, metformin, leucine-metformin-sildenafil combination, vitamin E, cysteamine, selonsertib, losartan, RO5093151, pradigastat, sitagliptin, vildagliptin, N GM282, pegbelfermin, PF-05231023, obeticholic acid, cilofexor, tropifexor, EDP-305, INT-767, galactoarabino-rhamnogalacturonate, liraglutide, semaglutide, exenatide, vorixivato, amlexanox, PF-06835919, leptin, metreleptin, simtuzumab, tipelukast, oltipraz, MSDC-0602K, ASP9831, roflumilast, elafibranor, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanifibranor, aramchol, ipragliflozin, dapagliflozin, empagliflozin, BI 1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, nalmafene, pentamidine, berberine, L-carnitine, EYP001a, silymarin, myricolinant, ursodeoxycholic acid, metadoxine, ezetimibe, cystadan, L-alanine, saroglitazar magnesium, vorixivato, elafibranor, nalmefene, solithromycin, 99m technetium-1, mebrofenin, S -Adenosylmethionine, pentoxifylline, oresoxime, AKR-001, seladelpearl, fisogatinib, doxorubicin, cabozantinib, deferoxamine, itacitinib, tiauranib, SF1126, anlotinib, P1101, varlitinib, SHR-1210, SHR6390, capmatinib, dabrafenib, trametinib, sapanisertib, meclizine, enzalutamide, H3B-6527, OBI-3424, brivanib,tepotinib, temsirolimus, epacadostat, RO7119929, guadecitabine, linrodostat, copanlisib, MIV-818, borolanib, RO7070179, axitinib, sunitinib, or zotiraclib citrate. In some embodiments of the methods disclosed herein, the method for treating or preventing a disease comprises administering to a patient an effective amount of (a) Compound I-1, Compound I-32, Compound I-61, or Compound III-1, or a pharmaceutically acceptable salt or solvate thereof, and (b) another pharmaceutically active agent, which is sorafenib, taxol, lenvatinib, tazemetostat, TBI-302, namodenoson, MM-310, cenicriviroc, elafibranor, eicosapentaenoic acid, galunisertib, LY2109761, LDE225, filsocostat, aparalenone, metformin, leucine-metformin-sildenafil combination, vitamin E, cysteamine, selonsertib, losartan, RO5093151, protease inhibitor, or steroid inhibitor. Radigastat, sitagliptin, vildagliptin, NGM282, pegbelfermin, PF-05231023, obeticholic acid, cilofexor, tropifexor, EDP-305, INT-767, galactoarabino-rhamnogalacturonate, liraglutide, semaglutide, exenatide, vorixibat, amlexanox, PF-06835919, leptin, metreleptin, simtuzumab, tipelukast, oltipraz, MSDC-0602K, ASP9831, roflumilast, elafibranor, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanifibranor, aramchol, ipragliflozin, dapagliflozin, empagliflozin, BI 1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, nalmafene, pentamidine, berberine, L-carnitine, EYP001a, silymarin, myricolinant, ursodeoxycholic acid, metadoxine, ezetimibe, cystadan, L-alanine, saroglitazar magnesium, vorixivato, elafibranor, nalmefene, solithromycin, 99m technetium-mebrofenin, S-adenosylmethionine, pentoxifylline, olesoxime,AKR-001, seladelpearl, fisogatinib, doxorubicin, cabozantinib, deferoxamine, itacitinib, tiauranib, SF1126, anlotinib, P1101, varlitinib, SHR-1210, SHR6390, capmatinib, dabrafenib, trametinib, sapanisertib, meclizine, enzalutamide, H3B-6527, OBI-3424, brivanib, tepotinib, temsirolimus, epacadostat, RO7119929, guadecitabine, linrodostat, copanlisib, MIV-818, borolanib, RO7070179, axitinib, sunitinib, or zotiraclib citrate. ,

[0300] In some embodiments of the methods disclosed herein, the method for treating or preventing a disease comprises administering an effective amount of (a) a compound of the invention and (b) another pharmaceutically active agent, which is sorafenib, taxol, carotuximab, pembrolizumab, lenvatinib, avelumab, durvalumab, tremelimumab, nivolumab, tazemetostat, cemiplimab, ABX196, a T-cell receptor (TCR) immune cell therapy, TBI-302, namodenoson, MM-310, a tumor-injected oncolytic virus, a gene-modified oncolytic virus, or an immunomodulatory gene therapy agent. In some embodiments of the methods disclosed herein, the method for treating or preventing a disease comprises administering an effective amount of (a) compound I-1, compound I-32, compound I-61, or compound III-1, or a pharmaceutically acceptable salt or solvate thereof, and (b) another pharmaceutically active agent, which is sorafenib, taxol, carotuximab, pembrolizumab, lenvatinib, avelumab, durvalumab, tremelimumab, nivolumab, tazemetostat, cemiplimab, ABX196, a T-cell receptor (TCR) immune cell therapy, TBI-302, namodenoson, MM-310, a tumor-injected oncolytic virus, a genetically engineered oncolytic virus, or an immunomodulatory gene therapy agent.

[0301] In some embodiments, the methods of the present invention comprise administering to a subject in need thereof an effective amount of a compound of the present invention and another pharmaceutically active agent described in an embodiment of Table D. In some embodiments, the other pharmaceutically active agent is administered simultaneously with, before, or after administration of a compound of the present invention or a composition of the present invention.

[0302] In some embodiments of the methods disclosed herein, the method further comprises administering radiation therapy to the subject. In some embodiments, the radiation therapy is gamma radiation therapy or X-ray radiation therapy. In some embodiments, the radiation therapy is administered via a gamma ray or X-ray radiation device.

[0303] In some embodiments, radiation therapy is administered simultaneously with, before, or after administration of a compound of the invention or a composition of the invention. In some embodiments, radiation therapy is administered before or after administration of a compound of the invention or a composition of the invention.

[0304] Methods for Making the Compounds of the Invention Synthesis and General Protocol Compounds of formula (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), and (IL) (collectively "Formula (I)") can be prepared via the synthetic methodology depicted in Schemes 1-7. Starting materials useful for preparing the compounds of the invention and intermediates thereto are either commercially available or can be prepared from commercially available materials using known synthetic methods and reagents.

[0305] Scheme 1: General synthesis of formula (I) [ka]

[0306] In Scheme 1, A can be a halogen, such as Cl, Br, or I. In some embodiments, A is Br. In Scheme 1, B can be a carbanion of a carboxylic acid or ester of a malonic acid ester. In Scheme 1, Q 1 and Q 2 are each independently -O-alkyl, -S-alkyl, -S-aryl, or -NR 1A R 2A , NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A , heteroaryl, or heterocyclyl, or each carbon atom can independently be a Q bonded to a carbon atom. 1 and Q 2 Together with R, they can form a heterocyclyl or carbocyclyl group. 1A and R 2A is as defined herein for formula (I).

[0307] Scheme 2: General synthesis of formula (I) [ka]

[0308] In Scheme 2, Q 1 and Q 2 are each independently -O-alkyl, -S-alkyl, -S-aryl, or -NR 1A R 2A , NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A , heteroaryl, or heterocyclyl, or each carbon atom can independently be a Q bonded to a carbon atom. 1 and Q 2 Together with R, they can form a heterocyclyl or carbocyclyl group. 1A and R 2A is as defined herein for formula (I).

[0309] Scheme 3: General synthesis of formula (I) where Z is -C(R 1 )(R 2 )-(CH2) c -X, where X is COOR 5 , or COOH, where c is 0). [ka]

[0310] In Scheme 3, Q 1 and Q 2 are each independently -O-alkyl, -S-alkyl, -S-aryl, or -NR 1A R 2A , NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A , heteroaryl, or heterocyclyl, or each carbon atom can independently be a Q bonded to a carbon atom. 1 and Q 2 Together with R, they can form a heterocyclyl or carbocyclyl group. 1A and R 2A is as defined herein for formula (I).

[0311] Scheme 3 illustrates the reaction of ortho, meta, or para ω-haloalkyl substituted arenes of formula 5, where p is an integer ranging from 2 to 5, and Hal is Cl, Br, or I, with dicarboxylic acids of formula 7, where R 1 and R 2 represents the conversion of a compound of formula R to a compound of formula R 1 R 2 CHCO2R 5 an ester of 1 and R 2is an alkyl and / or aryl moiety or is linked to a 3- to 7-membered ring, and R 5 is typically ethyl or methyl) is deprotonated with a strong base, preferably, but not limited to, butyllithium or lithium diisopropylamide, and then reacted with a dihalide of formula 5 to provide the corresponding diester of formula 6. Generally, the reaction is carried out at a temperature of about -78°C to about 25°C, and the reaction solvent is preferably THF or diethyl ether (for a discussion of the scope of this method, see Larock, RC, Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2002). nd ed.; Wiley-VCH, New York, 1999, pp. 1725-1726. For specific examples of this method, see Dasseux et al., US Pat. No. 6,646,170 and US Pat. No. 6,410,802, Oniciu et al., US Pat. No. 10,227,285, and Ackerley et al., J. Med. Chem. 1995, 38, 1608-1628. In the second step, the diester of formula 6 is saponified (for an overview, see Larock, RC, Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2000). nd ed.; Wiley-VCH, New York, 1999, pp 1959-1968, and Smith, MB; March, J. March's Advanced Organic Chemistry. Reactions, Mechanisms, and Structure, 5 th ed.; John Wiley and Sons, New York, 2001, pp. 469-474) to give the diacid of formula 7. Alternatively, this conversion of the dihalide of formula 5 to the diacid of formula 7 can also be carried out by reacting the dihalide of formula R 1 R 2 CHCO2H (in the formula, R 1 and R 2is alkyl and / or aryl) to the above R 1 R 2 CHCO2R 5 This can also be achieved in one step by double deprotonation under conditions similar to the alkylation of , followed by reaction with the dibromide 5 (for a discussion, see Larock, R.C. Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2 nd ed.; Wiley-VCH, New York, 1999, pp. 1717-1718). For example, a compound of formula 5 (ortho, p=3, Hal=Br) is reacted with lithioethyl isobutyrate (prepared from ethyl isobutyrate with lithium diisopropylamide) in a solvent mixture of THF and DMPU at temperatures ranging from about −78° C. to room temperature to give the corresponding diester of formula 7 (ortho, p=3). This diester is then hydrolyzed under standard conditions (aqueous ethanol, potassium hydroxide, reflux temperature) and, after reacidification with dilute aqueous hydrochloric acid, the dicarboxylic acid of formula 7 (ortho substitution pattern, R 1 =R 2 = methyl, and p = 3) is obtained. Alternatively, isobutyric acid is deprotonated twice with n-butyllithium and diisopropylamine in THF solution, first at about -20°C and then at about 50°C, as described in Gleiter et al., J. Org. Chem. 1992, 57, 252-258. After recooling to about -20°C, the compound of formula 5 (ortho, R 1 =R 2 = methyl, p = 3, Hal = Br) is added dropwise, maintaining the temperature below 10° C. The mixture is then stirred first at room temperature and then at about 40° C. and worked up in a typical manner to give the corresponding diacid 7. Halogenated derivatives of type 5 can be obtained by several methods, for example as described in Gleiter et al., J. Org. Chem. 1992, 57, 252-258.

[0312] Scheme 4: General synthesis of compound 5-Br (compound 5 where Hal=Br) [ka]

[0313] In Scheme 4, Q 1 and Q 2 are each independently -O-alkyl, -S-alkyl, -S-aryl, or -NR 1A R 2A , NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A , heteroaryl, or heterocyclyl, or each carbon atom can independently be a Q bonded to a carbon atom. 1 and Q 2 Together with R, they can form a heterocyclyl or carbocyclyl group. 1A and R 2A is as defined herein for formula (I).

[0314] Scheme 4 illustrates the synthesis of para-, meta-, and ortho-dibromoalkyl-substituted arene compounds 5-Br from the parent dicarboxylic acid 10, where (p-1) is an integer ranging from 1 to 2. Scheme 4 was first described by Larock, R.C., Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2002. nd ed.; Wiley-VCH, New York, 1999, pp 1932-1941, and Smith, MB; March, J. March's Advanced Organic Chemistry. Reactions, Mechanisms, and Structure, 5 thed.; John Wiley and Sons, New York, 2001, pp. 484-486, outlines the esterification of compounds of formula 10 to diesters of formula 20 (where R is an alkyl moiety such as, but not limited to, methyl, ethyl, or isopropyl). Diols 30 can be prepared from diesters 20 by known synthetic methods (for a discussion of suitable reduction methods, see, e.g., Hudlicky, M. Reductions in Organic Chemistry, 2001). nd ed.; ACS Monograph 188, Washington, DC, 1996, pp. 212-216). In the next step, the conversion of the alcohol functionality in compound 5-Br to a bromo moiety in 30 is carried out according to the procedure described by Larock, R.C., Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2000. ndThis conversion can be carried out by a variety of standard methods, such as those referenced in Schimelpfenig, C.W.J. Org. Chem. 1975, 40, 1493-1494, incorporated herein by reference. For example, a compound of formula 10 having a para-substitution pattern and (p-1)=1 (available from Aldrich Chemical Co., Milwaukee, Wisconsin) is treated with excess methanol and concentrated sulfuric acid at reflux to give the corresponding dimethyl ester of formula 2. Procedures that can be used for this conversion are found, for example, in Schimelpfenig, C.W.J. Org. Chem. 1975, 40, 1493-1494, incorporated herein by reference. Additionally, as disclosed in U.S. Patent Application No. 397,037, filed December 8, 1953, by Reynolds et al., U.S. Pat. No. 2,789,970, the compound of formula 20 (para, (p-1)=1) can be converted to the corresponding compound of formula 30 by reaction with a metal hydride complex, preferably, but not limited to, lithium aluminum hydride, in an aprotic organic solvent (e.g., THF or diethyl ether). Furthermore, the diol of formula 30 (para, p=1) can be converted to the bromide of formula 5-Br (para, p=1) by treatment with sodium bromide and concentrated sulfuric acid at elevated temperatures. A useful solvent for this conversion is water, as described by Schimelpfenig, C.W.J. Org. Chem. 1975, 40, 1493-1494.

[0315] Scheme 5: General synthesis of compound 5A-Br [ka]

[0316] In Scheme 5, Q 1 and Q 2 are each independently -O-alkyl, -S-alkyl, -S-aryl, or -NR 1A R 2A , NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A, heteroaryl, or heterocyclyl, or each carbon atom can independently be a Q bonded to a carbon atom. 1 and Q 2 Together with R, they can form a heterocyclyl or carbocyclyl group. 1A and R 2A is as defined herein for formula (I).

[0317] Scheme 5 illustrates the preparation of ortho-, meta-, and para-substituted arene compounds of formula 5A-Br bearing two 3-bromopropyl substituents. Specific examples for the synthesis of meta- and para-substituted compounds 5A-Br are described in Schimelpfenig, CWJ Org. Chem. 1975, 40, 1493-1494 and Gleiter et al., J. Org. Chem. 1992, 57, 252-258, respectively. For example, compound 50 is treated with malonic acid and piperidine in pyridine solution at approximately 90-110 °C to afford the α,β-unsaturated carboxylic acid of formula 60. The endpoint of this transformation is typically indicated by the cessation of CO2 effervescence. This procedure is known as the Knoevenagel-Doebner reaction, and a useful reaction protocol for this transformation is described in Organikum, Organisch-Chemisches Grundpraktikum, VEB Verlag Deutscher Wissenschaften, Berlin 1984, pp. 572-574. The reduction of compounds of formula 60 to compounds of formula 70 is described in Hudlicky, M. Reductions in Organic Chemistry, 2 ndThis can be achieved by catalytic hydrogenation over colloidal palladium, Raney nickel, or copper chromite, as discussed in [Chem. ed.; ACS Monograph 188, Washington, DC, 1996, pp. 196-197]. Meta-substitution of compound 60 to the corresponding compound 70 by treatment with hydrogen gas in aqueous sodium hydroxide over a palladium / carbon catalyst at a pressure of about 20-60 psi is reported in Schimelpfenig, CWJ Org. Chem. 1975, 40, 1493-1494, the entire contents of which are incorporated herein by reference. Further conversion of compound 70 to compound 5A-Br can then be achieved according to the methodology described in Scheme 4.

[0318] Scheme 6: General synthesis of compound 5-Br by chain extension [ka]

[0319] In Scheme 6, Q 1 and Q 2 are each independently -O-alkyl, -S-alkyl, -S-aryl, or -NR 1A R 2A , NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A , heteroaryl, or heterocyclyl, or each carbon atom can independently be a Q bonded to a carbon atom. 1 and Q 2 Together with R, they can form a heterocyclyl or carbocyclyl group. 1A and R 2A is as defined herein for formula (I).

[0320] Scheme 6 shows a general method for chain extension of bromides of formula 90, which have an alkyl chain consisting of (p-2) methylene groups, to bromides of formula 5-Br, which have an alkyl chain consisting of p methylene groups. The conversion sequence from alkyl halides (such as 90) to carboxylic acids (such as 120) is described in Smith, MB; March, J. March's Advanced Organic Chemistry. Reactions, Mechanisms, and Structure, 5 th ed.; John Wiley and Sons, New York, 2001, p 549, and Larock, RC Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2 nded.; Wiley-VCH, New York, 1999, p. 1765. Generally, monoalkylation of malonate esters (where R is typically ethyl or methyl) uses a basic solvent combination of sodium ethoxide in ethanol, which inhibits the formation of dialkylated by-products (Organic Reactions, Volume IX, editor-in-chief: R. Adams; Robert E. Krieger Publishing Company, Malabar, Florida, 1957, p. 132), to give compounds of formula 100. Compounds of formula 100 are then saponified to give compounds of formula 110, which can be decarboxylated to compounds of formula 120 by heating above their melting point. Conversion of dicarboxylic acid 120 to the chain-extended dibromide 5-Br via diester 20 is then carried out according to the methodology described in Scheme 4. Alternatively, direct decarbalkoxylation of the geminal diester 100 to the compound of formula 20 can be carried out by treatment with water and DMSO, with or without the addition of a salt. However, the decarbalkoxylation rate of these substrates can be improved by adding salts such as KCN, NaCl, or LiCl to the water / DMSO solvent (Fakhri, SA; Yousefi, BH Tetrahedron 2000, 56, 8301-8308). For example, ethyl malonate can be reacted with a solution of sodium metal in ethanol and the compound of formula 90 ((p-2) = 2), followed by the addition of ethyl malonate, to give the corresponding compound of formula 100. This tetraester can then be saponified, for example, using aqueous ethanol and potassium hydroxide, to give the corresponding tetraacid of formula 110. The tetraacid can then be decarboxylated at a temperature of about 200°C to give the diacid of formula 120. After esterification with methanol and concentrated sulfuric acid (see Scheme 4), diester 20 is obtained.A useful method for converting tetraesters of formula 100 (ortho, (p-2)=1, R=ethyl) to diesters of formula 20 is described in Fakhri, SA; Yousefi, BH Tetrahedron 2000, 56, 8301-8308, which is incorporated herein by reference in its entirety.

[0321] Scheme 7: General synthesis of compounds of formula 7 [ka]

[0322] In Scheme 7, Q 1 and Q 2 are each independently -O-alkyl, -S-alkyl, -S-aryl, or -NR 1A R 2A , NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A , heteroaryl, or heterocyclyl, or each carbon atom can independently be a Q bonded to a carbon atom. 1 and Q 2 Together with R, they can form a heterocyclyl or carbocyclyl group. 1A and R 2A is as defined herein for formula (I).

[0323] Scheme 7 illustrates the synthesis of ortho-, meta-, and para-substituted arene compounds of formula 7 via ω-carboxyalkyl substitution, where (p-1) is an integer ranging from 2 to 12, and R 1 and R 2is either an alkyl and / or aryl moiety, or two alkyl moieties linked by a 3- to 7-membered ring. The synthesis begins with the double deprotonation of ortho-, meta-, or para-xylene 3 with a strong base, such as, but not limited to, a combination of n-butyllithium and potassium tert-butoxide, in an aprotic solvent, such as, but not limited to, hexane, followed by the reaction of the formed dianion of 3 with a suitable electrophile, A-(CH2). p-1 -CR 1 R 2 -CH2O-PG(wherein, (p-1), R 1 and R 2 is defined above and A is Cl, Br, or I). "PG" is a hydroxyl protecting group. Examples of hydroxyl protecting groups are described in Greene, TW; Wuts, "PG Protective Groups in Organic Synthesis," 3, which are incorporated herein by reference. rd ed., John Wiley and Sons, New York, 1999, pp. 17-245. Methylarenes are described in Larock, R.C., Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2 nd ed.; Wiley-VCH, New York, 1999, p. 88, can be alkylated via deprotonation with a lithium base followed by alkylation with a suitable electrophile. For example, for an example of the preparation of xylylene dianions, see Bates et al., J. Am. Chem. Soc. 1981, 103, 5052-5058. In the next step, the protecting group of 190 is removed to liberate the terminal hydroxylmethyl moiety in 200, which is oxidized using a suitable oxidizing agent (Larock, RC Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 200). nded.; Wiley-VCH, New York, 1999, pp 1646-1648, and Smith, MB; March, J. March's Advanced Organic Chemistry. Reactions, Mechanisms, and Structure, 5 th ed.; John Wiley and Sons, New York, 2001, p 1537), to obtain the dicarboxylic acid of formula 7. For example, m-xylene (meth-3) is reacted with n-butyllithium and potassium tert-butoxide in hexane, first at room temperature and then at reflux temperature. After cooling to 0°C, the compound of formula 180 (A = Br, (p-1) = 3, R 1 =R 2 = methyl, PG = tetrahydropyranyl, prepared according to Dasseux et al., US 6,646,170 and US 6,410,802) is added and the reaction is continued at reflux temperature to obtain the corresponding compound of formula 190 after usual work-up and purification by column chromatography. 1 , R 2 Deprotection of the hydroxyl group (p = methyl, p = 3) is carried out by heating in methanol and concentrated aqueous hydrochloric acid (Vogel, AI Vogel's Textbook of Practical Organic Chemistry, 5 th ed., Longman Scientific and Technical, 1989, p. 552). Compound 200 is then treated with pyridinium dichromate in N,N'-dimethylformamide according to Vedejs, E.; Dent, W.H., III; Gapinski, D.M.; McClure, C.K.J. Am. Chem. Soc. 1987, 109, 5437-5446 to give the dicarboxylic acid of formula 7 (meta, p=3, R 1 , R 2 = methyl).

[0324] Scheme 8 shows an exemplary alternative synthesis method for compounds I-1 and I-32. Commercially available benzene-dicarboxaldehyde (Sigma-Aldrich, AK Scientific, etc.) is reacted with (5-ethoxy-4,4-dimethyl-5-oxopentyl)triphenylphosphonium bromide (220) (prepared as described in Oniciu, D.C. et al., WO2012 / 054535 and US8,349,833B2) in the presence of a base (such as, but not limited to, sodium or potassium hydroxide, potassium or sodium tert-butoxide, potassium or sodium carbonate, and sodium hydride) as a mixture of cis and trans isomers by the method described in Le Bigot Y. et al., 1988, Tetrahedron 44(4), pp.1057-1072. The mixture of cis and trans isomers of formula (230) or (240) can be catalytically reduced by methods known in the art for hydrogenating olefins, such as those described in H.-U. Blaser, F. Spindler, M. Thommen, "The Handbook of Homogeneous Hydrogenation," JG De Vries, CJ Elsevier, Eds. (Wiley-VCH, 2008), chap. 37; Scharnagl, FK et al., Sci. Adv. 2018;4:eaau1248, 21 September 2018, and the references cited therein. The resulting ester is subjected to hydrolysis after the hydrogenation reaction is deemed substantially complete using an appropriate analytical method. The reaction mixture containing the compound of formula (250) or (260), respectively, is hydrolyzed in refluxing alcohol in the presence of an alkaline earth metal salt or base, or oxide, or alkali metal salt or base for 2 to 96 hours. A typical example includes, but is not limited to, hydrolysis with K2CO3 in a refluxing mixture of DMSO and water.Other suitable procedures are found in Houben-Weyl, Methoden der Organische Chemie, Georg Thieme Verlag Stuttgart 1964, vol. XII / 2, pp. 143-210 and 872-879, or Anderson, NG, Practical Process Research & Development, Academic Press, London, 2000, pp. 93-94 and 181-182.

[0325] Scheme 8. Exemplary synthesis of compounds I-1 and I-32. [ka]

[0326] Scheme 9. General synthesis of compounds of formula (III) or (IIIA) where X=O, Z 1 , Z 2 =COOH, q=0, and R 1 and R 2 together form a cyclopropyl ring) [ka]

[0327] Compounds of formula (III) or (IIIA) where X=O can be prepared by the Williamson synthesis by reacting an alcohol with a derivative containing a leaving group such as a halide, tolylsulfonate, or mesylate. See Scheme 9.

[0328] Synthesis Example Example 1: Synthesis of (9-carboxymethylsulfanyl-5-oxo-nonylsulfanyl)-acetic acid (Compound II-3) [ka]

[0329] Reaction of ethyl 5-bromovalerate with lithium diisopropylamide in THF at room temperature produces the ketone ester 1-1 (see, e.g., Cooke, MPJ Org. Chem. 1993, 58, 2910-2912; Stetter, H.; Rauhut, H. Chem. Ber. 1958, 91). Decarboxylation of 1-1 with refluxing HCl / EtOH (Cooke, MPJ Org. Chem. 1993, 58, 2910-2912) produces crude 1-2, which can be purified by column chromatography using systems such as silica gel and a mixture of ethyl acetate / hexane in a ratio of 1 / 20 to 1 / 8. Sodium mercaptoacetate is prepared by treating mercaptoacetic acid dissolved in a mixture of ethanol and water with aqueous sodium hydroxide, and this is used to treat 1-2 in a solvent such as ethanol, as described in Agnus, A., Louis, Gissebrecht, JP, Weiss, R., J. Am. Chem. Soc., 1984, 106, 93 or Riesen, PC; Kaden, TA Helv. Chim. Acta. 1995, 78, 1325-1333, to give crude compound II-3. Crude compound II-3 can be purified by recrystallization from a solvent or solvent mixture such as MTBE and heptane.

[0330] Example 2: Synthesis of (9-carboxymethylsulfanyl-5-hydroxy-nonylsulfanyl)-acetic acid (Compound II-1) [ka]

[0331] Reduction of keto acid compound II-3 from Example 1 with sodium borohydride after salt formation with NaOH yields compound II-1 (see U.S. Pat. No. 7,119,221 for suitable reaction conditions). Compound II-3 (Example 1) is dissolved in NaOH solution (2-7 equivalents) to form the intermediate disodium salt in water. Isopropanol is then added, followed by the addition of sodium borohydride (1.05 equivalents) in portions. The reaction mixture is heated at about 45° C. for several hours to yield compound II-1. This product can be purified by recrystallization from MTBE, heptane, or a mixture thereof.

[0332] Example 3: Synthesis of [5-(5-carboxymethoxy-pentyloxy)-pentyloxy]-acetic acid (Compound II-12) [ka]

[0333] Compound II-12 is prepared via Williamson ether synthesis starting from 3-1 and 3-2 (prepared as described in Dasseux et al., US Pat. No. 6,459,003). The resulting 3-3 is deprotected in methanol in the presence of a catalytic amount of p-toluenesulfonic acid monohydrate to give diol 3-4. This diol is then coupled with tert-butyl bromoacetate in a two-phase system of aqueous NaOH and toluene in the presence of tetrabutylammonium bromide as a PTC catalyst, as described in US Pat. No. 10,227,285. Finally, the tert-butyl ester is cleaved under acidic conditions to give compound II-12.

[0334] Example 4: Synthesis of [5-(5-carboxymethoxy-pentylsulfanyl)-pentyloxy]-acetic acid (Compound II-20) [ka]

[0335] Compound 3-1 (prepared as described in U.S. Pat. No. 6,790,953) is treated with sodium sulfide to form the thioether 4-1, similar to the method by Edwards, D.; Stenlake, J.B.J. Pharmacy Pharmacol. 1955, 7, 852-860, which is deprotected in methanol in the presence of a catalytic amount of pyridinium p-toluenesulfonate (PPTS) as described by Miyashita, N.; Yoshikoshi, A.; Grieco, P.A.J. Org. Chem. 1977, 42(23), 3772-73. The resulting diol 4-2 is reacted with tert-butyl bromoacetate under phase transfer catalysis conditions using (BuN)(HSO) as catalyst according to the method by Nagatsugi, F.; Sasaki, S.; Maeda, M.J. Fluorine Chem. 1992, 56, 373-383 to give the tert-butyl ester 4-3. Subsequent cleavage of the tert-butyl ester with trifluoroacetic acid (TFA) affords the free acid compound II-20 in 90% yield, similar to the procedure of Nagatsugi, F.; Sasaki, S.; Maeda, M. J. Fluorine Chem. 1992, 56, 373-383.

[0336] Example 5: Synthesis of [5-(5-carboxymethoxy-pentane-1-sulfinyl)-pentyloxy]-acetic acid (Compound II-24) [ka]

[0337] Compound II-24 is prepared starting from compound II-12 (Example 4) in a manner similar to the procedure described in US Pat. No. 6,673,780 using hydrogen peroxide as the oxidizing agent.

[0338] Example 6: Synthesis of [5-(5-carboxymethylsulfanyl-pentyloxy)-pentylsulfanyl]-acetic acid (Compound II-6) [ka]

[0339] Compounds 6-1 and 6-2 were obtained according to the methods described in Harrison, GC; Diehl, H. Organic Synthesis 1955 Coll. Vol. 3, 370, and Francis, GW; Berg, JF Acta Chem. Scand. B 1977, 31, 721-722, respectively. 5-Chloro-pentan-1-ol is commercially available, and 3-4 was prepared as described in Example 3: mercaptoacetic acid (8.1 g, 87.9 mmol) was dissolved in a deionized water / ethanol solution (50 mL / 40 mL). A solution of sodium hydroxide (7.0 g, 175.5 mmol) in water (50 mL) was added under stirring. To this mixture, bis(4-chlorobutyl ether) (7.0 g, 35.1 mmol) in ethanol (20 mL) was added dropwise over 30 minutes. The mixture was refluxed for 20 hours, after which the ethanol was evaporated. The residue was diluted with water (20 mL). The aqueous layer was extracted with MTBE (4 x 20 mL) and the organic layer was discarded. The aqueous layer was acidified to pH 2 with concentrated HCl (approximately 12 mL) and extracted with MTBE (4 x 30 mL). The combined organic layers were checked by TLC (silica, CHCl:MeOH = 9:1) for the presence of starting mercaptoacetic acid (R f =0.7, bright blue spot with phosphomolybdic acid / EtOH). The organic layer was washed with water (approximately 700 mL portions) until the starting acid was completely consumed. The solvent was removed under reduced pressure to give a colorless oil (7.7 g), which solidified at room temperature. This solid was recrystallized from heptane / MTBE (50 / 60 mL) to give fine white crystals (6.2 g, 57% yield, 99% purity - RI, 91% - UV, mp 43-44 °C). An additional amount of product was obtained from the mother liquor (0.87 g, mp 38-40 °C).

[0340] Example 7: Synthesis of (11-carboxymethylsulfanyl-6-oxo-undecylsulfanyl)-acetic acid (Compound II-4) and (11-carboxymethylsulfanyl-6-hydroxy-undecylsulfanyl)-acetic acid (Compound II-2) [ka]

[0341] The synthesis of compounds II-4 and II-2 begins with 1,11-dibromoundecan-6-one (7-4), prepared as described above, starting with commercially available 6-bromohexanol. Protection of the hydroxyl group of 6-bromohexanol with dihydropyran yields intermediate 7-1, as described in U.S. Patents 6,646,170 and 6,410,802. 7-1 is reacted with ToSMIC in dimethylacetamide (DMAc) in the presence of sodium amylate (NaOAm-t) to form intermediate 7-2, which is then converted to diol 7-3. Removal of the THP protecting group and conversion of the isocyano-tosyl fragment to a ketone group proceed simultaneously in the presence of aqueous HCl in a mixture of solvents such as methylene chloride and methanol over approximately 12-24 hours. Diol 7-3 can be purified by column chromatography on silica gel and solvent mixtures such as ethyl acetate and methylene chloride. The resulting compound 7-3 is subjected to a Mitsunobu reaction to give bromide 7-4, which is subsequently treated with the sodium salt of mercaptoacetic acid in alcohol or a mixture of alcohols (ethanol, isopropanol) to give diacid compound II-4, which is reduced with sodium borohydride to give compound II-2 (see Example 2).

[0342] Example 8: Synthesis of [4-(4-carboxymethoxy-butoxy)-butoxy]-acetic acid (Compound II-11) [ka]

[0343] Commercially available bis(4-chlorobutyl ether) was converted to diol 8-2 via diacetate 8-1 [Kliem, A., Schniepp, LEJA Am. Chem. Soc., 1948, 70, 1839], which was then reacted with ethyl bromoacetate to give 8-3. Compound 8-3 was hydrolyzed to give II-11. Alternatively, bis(4-chlorobutyl ether) was treated with the dianion of hydroxyacetic acid via autoclaving or elevated temperature to give compound II-11.

[0344] Specifically, diacetate 8-1 is treated with potassium carbonate in methanol, similar to the method described in Kliem, A., Schniepp, LEJA Am. Chem. Soc., 1948, 70, 1839, and crude compound 8-2 is optionally purified by column chromatography. Diol 8-2 is deprotonated with sodium hydride (95% or 60% in mineral oil) in THF for about 2 to about 4 hours, and then reacted with ethyl bromoacetate to give diester 8-3. The final step, hydrolysis of 8-3, is carried out with KOH in ethyl alcohol for about 2 to about 8 hours. The product is then subjected to a workup involving acidification with aqueous HCl, followed by extraction with methylene chloride, to give crude compound II-11. Crude compound II-11 is optionally purified by gradient column chromatography on silica gel using solvents such as EtOAc and hexane, and mixtures thereof.

[0345] Example 9: Synthesis of 5,5'-(1,4-phenylene)bis(2,2-dimethylpentanoic acid) (Compound I-78) [ka]

[0346] (4-Methoxycarbonylmethylphenyl)-acetic acid methyl ester (A2) Concentrated sulfuric acid (40 mL) was added to phenylenediacetic acid (A1) (25.0 g, 0.129 mol) in MeOH (300 mL). The reaction mixture was heated at reflux overnight. Most of the MeOH was evaporated in vacuo. The residue was diluted with EtOAc (300 mL) and water (300 mL). The aqueous solution was separated and extracted with EtOAc (2 × 100 mL). The combined organic solution was washed with water (100 mL), saturated NaHCO3 solution (2 × 100 mL), and brine (100 mL) and dried over MgSO4. The solvent was evaporated to give (4-methoxycarbonylmethylphenyl)-acetic acid methyl ester as a white solid (27.1 g, 95%, 92.3% by HPLC). Mp59-60°C (51-54°C, Dynamit Nobel, UK Patent No. 1495472, Application No. 9008 / 75, filed March 4, 1975). 1 H NMR (CDCl3): δ= 7.25 (s, 4H), 3.70 (s, 6H), 3.60 (s, 4H). 13 C NMR (CDCl3): δ= 174.0, 132.5, 129.0, 52.0, 40.5.

[0347] 2-[4-(2-hydroxyethyl)-phenyl]-ethanol (A3) (4-Methoxycarbonylmethylphenyl)-acetic acid methyl ester (A2) (26.5 g, 0.12 mol) in THF (100 mL) was added to a solution of LiAlH (11.0 g, 0.29 mol) in THF (300 mL) with stirring at room temperature. The reaction mixture was heated at reflux for 2 h. Water (100 mL) was carefully added, followed by dilute aqueous HCl (75 mL of concentrated HCl in 100 mL of water). The aqueous phase was extracted with EtOAc (2 × 100 mL). The combined organic solution was washed with water (100 mL), saturated NaHCO solution (150 mL), and brine (100 mL) and dried over MgSO. The solvent was evaporated to give 2-[4-(2-hydroxyethyl)-phenyl]-ethanol (18.68 g, 94%, 93.5% pure by HPLC) as a white solid. Mp 89-90°C (87-88°C, Reynolds et al., US 2,789,970, Application No. 397,037, filed December 8, 1953).1 H NMR (CDCl3): δ=7.17 (s, 4H), 3.78 (t, J = 6.6 Hz, 4H), 2.81 (t, J = 6.6 Hz, 4H), 2.30 (br s, 2H). 13 C NMR (CDCl3): δ = 136.9, 129.4, 63.8, 39.0.

[0348] 1,4-bis-(2-bromoethyl)-benzene (A4) Concentrated sulfuric acid (30.0 g) was added dropwise over 1 h to a boiling mixture of 2-[4-(2-hydroxyethyl)-phenyl]-ethanol (A3) (18.29 g, 0.11 mol), NaBr (40.0 g, 0.39 mol), and water (50 mL). The reaction mixture was heated at reflux for 1 h. An additional portion of sulfuric acid (10 mL) and NaBr (16.0 g, 0.16 mol) was added, and heating at reflux was continued for 1.5 h. Water (100 mL) was added to the cooled mixture, and the product was extracted with methylene chloride (3 × 100 mL). The combined organic solution was washed with water (100 mL) and brine (100 mL) and dried over MgSO4. The solvent was evaporated, and the residue was purified by column chromatography (silica gel, EtOAc:hexane = 1:1). The solid product was recrystallized from hexane to give 1,4-bis-(2-bromoethyl)-benzene (22.27 g, 69%, 99.8% purity by HPLC) as a white solid. Mp 71-72 °C (70-71 °C, Longone, DT; Kusefoglu, SH; Gladysz, JA J Org. Chem. 1977, 42, 2787-2788). 1 H NMR (CDCl3): δ= 7.18 (s, 4H), 3.57 (t, J = 2.2 Hz, 4H), 3.16 (t, J = 7.8 Hz, 4H). 13 C NMR (CDCl3): δ= 138.6, 130.0, 40.1, 34.0.

[0349] 4-[4-(3-carboxy-3-methylbutyl)-phenyl]-2,2-dimethylbutyric acid A solution of lithium diisopropylamide (89 mL, 0.16 mol, 1.8 M in heptane / THF / EtPh) was added dropwise to a solution of ethyl isobutyrate (18.0 g, 155 mmol) in THF (100 mL) at −78 °C. The reaction mixture was stirred for 1 h, and a solution of 1,4-bis-(2-bromoethyl)-benzene (A4) (20.0 g, 68.5 mmol) in THF (50 mL) was added slowly, followed by DMPU (10 mL). The reaction mixture was warmed to room temperature over 2 h and stirred at 40–50 °C for 1 h. Water (200 mL) was added, and the aqueous solution was separated and extracted with EtOAc (3 × 80 mL). The combined organic solution was washed with water (100 mL) and brine (100 mL). After concentration under reduced pressure, the residue was purified by column chromatography (silica gel, EtOAc:heptane, 1:10) to give 4-[4-(3-ethoxycarbonyl-3-methylbutyl)-phenyl]-2,2-dimethylbutyric acid ethyl ester (24.0 g). This intermediate (24.0 g, 66.2 mmol) was dissolved in EtOH (300 mL) and water (50 mL), KOH (85%, 15.0 g, 227 mmol) was added, and the reaction mixture was refluxed for 3 h. The solvent was evaporated, and the residue was dissolved in water (150 mL) and extracted with MTBE (2 × 30 mL). The aqueous solution was acidified to pH 1–2 with aqueous HCl. The precipitate was filtered, recrystallized from CHCl3 / EtOH (1:1), and dried in vacuo to give 4-[4-(3-carboxy-3-methylbutyl)-phenyl]-2,2-dimethylbutyric acid (13.6 g, 64%, 94.8% purity by HPLC) as white crystals (compound I-78). Mp 214-215 °C. Elemental analysis (C 18 H 26 O4): Calculated for C: C, 70.56; H, 8.55; Found: C, 70.78, H, 8.64. 1 H NMR (CD3OD): δ= 7.06 (s, 4H), 4.90 (s, 2H), 2.54-2.48 (m, 4H), 1.80-1.74 (m, 4H), 1.22 (m, 12H). 13 C NMR (CD3OD): δ= 181.5, 140.9, 129.2, 44.3, 43.2, 32.3, 25.8. C 18 H26 O4(M + ) HRMS calculated: 306.1831, found: 306.1831.

[0350] Example 10: Synthesis of 6,6'-(1,4-phenylene)bis(2,2-dimethylhexanoic acid) (Compound I-1) [ka]

[0351] 4-[4-(3-Methoxycarbonylpropyl)-phenyl]-butyric acid methyl ester (B1) The compound was prepared by a modification of the method reported in Cram, DJ; Allinger, NL; Steinberg, HJ Amer. Chem. Soc. 1954, 76, 6132.

[0352] Under a N2 atmosphere, sodium (3.5 g, 0.152 mol) was dissolved in EtOH (200 mL) and ethyl malonate (50.0 g, 0.31 mol) was added to the warm solution. The reaction mixture was heated at reflux for 5 min, and a solution of 1,4-bis-(2-bromoethyl)-benzene (A4) (22.02 g, 75.4 mmol) in ethyl malonate (50 mL) was added dropwise over 5 min at room temperature. The reaction mixture was heated at reflux for 0.5 h. After the addition of water (150 mL) and EtOAc (200 mL), the solvent was evaporated and the residue was dissolved in EtOAc (200 mL). The solution was washed with water (100 mL) and brine (100 mL), dried over MgSO4, and concentrated in vacuo. The residue was dried under high vacuum at 80-100 °C (oil bath). The resulting crude 2-{2-[4-(3,3-bis-ethoxycarbonylpropyl)-phenyl]-ethyl}malonic acid diethyl ester was dissolved in aqueous EtOH (80%, 200 mL) and KOH (85%, 35.0 g, 0.53 mol) was added. The reaction mixture was heated at reflux for 2 h. The solvent was partially evaporated, and EtOAc (150 mL) was added. The aqueous layer was separated and extracted with EtOAc (2 × 100 mL). The combined organic solution was washed with brine (100 mL), dried over MgSO4, and concentrated. The crude 2-{2-[4-(3,3-bis-carboxypropyl)-phenyl]-ethyl}malonic acid (28.0 g) was heated in an oil bath at 200–210 °C for 1.5 h. The obtained crude 4-[4-(3-carboxypropyl)-phenyl]-butyric acid (16.3 g) was dissolved in MeOH (100 mL) and concentrated sulfuric acid (40 mL) was added. The reaction mixture was refluxed for 5 h and then stirred at room temperature overnight. MeOH was partially evaporated, and the residue was dissolved in EtOAc (150 mL), washed with water (150 mL) and brine (150 mL), and dried over MgSO. The solvent was evaporated to give crude 4-[4-(3-methoxycarbonylpropyl)-phenyl]-butyric acid methyl ester (B1) (17.9 g, 85%) as a yellow oil, which was used in the next step without purification. 1H NMR (CDCl3): δ = 7.10 (s, 4H), 3.67 (s, 6H), 2.59 (t, J = 7.4 Hz, 4H), 2.33 (t, J = 7.4 Hz, 4H), 1.95-1.90 (m, 4H). 13 C NMR (CDCl3): δ = 174.0, 138.9, 128.4, 51.5, 34.6, 33.3, 26.5.

[0353] 4-[4-(4-hydroxybutyl)-phenyl]-butan-1-ol (B2) The compound is prepared according to Cram, DJ; Allinger, NL; Steinberg, HJ Am. Chem. Soc. 1954, 76, 6132-6141. A solution of 4-[4-(3-methoxycarbonylpropyl)-phenyl]-butyric acid methyl ester (17.7 g, 63.6 mmol) in THF (50 mL) was added to a suspension of LiAlH4 (7.2 g, 0.19 mol) in THF (300 mL) with stirring at 0 °C. The reaction mixture was heated to reflux for 1 h. Water (100 mL) and aqueous HCl (10%, 200 mL) were added. The aqueous layer was separated and extracted with EtOAc (2 × 50 mL). The combined organic solution was washed with brine, dried over MgSO4, and concentrated. The residue was purified by column chromatography (silica gel, ETOAc:hexane, 1:1) to give 4-[4-(4-hydroxybutyl)-phenyl]-butan-1-ol (7.5 g, 53%, 96.2% purity by HPLC) as white crystals. Mp 60-62 °C (60.5-62.4 °C, Cram, DJ; Allinger, NL; Steinberg, HJ Am. Chem. Soc. 1954, 76, 6132-6141). 1 H NMR (CDCl3): δ = 7.10 (s, 4H), 3.63 (t, J = 6.4 Hz, 4H), 2.61 (t, J = 7.1 Hz, 4H), 2.12 (br s, 2H), 1.71-1.57 (m, 8H). 13 C NMR (CDCl3): δ = 140.7, 129.4, 63.8, 36.3, 33.4, 28.67.

[0354] 1,4-bis-(4-bromobutyl)-benzene (B3) Concentrated sulfuric acid (30 mL) was added dropwise over 1 h to a boiling mixture of 4-[4-(4-hydroxybutyl)-phenyl]-butan-1-ol (9.4 g, 42.3 mmol), NaBr (17.4 g, 0.169 mol), and water (50 mL). The reaction mixture was refluxed for 1 h. Additional concentrated sulfuric acid (10 mL) was added over 20 min, and refluxing was continued for 1.5 h. After addition of water (300 mL) and methylene chloride (500 mL), the aqueous solution was separated and extracted with methylene chloride (2 x 50 mL). The combined organic solution was washed with water (200 mL) and brine (150 mL) and dried over MgSO4. The solvent was evaporated and the residue was purified by column chromatography (silica gel, EtOAc:hexanes, 1:20) to give 1,4-bis-(4-bromobutyl)-benzene (11.8 g, 80%, 96.1% purity by HPLC) as an oil. 1 H NMR (CDCl3): δ = 7.14 (s, 4H), 3.46 (t, J = 6.6 Hz, 4H), 2.65 (t, J = 7.5 Hz, 4H), 1.96-1.89 (m, 4H), 1.83-1.75 (m, 4H). 13 C NMR (CDCl3): δ = 139.5, 128.6, 34.7, 34.0, 32.5, 30.1. The procedure is modified from that described by Cram, DJ; Allinger, NL; Steinberg, HJ Am. Chem. Soc. 1954, 76, 6132-6141.

[0355] 6-[4-(5-carboxy-5-methylhexyl)-phenyl]-2,2-dimethylhexanoic acid A solution of lithium diisopropylamide (90 mmol, 1.8 M in heptane / THF / EtPh, 50 mL) was added dropwise to a solution of ethyl isobutyrate (8.97 g, 77.2 mmol) in THF (200 mL) at -78 °C. After stirring the reaction mixture for 1 h, a solution of 1,4-bis-(4-bromobutyl)-benzene (11.2 g, 32.2 mmol) in THF (50 mL) was slowly added, followed by DMPU (10 mL). The reaction mixture was warmed to room temperature over 2 h and stirred at 40–50 °C for 1 h. Water (200 mL) was added, and the aqueous solution was separated and extracted with EtOAc (3 × 80 mL). The combined organic solution was washed with water (100 mL) and brine (100 mL). The solvent was evaporated, and the residue was dissolved in EtOH (100 mL). Water (50 mL) and KOH (85%, 15.0 g, 227 mmol) were added, and the reaction mixture was heated to reflux for 3 h. After adding water (200 mL) and cooling to room temperature, the reaction mixture was acidified to pH 1 with concentrated HCl and stirred for 1 h. The precipitate was filtered, washed with water, and dissolved in methylene chloride (400 mL). The solution was dried over MgSO4 and evaporated in vacuo. The residue was dissolved in EtOAc:hexane (1:30, 200 mL) under heat and cooled in a freezer. The solution was decanted from the oil and evaporated to a volume of 60 mL. The mixture was stirred overnight, and the precipitate was filtered, washed with hexane, and dried in vacuo to give 6-[4-(5-carboxy-5-methylhexyl)-phenyl]-2,2-dimethylhexanoic acid (8.02 g, 69%, 96.4% pure by HPLC) as a white solid (Compound I-1). Mp 129-131 °C. Elemental analysis (C 22 H 34 O4): Calculated: C, 72.89; H, 9.45. Found: C, 72.90; H, 9.49. 1 H NMR (CDCl3): δ = 7.05 (s, 4H), 2.66-2.62 (m, 4H), 1.68-1.56 (m, 4H), 1.53-1.47 (m, 4H), 1.17 (s, 12H), 1.08-0.98 (m, 4H). 13C NMR (CDCl3): δ = 185.3, 138.6, 128.5, 42.3, 41.5, 34.5, 30.6, 25.0, 23.2. C 22 H 34 O4(M + ) HRMS calculated: 362.2457, found: 362.2453.

[0356] Example 11: Synthesis of 1,4-bis(4-carboxy-4-methylpentyl)benzene (Compound III-1) [ka]

[0357] 1,4-bis(2-methoxycarbonylethyl)benzene(C2) A solution of 1,4-bis(2-carboxyethyl)benzene (C1) (10.0 g, 45.0 mmol) in anhydrous methanol (75 mL) and concentrated sulfuric acid (5.0 g) was heated to reflux for 5 h under an Ar atmosphere. The reaction mixture was cooled to room temperature, and the crystals were filtered, washed with MeOH (30 mL), and dried in vacuo to give 1,4-bis(2-methoxycarbonylethyl)benzene (11.0 g, 99%) as white crystals. Mp 116-117 °C (116-118 °C, Matsuoka, T.; Negi, T.; Otsubo, T.; Sakata, Y.; Misumi, S. Bull. Chem. Soc. Japan 1972, 45, 1825-1833). 1 H NMR (CDCl3): δ = 7.11 (s, 4 H), 3.69 (s, 6 H), 2.94 (t, J = 8.1 Hz, 4 H), 2.62 (t, J = 8.2 Hz, 4 H). 13 C NMR (CDCl3): δ = 173.3, 138.4, 128.4, 51.6, 35.6, 30.5. This known compound was synthesized by Matsuoka, T.; Negi, T.; Otsubo, T.; Sakata, Y.; Misumi, S. Bull. It was prepared by a method different from that described in Chem. Soc. Japan 1972, 45, 1825-1833.

[0358] 1,4-bis(3-hydroxypropyl)benzene(C3) C3 was prepared according to Matsuoka, T.; Negi, T.; Otsubo, T.; Sakata, Y.; Misumi, S. Bull. Chem. Soc. Japan 1972, 45, 1825-1833. Under an Ar atmosphere, lithium aluminum hydride (5.2 g, 13.7 mmol) was added in portions to anhydrous THF (300 mL). A solution of 1,4-bis(2-methoxycarbonylethyl)benzene (11.5 g, 45.9 mmol) in THF (50 mL) was added dropwise over 1 h, resulting in an exothermic reaction. The reaction mixture was refluxed for 5 min and stirred at room temperature for 3 h. The mixture was then hydrolyzed with water (100 mL) and a 10% aqueous solution of NH4Cl (50 mL). The organic layer was separated, and the aqueous solution was extracted with EtOAc (100 mL). The organic phases were combined, washed with brine (50 mL), dried over MgSO4, and concentrated to give 1,4-bis(3-hydroxypropyl)benzene (9.0 g, quantitative) as an oil, which was used in the next step without further purification. 1 H NMR (DMSO-d6): δ = 7.10 (s, 4 H), 4.43 (br s, 2 H), 3.41 (t, J = 8.1 Hz, 4 H), 2.59 (t, J = 8.2 Hz, 4 H), 1.71 (m, 2 H). 13 C NMR (DMSO-d6): δ = 139.0, 127.0, 60.0, 34.5, 31.2.

[0359] 1,4-bis(3-bromopropyl)benzene(C4) An emulsion of 1,4-bis(3-hydroxypropyl)benzene (9.0 g, 46.3 mmol) and sodium bromide (24.0 g, 0.23 mol) in deionized water (25 mL) was heated to reflux, and concentrated sulfuric acid (17 mL) was added dropwise over 1 h. After the addition, heating at reflux was continued for an additional 3.5 h. The solution was cooled to room temperature, diluted with water (40 mL), and extracted with CHCl (2 × 150 mL). The combined organic layers were washed with a saturated solution of NaHCO (100 mL), saturated NaCl solution (100 mL), and dried over MgSO. The solvent was evaporated, and the residue was purified by column chromatography (silica gel, 1:40 EtOAc:hexane) to give 1,4-bis(3-bromopropyl)benzene (11.6 g, 78%) as a colorless oil. 1 H NMR (CDCl3): δ = 7.15 (s, 4 H), 3.41 (t, J = 6.6 Hz, 4 H), 2.77 (t, J = 7.1 Hz, 4 H), 2.18 (m, 4 H). 13 C NMR (CDCl3): δ = 138.3, 128.7, 34.2, 33.4, 33.3. This known compound was prepared by a method different from that described in Matsuoka, T.; Negi, T.; Otsubo, T.; Sakata, Y.; Misumi, S. Bull. Chem. Soc. Japan 1972, 45, 1825-1833 and Ruzicka, L.; Buijs, JB; Stoll, M. Helv. Chim. Acta 1932, 15, 1220.

[0360] 1,4-bis(4-ethoxycarboxy-4-methylpentyl)benzene(C5) Under a N2 atmosphere, lithium diisopropylamide (46.7 mL, 84.0 mmol) (1.8 M solution in heptane / THF / EtPh, 1.8 M solution) was added dropwise to a solution of ethyl isobutyrate (9.0 g, 77.5 mmol) in anhydrous THF (300 mL) at -78 °C. After 1 h, a solution of 1,4-bis(3-bromopropyl)benzene (11.6 g, 36.3 mmol) in anhydrous THF (70 mL) was added dropwise, followed by the addition of DMPU (20 mL). The reaction mixture was allowed to warm to room temperature overnight, then cooled in an ice bath and hydrolyzed with saturated NH4Cl solution (100 mL). Water (100 mL) was added and the layers were separated. The aqueous layer was extracted with ethyl acetate (2 × 50 mL). The combined organic layers were washed with saturated NaCl solution (100 mL), dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc:hexanes, 1:10) to give 1,4-bis(4-ethoxycarboxy-4-methylpentyl)benzene (13.3 g, 94%) as a colorless oil. 1 H NMR (CDCl3): δ = 7.09 (s, 4 H), 4.11 (q, J = 7.1 Hz, 4 H), 2.57 (m, 4 H), 1.57 (m, 8 H), 1.24 (t, J = 7.1 Hz, 6 H), 1.47 (s, 12 H). 13 C NMR (CDCl3): δ = 177.9, 139.6, 128.2, 60.1, 42.0, 40.2, 35.8, 26.8, 25.1, 14.2. C 24 H 39 O4(MH + ) HRMS calculated: 391.2838, found: 391.2836.

[0361] 1,4-bis(4-carboxy-4-methylpentyl)benzene A solution of 1,4-bis(4-ethoxycarboxy-4-methylpentyl)benzene (13.0 g, 33.3 mmol) and potassium hydroxide (85%, 7.0 g, 106 mmol) in ethanol (25 mL) and water (15 mL) was heated at reflux for 3.5 h. The reaction mixture was cooled to room temperature, diluted with water (100 mL), and acidified to pH 1 with HCl (2 M aqueous solution). A precipitate formed immediately. The mixture was stirred for 1 h, and the precipitate was filtered and washed with water (2 × 50 mL). The crude precipitate was dissolved in methylene chloride (700 mL), and the solution was dried over MgSO4 overnight. The solvent was evaporated, and the residue was recrystallized (methylene chloride:hexane = 1:1) to give 1,4-bis(4-carboxy-4-methylpentyl)benzene (9.5 g, 85%, 100% pure by HPLC) as white crystals (compound III-1). Mp131℃ (125-126℃, Gleiter, R.; Kramer, R.; Irngartinger, H.; Bissinger, C. Synthesis and Properties of 4,4,9,9-Tetramethyl

[12] paracyclophane-5,6,7,8-tetrone. J.Org.Chem.1992,57,252-258). Elemental analysis (C 20 H 30 O4): Calculated: C, 71.82; H, 9.04, Found: C, 71.10; H, 9.00. 1 H NMR (CDCl3): δ = 7.07 (brs, 4H), 2.55 (m, 4H), 1.59 (m, 8H), 1.18 (s, 12H). 13 C NMR (CDCl3): δ = 184.9, 139.6, 128.1, 42.1, 40.3, 35.8, 26.8, 24.9. This known compound was prepared by a modification of the method described in Gleiter, R.; Kramer, R.; Irngartinger, H.; Bissinger, C. Synthesis and Properties of 4,4,9,9-Tetramethyl

[12] paracyclophane-5,6,7,8-tetrone. J. Org. Chem. 1992, 57, 252-258.

[0362] Example 12: Synthesis of 5,5'-(1,3-phenylene)bis(2,2-dimethylpentanoic acid) (Compound I-31) [ka]

[0363] Dimethyl m-benzene-bis(2,2-dimethyl)pentanoate (D2) Under an Ar atmosphere, lithium diisopropylamide (2.0 M in heptane / THF / ethylbenzene, 91.5 mL, 183 mmol) was added dropwise to a solution of ethyl isobutyrate (21.2 g, 24.4 mL, 183 mmol) in anhydrous THF (200 mL) at −78° C. After 1 h, a solution of m-bis(3-bromopropyl)benzene (D1) (prepared according to Schimelpfenig, C.W.J. Org. Chem. 1975, 40, 1493-1494 and Effenberger, F.; Kurtz, W. Chem. Ber. 1973, 106, 511-524, 26.6 g, 83.1 mmol) in anhydrous THF (50 mL) was added dropwise, followed by the addition of DMPU (25 mL). The reaction mixture was allowed to warm to room temperature overnight, then cooled in an ice bath and hydrolyzed with saturated NH4Cl solution (100 mL). Deionized water (100 mL) was added and the layers were separated. The aqueous layer was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with saturated NaCl solution (100 mL), 1N hydrochloric acid (2 × 100 mL), saturated NaHCO3 solution (100 mL), and saturated NaCl solution (100 mL). The combined organic phases were dried over MgSO4, concentrated in vacuo, and dried under high vacuum. The residue was purified by flash chromatography on silica (hexane / ethyl acetate = 95 / 5) to give diethyl 5,5'-(1,3-phenylene)bis(2,2-dimethylpentanoate) (15.7 g, 48%) as a yellow oil. 1H NMR (CDCl3): δ = 7.17 (t, 1 H, J = 7.0 Hz), 6.97 (m, 3 H), 4.09 (q, 4 H, J = 7.3 Hz), 2.55 (m, 4 H), 1.56 (m, 8 H), 1.22 (t, 6 H, J = 7.3 Hz), 1.15 (s, 12H). 13 C NMR (CDCl3): δ = 178.02, 142.37, 128.58, 128.32, 125.86, 60.31, 42.25, 40.52, 36.48, 27.03, 25.30, 14.39.

[0364] 5,5'-(1,3-phenylene)bis(2,2-dimethylpentanoic acid) A solution of diethyl 5,5'-(1,3-phenylene)bis(2,2-dimethylpentanoate) (D2) (10.6 g, 27.14 mmol) and potassium hydroxide (85%, 6.3 g, 95.00 mmol) in ethanol (20 mL) and water (10 mL) was heated at reflux for 4 h. The reaction mixture was cooled to room temperature, diluted with water (50 mL), and the ethanol was removed under reduced pressure. The remaining aqueous solution was extracted with dichloromethane (2 × 50 mL). The aqueous layer was acidified to pH 1 with concentrated hydrochloric acid (10 mL) and extracted with dichloromethane (3 × 50 mL). The combined organic layers were washed with saturated NaCl solution (50 mL), dried over MgSO4, concentrated in vacuo, and dried under high vacuum to give a viscous oil (9.3 g). This oil was crystallized from pentane / dichloromethane (75 mL / 5 mL) at −5° C. to give 5,5′-(1,3-phenylene)bis(2,2-dimethylpentanoic acid) (4.78 g, 49%, 93.2% purity by HPLC) as a white powder (compound I-31). Mp 79° C. Elemental analysis (C 20 H 30 O4): Calculated: C, 71.82; H, 9.04, Found: C, 71.71; H, 9.22. 1H NMR (DMSO-d6): δ = 12.2 - 11.7 (mbr, 2H), 7.17 (m, 1H), 6.98 (m, 3H), 2.52 (m, 4H), 1.49 (m, 8H), 1.07 (s, 12H). 13 C NMR (DMSO-d6): δ = 178.86, 141.96, 128.26, 125.69, 41.21, 39.91, 35.68, 26.62, 25.06. C 30 H 31 O3(MH + ) HRMS calculated: 335.2222, found: 335.2232.

[0365] Example 13: Synthesis of 6-[3-(5-carboxy-5-methylhexyl)-phenyl]-2,2-dimethylhexanoic acid (Compound I-32) [ka]

[0366] [1,3-bis(5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl]-phenylene (E2) A solution of n-butyllithium (38.8 mL, 2.5 M in hexane / THF / EtPh, 96.9 mmol) was added to a mixture of m-xylene (E1) (5.0 g, 47.1 mmol) and potassium tert-butoxide (5.4 g, 48.1 mmol) in hexane (100 mL) at room temperature. The reaction mixture was heated at reflux for 1 h. A yellow precipitate formed. The reaction mixture was cooled to 0 °C, and 2-(5-bromo-2,2-dimethylpentyloxy)-tetrahydropyran (prepared according to Dasseux et al., US 6,646,170 and US 6,410,802, 30.0 g, 107.5 mmol) was added dropwise. The reaction mixture was heated at reflux for 20 h. Water (150 mL) was added, and the organic phase was separated. The aqueous solution was extracted with EtOAc (2 × 100 mL). The organic phases were combined, washed with brine (50 mL), and dried over MgSO. The solvent was evaporated, and the residue was purified by column chromatography (silica gel, EtOAc:hexane, 1:30) to give [1,3-bis(5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl]-phenylene (14.8 g, 62%, 96.1% purity by HPLC) as an oil. 1 H NMR (CDCl3): δ = 7.17-7.14 (m, 1H), 7.00-6.98 (m, 3H), 4.54 (t, J = 3.0 Hz, 2H), 3.78-3.86 (m, 2H), 3.50-3.45 (m, 2H), 3.47 (d, J = 9.1 Hz, 2H) 2.98 (d, J = 9.1 Hz, 2H), 2.59 (t, J = 7.6 Hz, 4H), 1.90-1.28 (m, 24H), 0.89 (s, 12H). 13 C NMR (CDCl3): δ = 142.8, 128.5, 128.1, 125.6, 99.1, 77.5, 61.8, 39.2, 36.0, 34.2, 32.5, 30.7, 25.6, 24.6, 23.7, 19.4. C 32 H 54 O4(M + ) HRMS calculated: 501.3943, found: 501.3943.

[0367] 6-[3-(6-hydroxy-5,5-dimethylhexyl)-phenyl]-2,2-dimethylhexan-1-ol (E3) Concentrated aqueous HCl (20 mL) was added to 1,3-bis(5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl)phenylene (18.0 g, 35.7 mmol) in MeOH (200 mL). The reaction mixture was heated to reflux for 2 h and stirred at room temperature overnight. MeOH was evaporated in vacuo and the residue was dissolved in methylene chloride (200 mL). The solution was washed with water (100 mL), saturated NaHCO solution (100 mL), and brine (100 mL) and dried over MgSO. The solvent was evaporated and the residue was purified by column chromatography (silica gel, EtOAc:hexane=1:1) to give 6-[3-(6-hydroxy-5,5-dimethylhexyl)-phenyl]-2,2-dimethylhexan-1-ol (10.41 g, 87%, 86.4% by HPLC) as an oil. 1 H NMR (CDCl3): δ = 7.21-7.19 (m, 1H), 7.02-6.99 (3H), 3.32 (s, 4H), 2.62 (t, J = 7.8 Hz, 4H), 1.64-1.26 (m, 12H), 0.89 (s, 12H). 13 C NMR (CDCl3): δ = 142.6, 128.5, 128.1, 125.6, 71.9, 38.4, 35.8, 35.0, 32.4, 23.7, 23.5. C 22 H 38 O4(M + ) HRMS calculated: 335.2950, ​​found: 335.2950.

[0368] 6-[3-(5-carboxy-5-methylhexyl)-phenyl]-2,2-dimethylhexanoic acid Pyridinium dichromate (74.85 g, 199 mmol) was added to a solution of 6-[3-(6-hydroxy-5,5-dimethylhexyl)-phenyl]-2,2-dimethylhexan-1-ol (8.5 g, 25.4 mmol) in DMF (200 mL) at room temperature. The reaction mixture was stirred for 30 hours and then heated to 40 °C for 10 hours. Ethyl acetate (100 mL) was added, followed by water (200 mL) and concentrated H2SO4 (20 mL) with stirring. The organic layer was separated, and the aqueous layer was extracted with EtOAc (3 × 100 mL). The combined organic solution was washed with water (100 mL), saturated NaHCO3 solution (100 mL), and brine (2 × 100 mL) and dried over MgSO4. The solvent was evaporated, and the residue was purified by column chromatography (silica gel, EtOAc:hexane = 1:1). The resulting oil was stirred in EtO:hexane (1:10, 50 mL) for 3 h, and the precipitated solid product was filtered (7.2 g, 78%, 96.1% by HPLC) (compound I-32). Mp 99-101 °C. Elemental analysis (C 22 H 34 O4): Calculated: C, 72.89; H, 9.45; Found: C, 73.02; H, 9.57. 1 H NMR (CDCl3): δ = 7.19-7.16 (m, 1H), 6.99-6.94 (m, 3H), 2.58 (t, J = 7.1 Hz, 4H), 1.63-1.56 (m, 8H), 1.32-1.22 (m, 4H), 1.18 (s, 12H). 13 C NMR (CDCl3): δ = 185.5, 142.2, 128.6, 128.3, 126.0, 42.0, 40.8, 35.7, 31.0, 25.1, 24.4. C 22 H 35 O4(MH + ) HRMS calculated: 363.2535, found: 363.2530.

[0369] Example 14: Synthesis of 5,5'-(1,2-phenylene)bis(2,2-dimethylpentanoic acid) (Compound I-61) [ka]

[0370] 3-[2-(3-hydroxypropyl)-phenyl]-propanol (F2) Under an Ar atmosphere, a solution of 3-[2-(2-ethoxycarbonylethyl)-phenyl]-propionic acid ethyl ester (prepared according to Fakhri, SA; Behrooz, YH Tetrahedron 2000, 56, 8301-8308, 14.5 g, 52.1 mmol) in THF (100 mL) was added dropwise to a suspension of lithium aluminum hydride (3.0 g, 78.2 mmol) in anhydrous THF (100 mL) over a period of 50 minutes at room temperature with stirring. The mixture was stirred for 2 hours, then cooled in an ice bath and carefully hydrolyzed by the dropwise addition of deionized water (100 mL). Hydrolysis was completed by the dropwise addition of 10% sulfuric acid at room temperature and stirring overnight. The mixture was extracted with dichloromethane (200 mL, 2 × 100 mL). The combined organic layers were washed with saturated sodium chloride solution (100 mL), dried over MgSO, concentrated in vacuo, and dried under high vacuum to give 3-[2-(3-hydroxypropyl)-phenyl]-propanol (8.6 g, 85%, 87.9% purity by GC) as a cloudy oil, which was used for the next step without further purification. 1 H NMR (CDCl3): δ = 7.20 - 7.05 (m, 4 H), 3.67 (t, 4 H, J = 6.1 Hz), 3.50 - 3.20 (m br., 2 H), 2.72 (m, 4 H), 1.82 (m, 4 H). 13 C NMR (CDCl3): δ = 139.98, 129.43, 126.24, 62.35, 34.36, 29.01. C 12 H 19 O2(MH + HRMS calculated for ) 195.1385, found 195.1388. This known compound was prepared by a different method from that described in Uenaka, M.; Kubota, B. Bull. Chem. Soc. Jpn. 1936, 11, 19-26.

[0371] 1,2-bis-(3-bromopropyl)-benzene (F3) A mixture of 3-[2-(3-hydroxypropyl)-phenyl]-propanol (8.6 g, 44.27 mmol), sodium bromide (18.6 g, 180.62 mmol), and water (16 mL) was heated to reflux, and concentrated sulfuric acid (13.3 mL) was added dropwise over 20 minutes. The solution was heated at reflux for an additional 75 minutes, then cooled to room temperature and diluted with deionized water (200 mL). The mixture was extracted with dichloromethane (3 × 100 mL), and the combined organic layers were washed successively with water (100 mL), saturated sodium bicarbonate solution (100 mL), 10% aqueous sodium thiosulfate solution (200 mL), and saturated sodium chloride solution (100 mL). The organic layer was dried over MgSO, concentrated in vacuo, and dried under high vacuum to give the crude product (11.2 g) as a brown oil. The crude material was purified by flash chromatography (silica, hexane, then hexane / ethyl acetate=90 / 10) to give 1,2-bis-(3-bromopropyl)-benzene (8.25 g, 58%, 95.9% pure by GC) as a viscous yellow oil. 1 H NMR (CDCl3): δ = 7.16 (s, 4 H), 3.33 (t, 4 H, J = 6.3 Hz), 2.79 (m, 4 H), 2.12 (m, 4 H). 13 C NMR (CDCl3): δ = 138.69, 129.69, 126.66, 34.14, 33.62, 30.99. C 12 H 16 Br2(M + ) HRMS calculated: 317.9619, found: 317.9624. This known compound was prepared by a method different from that described in Uenaka, M.; Kubota, B. Bull. Chem. Soc. Jpn. 1936, 11, 19-26.

[0372] 5-[2-(4-ethoxycarbonyl-4-methylpentyl)-phenyl]-2,2-dimethylpentanoic acid ethyl ester (F4) Under an Ar atmosphere, a solution of lithium diisopropylamide (2.0 M in heptane / THF / ethylbenzene, 41.2 mL, 82.48 mmol) was added dropwise over 15 min to a solution of ethyl isobutyrate (8.7 g, 10.0 mL, 74.98 mmol) in anhydrous THF (100 mL) at −78°C. After 85 min, a solution of 1,2-bis-(3-bromopropyl)-benzene (8.0 g, 74.98 mmol) in anhydrous THF (25 mL) was added dropwise over 10 min, followed by DMPU (15 mL). The mixture was stirred at −78°C for an additional 1 h, then slowly warmed to room temperature over the next 2 h and stirred overnight. The reaction mixture was cooled in an ice bath and hydrolyzed by the addition of saturated NH4Cl solution (100 mL) and deionized water (100 mL). The layers were separated, and the aqueous layer was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with water (100 mL), 1N hydrochloric acid (100 mL), water (100 mL), and saturated sodium chloride solution (100 mL). The organic phase was then dried over MgSO4 and concentrated in vacuo to give the crude product (14.0 g) as a red oil. Purification by flash chromatography (silica, hexane / ethyl acetate = 95 / 5) gave 5-[2-(4-ethoxycarbonyl-4-methylpentyl)-phenyl]-2,2-dimethylpentanoic acid ethyl ester (8.2 g, 84%, 79% purity by GC) as a pale yellow oil. 1 H NMR (CDCl3): δ = 7.11 (s, 4 H), 4.10 (q, 4 H, J = 7.0 Hz), 2.56 (t, 4 H, J = 7.6 Hz), 1.68 - 1.42 (m, 8 H), 1.23 (t, 6 H, J = 7.0 Hz), 1.16 (s, 16 H). 13 C NMR (CDCl3): δ = 177.95, 140.01, 129.12, 126.04, 60.34, 42.26, 40.79, 33.11, 26.75, 25.29, 14.41. C 24 H 39 O4(MH + ) HRMS calculated: 391.2848, found: 391.2846.

[0373] 5,5'-(1,2-phenylene)bis(2,2-dimethylpentanoic acid) (or 5-[2-(4-carboxy-4-methylpentyl)-phenyl]-2,2-dimethylpentanoic acid) A solution of 5-[2-(4-ethoxycarbonyl-4-methylpentyl)-phenyl]-2,2-dimethylpentanoic acid ethyl ester (8.3 g, 21.25 mmol) and potassium hydroxide (>85%, 4.91 g, 74.38 mmol) in ethanol (20 mL) and water (10 mL) was heated under reflux for 4 hours. After cooling to room temperature, the mixture was diluted with water (50 mL) and concentrated in vacuo to a volume of approximately 60 mL. The aqueous solution was extracted with dichloromethane (2 × 30 mL) and then acidified to pH 1 with 1 N hydrochloric acid (8 mL). The aqueous layer was extracted with dichloromethane (3 × 30 mL). The combined organic extracts were washed with saturated NaCl solution (30 mL), dried over MgSO4, and concentrated in vacuo to give the crude product (5.50 g) as a white solid / viscous oil. The crude material was crystallized from heptane / dichloromethane at -5 °C to give a small amount of white crystals, which were washed with chilled heptane (10 mL) and dried under high vacuum (5.05 g, 71%, 98.3% purity by HPLC) (compound I-61). Mp 108-109 °C. Elemental analysis (C 20 H 30 O4): Calculated: C, 71.82; H, 9.04, Found: C, 71.14; H, 9.06. 1 H NMR (DMSO-d6): δ = 12.7 - 11.5 (mbr, 2H), 7.11 (s, 4H), 2.55 (t, 4H, J = 7.3 Hz), 1.62 - 1.38 (m, 8H), 1.09 (s, 12H). 13 C NMR (DMSO-d6): δ = 178.83, 139.69, 128.98, 125.89, 41.25, 40.20, 32.49, 26.57, 25.04. C 20 H 31 O4(MH + ) HRMS calculated: 335.2222, found: 335.2232.

[0374] Biological assays Example 15: Antiproliferative effects of compounds I-32, I-61, I-1, and III-1 in Hep3B and Hepa1-6 liver cancer cells Human liver cancer cells Hep3B and mouse liver cancer cells Hepa1-6 were seeded at a cell density of 3,000 cells / well in 96-well plates using Eagle's Minimum Essential Medium (Corning) for Hep3B or Dulbecco's Modified Eagle Medium (DMEM) High Glucose (Gibco) for Hepa1-6 cells, supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% Antibiotic-Antimycotic Solution (Thermo-Fisher Scientific). The next day, cells were treated with 0 (vehicle control), 0.1, 0.5, 1, 5, 10, 30, 50, or 100 μM of compounds I-32, I-61, I-1, or III-1 (final concentration of DMSO 0.1%) and grown at 37°C for 72 hours. On day 5, 10 μL of PrestoBlue™ cell viability reagent (Invitrogen) was added to each well, and the plates were incubated for an additional 1–2 h at 37°C. After incubation, the fluorescent signal was measured using a SpectraMax M5 microplate reader (Molecular Devices) at excitation / emission wavelengths of 560 / 590 nm.

[0375] The effects of compounds I-32, I-61, I-1, and III-1 on cell proliferation in Hepa1-6 cells are shown in Figures 2A-2D (n = 4 replicates, single experiment; error bars represent standard deviation) as a percentage of vehicle control (DMSO, 0.1% final concentration). The effects of compounds I-32, I-61, I-1, and III-1 on Hep3B cell proliferation are shown in Figures 3A-3D (n = 5, single experiment; error bars represent standard deviation) as a percentage of vehicle control (DMSO, 0.1% final concentration).

[0376] Example 16: Anti-clonogenic effects of compounds I-32, I-61, I-1, and III-1 in Hep3B and Hep1-6 liver cancer cells. The liver cancer cell lines Hep3B (human) and Hepa1-6 (mouse) were maintained in Eagle's Minimum Essential Medium (Corning) for Hep3B or High Glucose DMEM (Gibco) for Hepa1-6 cells, supplemented with 10% FBS (Gibco) and 1% Antibiotic-Antimycotic Agent (Thermo-Fisher Scientific). Each cell line was seeded at 1,000 cells / well in a 12-well plate. The following day, the medium was replaced, and the cells were treated with 0 (vehicle control, 0.1% DMSO), 1, 5, 10, 30, 50, or 100 μM of compounds I-32, I-61, I-1, or III-1 (final concentration of 0.1% DMSO) for 7 days. On day 9, the medium was removed, and the cells were fixed with 10% formalin (500 μl) for 10 minutes at room temperature, washed with 1x PBS, and stained with crystal violet. After 10 minutes, excess dye was removed by rinsing three times with tap water. The plates were allowed to dry overnight, and then the number of colonies (>50 cells) in each well was counted using a light microscope as previously described by Villiani LA, et al.

[0377] The effects of compounds I-32, I-61, I-1, and III-1 on clonogenicity in Hepa1-6 cells are shown in Figures 4A-4D (n = 2, error bars represent standard deviation) relative to the vehicle control (DMSO, 0.1% final concentration). The effects of compounds I-32, I-61, I-1, and III-1 on clonogenicity in Hep3B cells are shown in Figures 5A-5D (n = 2, error bars represent standard deviation) relative to the vehicle control (DMSO, 0.1% final concentration).

[0378] Table 1 summarizes the biological results from Examples 15-17. ND = not determined. [Table 12]

[0379] Example 17: Synergistic effects of exemplary compounds of the present invention with sorafenib or lenvatinib. Combination studies with compounds of the present invention were conducted to determine potential synergistic effects of sorafenib or lenvatinib in the presence of Compound I-32 or Compound I-61. In separate experiments, the IC for growth inhibition by sorafenib in the absence of a compound of the present invention and growth inhibition by lenvatinib in the absence of a compound of the present invention were compared. 50 were measured to be 3 μM and 0.5 μM in Hep3B cells, and 5 μM and 30 μM in Hepa1-6 cells, respectively (data not shown).

[0380] Hep3B (provided by ATCC) or Hepa1-6 (provided by ATCC) cells were seeded in 96-well plates at a density of 500 cells / well in complete medium. On day 2, the medium in each well was aspirated and replaced with 100 μl of fresh complete medium, and the cells were treated with sorafenib or lenvatinib in a concentration-dependent manner (compound I-32 (100 μM) or compound I-61 (100 μM)), alone or in combination with sorafenib (3 μM) or lenvatinib (0.5 μM), in the presence or absence of a compound of the present invention. The cells were then incubated for 72 hours in an incubator. On day 5, 10 μl of Presto Blue (Invitrogen, catalog no. A13261) cell viability reagent was added to each 96-well plate and incubated at 37°C for 1-2 hours. After incubation, fluorescence was measured at excitation / emission wavelengths of 560 / 590 nm. Results were presented as mean ± standard deviation (SD). All bar and line graphs were generated using Graph Pad Prism 8 software. IC of proliferation 50 Values ​​were calculated using a nonlinear regression model in Graph Pad Prism 8. For each cell type, combination treatment demonstrated reduced cell proliferation compared to sorafenib or lenvatinib alone. Results for Hep3B cells are shown in Figures 6A-6B, and results for Hepa1-6 cells are shown in Figures 7A-7B.

[0381] Sorafenib and lenvatinib have the following structures: [ka]

[0382] Because further inhibition of cell proliferation was observed in the combination studies, the results were analyzed using CompuSyn software (provided by ComboSyn Inc.) to determine whether there was a synergistic or additive effect on antiproliferative activity. Figures 8A-8D show that both compounds I-32 and I-61 exhibited synergistic inhibition in the presence of sorafenib or lenvatinib.

Claims

1. The following structure 【Chemistry 1】 or a pharmaceutically acceptable salt or solvate thereof.

2. The following structure 【Chemistry 2】 or a pharmaceutically acceptable salt or solvate thereof.

3. (i) a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, and (ii) a pharmaceutically acceptable carrier or vehicle.

4. The composition of claim 3, further comprising sorafenib or lenvatinib.

5. 4. The composition of claim 3, further comprising bevacizumab, avelumab, axitinib, cabozantinib, ipilimumab, pembrolizumab, nivolumab, sunitinib, temsirolimus, durvalumab, bempegaldesleukin, tremelimumab, borolanib, toripalimab, atezolizumab, camrelizumab, cemiplimab, guadecitabine, sitravatinib, Pexastimogene Devacirepvec, ramucirumab, eicosapentaenoic acid, anlotinib, or trametinib.

6. (i) a compound according to claim 2, or a pharmaceutically acceptable salt or solvate thereof; and (ii) a pharmaceutically acceptable carrier or vehicle.

7. The composition of claim 6, further comprising sorafenib or lenvatinib.

8. 7. The composition of claim 6, further comprising bevacizumab, avelumab, axitinib, cabozantinib, ipilimumab, pembrolizumab, nivolumab, sunitinib, temsirolimus, durvalumab, bempegaldesleukin, tremelimumab, borolanib, toripalimab, atezolizumab, camrelizumab, cemiplimab, guadecitabine, sitravatinib, Pexastimogene Devacirepvec, ramucirumab, eicosapentaenoic acid, anlotinib, or trametinib.

9. 10. A composition comprising the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, for treating or preventing hepatocellular carcinoma (HCC).

10. The composition of claim 9, wherein the composition further comprises sorafenib or lenvatinib.

11. 10. A composition comprising the compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, for treating or preventing hepatocellular carcinoma (HCC).

12. The composition of claim 11, wherein the composition further comprises sorafenib or lenvatinib.

13. 10. A composition comprising the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, for treating or preventing renal cell carcinoma.

14. The composition of claim 13 , wherein the composition further comprises another pharmaceutically active agent.

15. 15. The composition of claim 14, wherein the additional pharmaceutically active agent is sorafenib, lenvatinib, bevacizumab, avelumab, axitinib, cabozantinib, ipilimumab, pembrolizumab, nivolumab, sunitinib, temsirolimus, durvalumab, bempegaldesleukin, tremelimumab, borolanib, toripalimab, atezolizumab, camrelizumab, cemiplimab, guadecitabine, sitravatinib, or Pexastimogene Devacirepvec.

16. 15. The composition of claim 14, wherein the additional pharmaceutically active agent is sorafenib or lenvatinib.

17. 10. A composition comprising the compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, for treating or preventing renal cell carcinoma.

18. 20. The composition of claim 17, wherein the composition further comprises another pharmaceutically active agent.

19. 19. The composition of claim 18, wherein the additional pharmaceutically active agent is sorafenib, lenvatinib, bevacizumab, avelumab, axitinib, cabozantinib, ipilimumab, pembrolizumab, nivolumab, sunitinib, temsirolimus, durvalumab, bempegaldesleukin, tremelimumab, borolanib, toripalimab, atezolizumab, camrelizumab, cemiplimab, guadecitabine, sitravatinib, or Pexastimogene Devacirepvec.

20. 19. The composition of claim 18, wherein the additional pharmaceutically active agent is sorafenib or lenvatinib.

21. 10. A composition comprising the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, for treating or preventing colon cancer.

22. 22. The composition of claim 21, wherein the composition further comprises another pharmaceutically active agent.

23. 23. The composition of claim 22, wherein the additional pharmaceutically active agent is sorafenib, lenvatinib, bevacizumab, ramucirumab, pembrolizumab, nivolumab, avelumab, durvalumab, eicosapentaenoic acid, anlotinib, camrelizumab, atezolizumab, cabozantinib, trametinib, or tremelimumab.

24. 23. The composition of claim 22, wherein the additional pharmaceutically active agent is sorafenib or lenvatinib.

25. A composition comprising the compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, for treating or preventing colon cancer.

26. 26. The composition of claim 25, wherein the composition further comprises another pharmaceutically active agent.

27. 27. The composition of claim 26, wherein the additional pharmaceutically active agent is sorafenib, lenvatinib, bevacizumab, ramucirumab, pembrolizumab, nivolumab, avelumab, durvalumab, eicosapentaenoic acid, anlotinib, camrelizumab, atezolizumab, cabozantinib, trametinib, or tremelimumab.

28. 27. The composition of claim 26, wherein the additional pharmaceutically active agent is sorafenib or lenvatinib.

29. 10. A composition comprising the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, for treating or preventing nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

30. 10. A composition comprising the compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, for treating or preventing non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

31. A composition for treating or preventing hepatocellular carcinoma (HCC), comprising (a) a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, and (b) for administration in combination with sorafenib or lenvatinib.

32. A composition for treating or preventing hepatocellular carcinoma (HCC), comprising: (a) a compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof; and (b) a composition for administration in combination with sorafenib or lenvatinib.

33. 10. A composition for treating or preventing renal cell carcinoma, comprising: (a) a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof; and (b) for administration in combination with another pharmaceutically active agent.

34. 10. A composition for treating or preventing renal cell carcinoma, comprising: (a) a compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof; and (b) for administration in combination with another pharmaceutically active agent.

35. 35. The composition of claim 33 or 34, wherein the additional pharmaceutically active agent is sorafenib, lenvatinib, bevacizumab, avelumab, axitinib, cabozantinib, ipilimumab, pembrolizumab, nivolumab, sunitinib, temsirolimus, durvalumab, bempegaldesleukin, tremelimumab, borolanib, toripalimab, atezolizumab, camrelizumab, cemiplimab, guadecitabine, sitravatinib, or Pexastimogene Devacirepvec.

36. 35. The composition of claim 33 or 34, wherein the other pharmaceutically active agent is sorafenib or lenvatinib.

37. 10. A composition for treating or preventing colon cancer, comprising: (a) a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof; and (b) for administration in combination with another pharmaceutically active agent.

38. 10. A composition for treating or preventing colon cancer, comprising: (a) a compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof; and (b) for administration in combination with another pharmaceutically active agent.

39. 39. The composition of claim 37 or 38, wherein the additional pharmaceutically active agent is sorafenib, lenvatinib, bevacizumab, ramucirumab, pembrolizumab, nivolumab, avelumab, durvalumab, eicosapentaenoic acid, anlotinib, camrelizumab, atezolizumab, cabozantinib, trametinib, or tremelimumab.

40. 39. The composition of claim 37 or 38, wherein the other pharmaceutically active agent is sorafenib or lenvatinib.

41. 10. A composition comprising the compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, for inhibiting, reducing, or slowing the development of liver fibrosis in a subject.

42. 10. A composition comprising the compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, for inhibiting, reducing, or slowing the development of liver fibrosis in a subject.

Images